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ABSTRACT
Background
Conjugate vaccines have been developed against some bacterial pathogens such as
Haemophilus influenzae type b (Hib), Neisseria meningitidis, and Streptococcus
pneumoniae. Conjugate vaccines are immunologically superior to the
polysaccharides vaccines, but more expensive. They involve the joining of a purified
polysaccharide moiety of bacterial capsule to a protein molecule known as carrier
protein. The carrier protein enables the vaccines to elicit a T-cell response and
thereby induce memory. The carrier protein has antigenic similarity to the
components of diphtheria, tetanus and pertussis vaccine (DTP) or adult tetanus,
diphtheria, and pertussis vaccine (Tdap). The concurrent or sequential
administration of a conjugate vaccine with DTP antigen may have positive or
negative immunological impacts; positive if it primes the immune system for a
stronger response to the polysaccharide antigen, negative if a carrier overload
results in suppression of the subsequently administered conjugate vaccine. Finding a
conclusive evidence of the positive interaction (carrier priming) could be
implemented to enhance the immunogenicity of a conjugate vaccine. This may
contribute to reducing the number of doses required to adequately immunise infants
in the hope that might lead to substantial economic savings through a reduced
dosing regimen. The research reported here examines conjugate vaccine interactions
with DTP and explores optimising the immune responses to conjugate vaccines
among vulnerable populations. The study groups chosen were infants and adult Hajj
pilgrims who are eligible to receive multiple vaccines, because of their vulnerability.
The primary objective of this work was to examine and categorise conjugate and DTP
vaccine interactions and establish whether they entail priming of -or interference -
with antibody responses. Its secondary objective was to explore the uptake and
barriers to receiving conjugate vaccines among Hajj pilgrims.
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Methods
In this thesis, I present nine publications that explore both conjugate and DTP
vaccine interactions and assess uptake of and barriers to conjugate vaccines.
Publications #1 and #2 represent a thorough literature review of conjugate vaccine
interaction with DTP and potential implications for vulnerable populations such as
infants in developing countries.
Publications #3-5 report a survey exploring pneumococcal vaccine uptake in Hajj
travellers and assess the pilgrims’ knowledge about some travel related infectious
diseases and their respective vaccines as well as addressing barriers to optimal
vaccine uptake.
Publication #6, a retrospective data analysis, provides evidence suggestive of clinical
protection in infants as a result of positive interaction between DTP vaccine and
pneumococcal conjugate vaccine (PCV).
Publications #7-9, present the results of two one-year randomised controlled trials
(RCTs) designed specifically to examine the sequential and concurrent interaction of
Tdap upon two conjugate vaccines (the 13-valent PCV [PCV13] and the quadrivalent
meningococcal conjugate vaccine [MCV4]) in adult Hajj pilgrims.
Results
The survey (Publication #3) demonstrated that the uptake of pneumococcal vaccine
among Hajj pilgrims in the years 2011, 2012 and 2013 was suboptimal (28.5%, 28.7%
and 14.2% respectively). Publication #4 showed that there were several
misconceptions surrounding the vaccines and their respective infections. Moreover,
immunisation providers were focusing more on classic vaccines against food-borne
infections than on vaccines against respiratory infections, even though the latter are
more common in Hajj settings (Publication #5).
In regard to the conjugate vaccine interactions, the literature review (Publication #1)
provided some evidence for positive interaction between DTP vaccine and PCV and
Hib conjugate vaccines, especially in infants and young children, which was further
supported by my retrospective data analysis in Australian infants (Publication #6).
This interaction could be attributed to an immunological phenomenon known as
‘carrier priming’ which leads immunogenicity enhancement of a conjugate vaccine
after prior exposure to DTP vaccine or one of its components. However, the
literature review (Publication #1) findings were different and variable for adults.
My detailed investigation through two RCTs involving adult travellers (Publications
#7-9) showed that upon prior exposure to Tdap vaccine, there was a suppression in
the immunogenicity of two subsequently administered conjugate vaccines (PCV13
and MCV4), irrespective of their carrier protein type: The first trial conducted in the
year 2014 demonstrated that prior administration of Tdap vaccine significantly (p <
0.05) suppressed the subsequent geometric mean concentrations (GMTs) to six (3, 5,
18C, 4, 19A and 9V) of the 13 pneumococcal serotypes in PCV13 (Publication #7). The
subsequent trial in 2015, showed that administering Tdap vaccine 3-4 weeks before
the coadministration of (PCV13 and MCV4) significantly (p < 0.05) suppressed the
GMTs to seven (1, 3, 4, 5, 14, 18C and 9V) of the 13 pneumococcal serotypes in
PCV13, and significantly (p < 0.05) reduced the proportion of subjects achieving a ≥4-
fold rise in serum bactericidal antibody (SBA) for serogroup W in MCV4 (Publications
#8 and 9).
A reverse effect was noted upon administering the conjugate vaccine before Tdap
vaccine (Publications #7 and 8), enhancing the anti-diphtheria and anti-tetanus
antibody response.
No serious adverse events were reported either in concurrent or sequential
administration of the trials’ vaccines.
Conclusion
Across all the publications’ analyses, the review article (Publication #1) and the
retrospective data analysis in Australian infants (Publication #6) showed a promising
role for carrier priming in children in enhancing the immunogenicity of the conjugate
vaccines and reducing their costs, particularly for PCV (the most expensive conjugate
vaccine).
 On the other hand, the trials in adults (Publications #7-9) demonstrated that  there
was suppression of PCV13 and MCV4 immune response in adults upon prior 
exposure to Tdap vaccine.
In infants, there is a promising role for carrier priming. However, in adults when 
multiple vaccines are required, administering the conjugate vaccine with, or before 
Tdap vaccine might avoid interference to the conjugate vaccine immunogenicity, and 
could yield a better immune response to Tdap.
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This chapter briefly introduces the reader to the history of vaccines and how it
developed over centuries to several types including conjugate vaccines, which rely
on carrier proteins to elicit a better immune response. The chapter then explains
major issues with the conjugate vaccine, their high cost and potential to interact
with other vaccines with similar component such as diphtheria, tetanus and pertussis
vaccine (DTP). Finally, I present my aims in this thesis: investigate the best approach
of administering the vaccines with avoidance of any interference and assessing
vaccine uptake and factors affecting it.
1.1 History of vaccines
The invention of vaccination was one of the greatest contributions of modern
medicine for humanity (1). Vaccines currently save an estimated three million lives
per year, marking them as one of most powerful and cost-effective prophylactic
measure to protect against deadly diseases (1). A major advance occurred in the
early 1700s, when lady Mary Wortley Montagu, the wife of the British Ambassador
to Turkey, observed variolation against smallpox by Turkish women. She described
the practice of inoculating healthy children with a weakened strain of smallpox to
confer immunity from the more virulent strains of the disease. She had the
procedure administered to her two children, who recovered quickly. She brought her
experiment back to England, where the inoculation was trialled on condemned
criminals and expanded later to include other English people including the royal
family. Although some people did die as a result of variolation, the overall effect was
that the death rate from smallpox declined (2). After more than 90 years later, the
world’s first vaccine was reported in the 8-year-old boy, James Phipps, who was
inoculated in 1796 by Dr Edward Jenner with a cowpox lesion from a milkmaid’s
hand. Six weeks later Jenner variolated two sites on Phipps’s arm with smallpox; the
boy was unaffected by this as well as subsequent exposures (3). The publication of
this finding entitled ‘Inquiry into the Causes and Effects of the Variolae Vaccine’ laid
the foundation for modern ‘Vaccinology’.
In the year 1885 rabies vaccine was developed by Louis Pasteur and subsequent
variety of vaccines were developed and used for the prevention of disease against a
variety of bacterial, viral and parasitic diseases (Table 1). Today, vaccine is defined as
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a suspension of live (usually attenuated) or inactivated microorganisms, e.g. bacteria
or viruses or fractions thereof, administered to induce immunity and prevent
infectious diseases or its sequelae (1).
Table 1) Outline of the development of human vaccines
Live attenuated Killed whole organisms Purified proteins or
polysaccharide
Genetically
engineer
18th century · Smallpox 1798
19th century · Rabies 1885 · Typhoid 1896
· Cholera 1896
· Plague 1897
Early 20th
century
· Bacille Calmette-Guerin
1927 (tuberculosis)
· Pertussis 1926
(whole cell)
· Diphtheria 1923
· Yellow fever 1935 · Influenza 1936 · Tetanus 1927
· Rickettsia 1938
Post-World
War II
(cell culture)
· Polio (oral) · Polio (injected) · Pneumococcus · Hepatitis B
recombinant
· Measles · Rabies (new) · Meningococcus
· Mumps · Japanese B encephalitis · Haemophilus
influenzae (PRP)
· Rubella · Hepatitis A · Hepatitis B
(plasma-derived)
· Adenovirus · Tickborn encephalitis · H. influenzae PRP
protein
(conjugate)
· Typhoid (Salmonella) · Typhoid (Vi)
· Varicella · Acellular pertussis
Adapted from (Plotkin, 2002) (4)
1.2 History and development of the conjugate vaccines
One of the recently developed types of vaccines are the conjugate vaccines. They are
a special type of subunit vaccine. Conjugate vaccines, comprising a conjugate
between an antigenic protein and a polysaccharide, have been developed against a
variety of bacterial species, such as S. pneumoniae, Neisseria meningitidis and
Haemophilus influenzae type b (Hib) (5). They are considered as a new generation of
the plain polysaccharide vaccines. The latter were initially introduced in the late
1960s and utilise polysaccharide antigens which are large molecules present in the
cell wall of the encapsulated bacteria. (6). These polysaccharide vaccines are
considered T-cell-independent, because their antigens cannot be processed and
bound to major histocompatibility complex class II (MHC II) molecules for
presentation to T-helper cells, instead, they interact directly with B cells, and
stimulate immediate B-cell responses by cross-linking the B-cell receptors (5). This
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results in B-cell differentiation to plasma cells and the production of antibodies. The
process does not lead to an expansion of serotype-specific B cells, or to the creation
of serotype-specific memory B cells. Therefore, the polysaccharide vaccines have a
limited antibody response and are not able to induce immunologic memory (1).
Moreover, the production of capsular polysaccharide specific antibodies is absent or
limited in young infants. This is because their spleen marginal zone is not fully
formed until the age of 1−2 years and complement and numbers of CD21-expressing
marginal zone B cells are very low at birth, (7). However, it was found afterwards
that when the polysaccharide antigen is conjugated to a carrier protein, it had the
ability to elicit a T-cell-dependent response. The polysaccharide antigens bind to
specific naive B cells along with the carrier protein, which are also processed within
the B-cell. The peptides produced are presented to carrier-peptide-specific helper T
cells via MHC class II molecules. The helper T cells are themselves primed to the
peptides through interaction with antigen-presenting cells (APC) that have also
processed the carrier protein (8). The resulted immune response is better with a
greater functionality and specificity due to the helper T-cell process. Memory B cells
are also produced, which enables the provocation of anamnestic response after a
subsequent dose of the vaccine or enables a booster response upon exposure to the
antigen during natural infection (9). The transformation of T-cell independent
polysaccharide vaccine to T cell-dependent vaccine makes the conjugate vaccines
much more immunogenic even in infants, who naturally have an immature immune
system. The conjugate vaccines were shown to have the ability to produce
antibodies with high avidity, establish immunologic memory, and create a herd
immunity effect. The crucial role of T cells in mucosal immunity plays a role in
explaining the dramatic effect of conjugate vaccines also in the reduction of
nasopharyngeal colonisation (5).
1.2.1 Haemophilus influenzae type b (Hib) conjugate vaccine
The first conjugate vaccines to be developed were against Hib disease. In 1980 the
research group at the Center for Biologics Evaluation and Research described
conjugates of Hib polysaccharides to diphtheria toxoid (DT) and tetanus toxoid (TT)
proteins that enhanced the antibody response in animal models (10). The first Hib
4
glycoconjugate vaccine for human was licensed in the USA in 1987 and shortly
thereafter was introduced into the Australian infant immunisation schedule in 1993
(1). The world health organization (WHO) recommends Hib vaccine introduction in
all countries, even where disease burden is unclear (11). It is currently on the WHO's
List of ‘Essential Medicines’ as one of the most effective and safe medicines needed
in a health system (12). Four types of Hib conjugate vaccine have been licensed for
use, each conjugated with a different carrier protein: diphtheria toxoid polyribosyl-
ribitol phosphate conjugated Hib vaccine (PRP-DT), outer membrane protein of
Neisseria meningitidis conjugated Hib vaccine (PRP-OMP), cross reacting material of
diphtheria toxin with amino acid 197 substitution (CRM197) conjugated Hib vaccine
(PRP-CRM197) and tetanus toxoid conjugated Hib vaccine (PRP-TT) (11).
1.2.2 Meningococcal conjugate vaccine
The introduction of polysaccharide vaccines against disease caused by meningococci
with group A, C, W and Y capsules was in1970s, most commonly in military recruits
(13, 14). The first licensed meningococcal C conjugate vaccine (MenCV) was in the
United Kingdom in 1999 (15). Two quadrivalent conjugated meningococcal vaccines
MenACWY-DT (MenactraTM) and MenACWY-CRM197 (MenveoTM) using DT and
CRM197 respectively as carrier proteins have been licensed in the US in 2005. They
induced higher levels of serum bactericidal antibody (SBA) titers and provided long-
lasting protection (16).  Recently, a quadrivalent meningococcal vaccine conjugated
to TT (MenACWY-TT; NimenrixTM) has been approved for use in Europe in 2012 (6).
In Australia, MenCV was introduced to the National Immunisation Program (NIP) in
2003 whereas the quadrivalent meningococcal vaccine (MCV4) is available in the
private market (17).
1.2.3 Pneumococcal conjugate vaccine
The first tetravaleinnt pneumococcal polysaccharide vaccine (PPSV4) was used in
1945. In 1970s, Robert Austrian championed the manufacture and distribution of a
14-valent PPSV which evolved in 1983 to the 23-valent formulation (PPSV23) (18).
Pneumococcal conjugate vaccine (PCV) was first licensed in 2000 as a formulation
that provided protection against seven of the most common pneumococcal
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serotypes (4, 6B, 9V, 14, 18C, 19Fand 23F). At the time of the introduction, these
seven types were responsible for 80–90% of the invasive pneumococcal diseases
(IPDs) among children less than 5 years in the US and Western Europe (19). In 2006,
WHO recommended including PCV into all routine immunisation programs,
especially in countries with high pneumococcal disease burden.
The introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) vaccination
in the infant vaccination schedule did not only substantially reduce IPD cases in
vaccine recipients but it also reduced it among unvaccinated population through
herd effects. Since 2010, two improved PCVs were introduced in the market. These
vaccines covered the seven serotypes included in the PCV7, and additional serotypes
responsible for an increasing proportion of IPD. The 10-valent pneumococcal
conjugate vaccine (PCV10) (“SynflorixTM”, GSK) included additional antigens from
serotypes 1,5 and 7F and the 13-vale pneumococcal conjugate vaccine (PCV13)
(“Prevnar13TM”, Pfizer) included antigens from serotypes 1, 3, 5, 6A, 7F and 19A (20).
The introduction of universal PCV13 immunisation, lead to significant reduction even
in the rates of bacteraemia in previously healthy children 3 to 36 months old (21).
There are currently several other additional serotypes under development for 15-
valent pneumococcal conjugate vaccine (PCV15); however, scientists claim that
there are some limits to the antigen numbers that can practicably be included (22).
1.2.4 The carrier proteins
The carrier protein is defined as the protein to which the saccharide is covalently
linked to for the purpose of eliciting a T-cell-dependent immune response to the
polysaccharide antigen (23). The structure (and immunogenicity) of the conjugate
vaccine depends heavily on the amounts of the antigen, the protein carrier, and the
conjugation chemistry employed. To date, five carrier proteins have been used in
licensed conjugate vaccines: H. influenzae protein D (HiD), the outer membrane
protein complex of serogroup B meningococcus (OMPC), TT, CRM197 and DT. DT is
derived from formaldehyde treatment of diphtheria toxin whereas CRM197 contains
a point mutation in fragment A, which alters the active domain and leads to loss of
enzymatic activity and its toxic properties (24). The structural characteristics of
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CRM197 are maintained, since formaldehyde detoxification is not needed during the
CRM197 manufacturing process (25). Although CRM197 and DT are serologically
related, they have different immunogenic properties when they are used as carrier
proteins. While some may argue that as a free protein, CRM197 is less immunogenic
than DT (26). Others claim that since CRM197 is not treated with formaldehyde, the
T-helper epitopes are better preserved resulting in a better carrier effect of CRM197
versus DT (27).
1.3 Vulnerable populations and the requirement of multiple vaccinations (What
this thesis addresses)
Infants pose a special risk group because they are highly vulnerable to infections.
This is attributed to their immunological naivety in addition to their structural
immaturity due to the fragility of integument and mucosae (22). Early stage
protection is critical for infants and the immunisation in the first year is especially
crucial. Hence, to protect them against many fatal infections during infancy, it is
essential that infants receive all recommended vaccines at the right time. Some
vaccines require multiple doses to achieve full protection and every child thus, must
complete a particular immunisation schedule (28). Despite a substantial vaccination
effort over the past years, nearly one in five deaths in children younger than 5 years
is still caused by a vaccine preventable disease (29). There are several factors that
hinder the proper usage and implementation of the conjugate vaccines worldwide,
particularly with PCV, cost is one of them.
In addition to infants as a vulnerable population, this thesis also addresses the needs
of another vulnerable category, Hajj pilgrims.
Hajj is the largest annual mass gathering on the planet. The World Health
Organization (WHO) defines “mass gatherings” as events attended by a sufficient
number of people to potentially strain the planning and response resources of the
community, city or nation hosting the event (30). Each year, 2-3 million Muslims
gather from all over the globe to visit Mecca, Saudi Arabia to perform the fifth tenet
in Islam, Hajj. Every physically, mentally and financially able Muslim is obliged by
their faith to perform Hajj at least once in a lifetime. The Hajj rituals should be
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performed on specific days in the last month of the lunar calendar (Islamic calendar)
which is called Dhul-Hijjah (31). What makes Hajj unique is being the most
geographically, ethnically, and culturally diverse mass gathering in the world. In the
near future, once the ongoing expansion work of the Great Mosque in Mecca is
complete, the number of pilgrims attending Hajj is expected to be more than double,
and the Saudi Vision 2030 specifically focusses on improving the quality of the
services offered to Umrah (minor pilgrimage) visitors, which would make it possible
for over 15 million Muslims per year to perform Umrah pilgrimage (32). In Australia,
Muslims are the fourth largest religious group (33) and every year about 4,500
Australian Muslims perform Hajj.
The fundamental rites of Hajj last for just five to six days, beginning on the eighth
day of the month of Dhul-Hijjah. However, many pilgrims stay for over a month to
visit the holy sites. A major part of the journey involves staying inside large tents in
the valley of Mina. This phase lasts for three to four nights. The valley contains
thousands of tents and each large tent can accommodate as many as 100 pilgrims
(34). Additionally, the pilgrims are required to perform the ritual of seven
circumambulations around the Kaaba in the holy mosque and repeat this about
three-four times during Hajj period.
Because of the shared accommodation, compromised hygiene, extreme crowding at
the holy mosque and inside the tents, and the prolonged contact, respiratory
infections can spread very easily from one person to another. Respiratory illnesses
can also spread easily during circumambulation with prolonged close contact in a
semi-closed environment (35).
Recently, respiratory tract infections (RTIs), including influenza and pneumonia, have
been identified as the leading health risks at the Hajj (36, 37). Pneumonia was the
leading cause of hospital admission during Hajj and also an important cause of
admission to the intensive care units (ICUs) at Hajj time (38). Streptococcus
pneumoniae (S. pneumoniae) was isolated from 4.8% and 12.3% of symptomatic
pilgrims during the Hajj 1991 and 1992 respectively  (39).  In the year 1994, S.
pneumoniae was detected in 9.4% pneumonia cases of pilgrims admitted to Mecca
hospitals (40). S. pneumoniae accounted for 19% (12/64) of bacteriological isolates
from patients admitted to ICU with sepsis during the Hajj 2004 (38). Community-
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acquired pneumonia (CAP) was responsible for 39% of total hospital admissions in
2002 (41) , 20% of admissions in 2003 (42), and 27% of ICU admissions in 2009–2010
(43). Microbiological analysis identifies S. pneumoniae to be a common cause for
CAP (38, 44), severe sepsis and septic shock among Hajj pilgrims (38).
In contrast, among Australian adults, the pneumococcal pneumonia hospitalisation
incidence was 274 per 100,000 population in 2011–2012. From 2004 to 2012, a
mean of 2,235 pneumonia hospitalisation deaths were recorded, corresponding to a
case fatality rate of 6.1%. The healthcare and economic burden of pneumococcal
disease in adults aged ≥65 years in Australia is substantial, with the incidence of
pneumococcal pneumonia hospitalisation nearly 15-fold higher than for IPD (45).
Statistics point out that a considerable proportion of Hajj pilgrims suffer from pre-
existing medical conditions which make them vulnerable to various infectious
diseases for which several vaccines are required (46), in addition to standard
meningococcal vaccine required for the visa (47).  The Hajj vaccines could be
administered concurrently or sequentially depending on the choice of the provider
and/or the preference of the pilgrim.
1.3.1 The issue with concurrent and/or sequential vaccine administration
The first concern with receiving multiple vaccines, such as the conjugate ones, is
their ability to interact/interfere with each other and with other vaccine containing
similar components such as DTP vaccine. An appropriate immunisation schedule
must aim to maximise public health impact while minimising costs, and also be
programmatically feasible. Coadministration of multiple vaccination greatly simplify
immunisation schedules and provide increased ease of administration in addition to
greater comfort as well as convenience to the patient by reducing the number of
injections required and possibly the number of attendances (48). However, the
receipt of multiple vaccinations raises several concerns, such as the augmentation of
adverse events (AEs), the lack of compliance and most importantly the potential
interaction among the administered vaccines (28).
As new vaccines are added to routine vaccination schedules, there is increasing
concern about potential interactions that may reduce the desired protective effects.
Antigen competition may play a role in reducing vaccine efficacy; this role will need
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to be evaluated with each new product (49). The interaction of co-administered
vaccines can result in either impairment or enhancement of the immune response to
any of the vaccine antigens. The mechanisms of these interactions are poorly
understood, difficult to predict and may be the result of variable immunological
phenomena such as carrier specific T-helper cell interactions, T-cell bystander
interferences or carrier induced epitopic suppression (CIES) (50). Hib vaccine,
MenCV, and PCV are all vulnerable to reduced antibody response as a result of
carrier protein overload in combination vaccines or when given concomitantly (51).
1.3.2 Cost of the conjugate vaccines and the struggle in their implementation
The second concern with receiving multiple vaccines is the cost. For instance, there
are now globally an estimated 14.5 million episodes of serious pneumococcal disease
(including pneumonia, meningitis, and sepsis) that occur each year in children aged
<5 years, resulting in approximately 500,000 deaths, almost all of which occur in low-
and middle-income countries (52). Low- and middle-income countries lag behind
high-income countries because they cannot afford the cost of some expensive
conjugate vaccines. Some models suggest that the inclusion of just one dose of
PCV13 to a country like the USA would cost $16 million per annum (53), let alone the
fact that infants may need 3-4 doses to gain full protection. Middle-income countries
need to weigh vaccine procurement and operational costs against costs of other
health priorities (52).
1.4 Aim and structure of this thesis
1.4.1 Aim
The general aim of this PhD project is to find ways to better protect vulnerable
populations (infants and Hajj travellers) especially in terms of understanding the
interaction between conjugate vaccines and DTP/Tdap. This exercise could lead to a
novel approach to help reduce the cost of conjugate vaccines in infants (and may be
adults) by implementing the carrier priming approach.
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While current literature focuses on concurrent vaccine coadministration, this thesis
predominantly focuses on the benefits (or harms) of sequential conjugate vaccine
administration in enhancing (or suppressing) the immunogenicity of conjugate
vaccines. The primary objective is to find a positive interaction, such as carrier
priming, that could be used to reduce the number of required conjugate doses; or
find evidence of negative interaction (immune interference) to avoid it. However,
while this thesis primarily focuses on the aspect of conjugate vaccine interactions to
optimise the immunity of vulnerable populations, I also took the opportunity to
explore other relevant aspects such as the uptake of the vaccines and the barriers to
optimum uptake in addition to pilgrims’ knowledge concerning respiratory
infections.
1.4.2 Structure of the thesis
This thesis is presented as a combination of nine published papers as shown in
Diagram 1.
1.4.2.1 Introduction
· Publication#1:
Entitled: “Carrier priming or suppression: Understanding carrier priming
enhancement of anti-polysaccharide antibody response to conjugate
vaccines”; this paper represents a review of the literature and summarises
current findings with regard to conjugate vaccine interactions with other
vaccines containing similar antigens such as DTP/Tdap vaccine.
· Publication#2:
Entitled: “Carrier priming to improve pneumococcal disease control and
reduce the international program’s cost in children”; this was a subsequent
commentary that builds on the review article’s findings and presents
additional updated references in the field of conjugate vaccine interaction
and elaborates on the implication of the finding in vulnerable populations
such as infants in developing countries.
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1.4.2.2 Results
1.4.2.2.1 Section A: Publications assessing vaccine uptake and factors influencing it
· Publication #3:
Entitled: “Pneumococcal Vaccine Uptake Among Australian Hajj Pilgrims in
2011-13”; this paper presents the findings of a survey that explores the
pneumococcal vaccine uptake among vulnerable population (Hajj travellers)
during three consecutive years (2011-2013).
· Publication #4:
Entitled: “Australian Hajj pilgrims’ knowledge about MERS-CoV and other
respiratory infections”; this was a published letter to the editors assessing
Hajj travellers’ knowledge, attitude and practice (KAP) towards respiratory
infections and their respective vaccines. This paper focuses predominantly on
infections and vaccines related to this thesis. i.e pneumococcal,
meningococcal and whooping cough diseases; additionally, it explores the
pilgrims’ understanding about MERS-CoV in the year 2014 because at that
time it was one of the major public health concerns among Hajj pilgrims.
· Publication #5:
Entitled: “Barriers of vaccinations against serious bacterial infections among
Australian Hajj Pilgrims”; when I found that the uptake of the pneumococcal
vaccine was low, I conducted and published this survey that addresses the
barriers against the optimum vaccine uptake in Hajj pilgrims.
1.4.2.2.2 Section B: Publications assessing conjugate vaccine interactions
· Publication #6:
Entitled: “Potential carrier priming effect in Australian infants after 7-valent
pneumococcal conjugate vaccine introduction”; I started exploring conjugate
vaccine interaction in the infants’ age group by this paper. The paper was a
retrospective data analysis that provides suggestive evidence of clinical
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protection in a vulnerable population (Australian infants) as a result of carrier
priming, which occurs to conjugate vaccine after exposure to DTP vaccine.
· Publication #7:
Entitled: “Effect of Tdap when administered before, with or after the 13-
valent pneumococcal conjugate vaccine (coadministered with the
quadrivalent meningococcal conjugate vaccine) in adults: A randomised
controlled trial”. After infants, I embarked on examining conjugate vaccine
interactions in adults; this paper was an RCT that presents the effect of Tdap
(BoostrixTM) vaccine on PCV13 (Prevnar13TM) and conducted in the year 2014.
· Publication #8 and #9:
Entitled: “Effect of Tdap upon antibody response to meningococcal
polysaccharide when administered before, with or after the quadrivalent
meningococcal TT-conjugate vaccine (coadministered with the13-valent
pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: a
randomised controlled trial” and “Effect of Tdap upon antibody response to
meningococcal polysaccharide when administered before, with or after the
quadrivalent meningococcal TT-conjugate vaccine (coadministered with
the13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj
pilgrims: a randomised controlled trial”. These two publications present the
outcome of the RCT conducted in the year 2015; they respectively report the
effect of Tdap (BoostrixTM) vaccine on MCV4 (NimenrixTM) and the effect of
Tdap (BoostrixTM) vaccine on PCV13 (Prevnar13TM).
Each publication contains its own methods, discussion and reference list, therefore
detailed methodologies will not be displayed separately from the papers. However,
an overarching discussion interpreting the main findings will be integrated at the end
of the thesis.
Appendices and supplementary material related to the publications are presented at
the end of this thesis.
13
Commentary about carrier priming and its implementation in young children
Diagram 1.  Flow chart demonstrating the flow of this thesis
I. Introduction Review article about interactions; carrier priming and suppression
#1
#2
14
 Assessing the uptake of pneumococcal vaccine among Hajj travellers
Assessing knowledge about respiratory infections and barriers to vaccine uptake in pilgrims
II. Results: Section A: Assessing vaccine uptake and factors influencing it
#3
#4 #5
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Assessing interaction by clinical protection: Retrospective data analysis examining carrier priming in Australian infants
Assessing interaction by immunogenicity: Three papers from two RCTs in Australian pilgrims examining the conjugate vaccines interactions
II. Results: Section B:  Assessing conjugate vaccine interactions
#7 #8 #9
#6
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Introduction:  With  the availability  of  newer  conjugate  vaccines,  immunization  schedules  have  become
increasingly  complex  due  to the  potential  for unpredictable  immunologic  interference  such as  ‘carrier
priming’  and  ‘carrier  induced  epitopic  suppression’.  Carrier  priming  refers  to an  augmented  antibody
response  to  a carbohydrate  portion  of a glycoconjugate  vaccine  in  an  individual  previously  primed with
the  carrier  protein.  This  review  aims  to provide  a  critical  evaluation  of  the  available  data  on  carrier  priming
(and  suppression)  and  conceptualize  ways  by which  this phenomenon  can  be  utilized  to  strengthen
vaccination  schedules.
Methods: We  conducted  this  literature  review  by searching  well-known  databases  to  date  to  identify
relevant  studies,  then  extracted  and  synthesized  the data  on carrier  priming  of  widely  used conju-
gate  polysaccharide  vaccines,  such  as, pneumococcal  conjugate  vaccine  (PCV),  meningococcal  conjugate
vaccine  (MenCV)  and  Haemophilus  inﬂuenzae  type  b conjugate  vaccines  (HibV).
Results: We  found  evidence  of  carrier  priming  with  some  conjugate  vaccines,  particularly  HibV and PCV,
in  both  animal  and  human  models  but  controversy  surrounds  MenCV.  This  has  implications  for  the
immunogenicity  of conjugate  polysaccharide  vaccines  following  the  administration  of tetanus-toxoid
or  diphtheria-toxoid  containing  vaccine  (such  as  DTP).
Conclusion: Available  evidence  supports  a promising  role  for carrier  priming  in terms  of maximizing  the
immunogenicity  of  conjugate  vaccines  and  enhancing  immunization  schedule  by  making  it more  efﬁcient
and  cost  effective.
©  2014  Elsevier  Ltd. All rights  reserved.
1. Introduction
Conjugate vaccines are one of the greatest triumphs in mod-
ern medicine. Since their introduction into routine vaccination
schedules they have had a tremendous impact in reducing the bur-
den of childhood disease and mortality from the polysaccharide
∗ Corresponding author at: National Centre for Immunisation Research and
Surveillance  of Infectious Diseases (NCIRS), The Children’s Hospital at Westmead,
Cnr  Hawkesbury Road and Hainsworth Street, Locked Bag 4001,Westmead, NSW
2145, Australia. Tel.: +61 43 575 2969; fax: +61 298451418.
E-mail addresses: Mohamed.tashani@health.nsw.gov.au,
toshani2003@gmail.com (M. Tashani).
1 These authors have made equal contributions.
encapsulated bacteria; Haemophilus inﬂuenzae type b (Hib), Neisse-
ria meningitidis serogroup C and Streptococcus pneumoniae [1–3]. In
children under the age of two years, capsular polysaccharide (CPS)
antigens are believed to elicit a T-independent immune response,
characterized by lack of memory and poor immunogenicity [4].
Efforts to overcome the poor immunogenicity of CPS have led to
the development of conjugate vaccines. Studies have shown that by
conjugating CPS to proteins, both T and B cell arms of the immune
system are activated such that a vigorous antibody response and
immunological memory is achieved [5,6].
A paper by Avci et al. [7] in Nature Medicine has shed light on
the molecular mechanisms of conjugate vaccines. The model pro-
poses a role of the carrier peptide, where it acts to anchor the
polysaccharide to the B cell Major Histocompatibility Complex II
0264-410X/$ – see front matter © 2014 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.vaccine.2014.01.047
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Fig. 1. Proposed molecular mechanisms for conjugate vaccines. A novel mechanism proposes that peptide from carrier acts to anchor the sugar epitope to the MHC  and
allows  presentation of the sugar epitope to polysaccharide speciﬁc T cell. Necessary signals are then produced for B cell activation, maturation and production of speciﬁc
antibodies against the polysaccharide moiety of the target bacteria [7].
(MHC-II), allowing for the presentation of the carbohydrate moi-
ety to the T cell. This suggests that that some T cell receptors
(TCR) have the speciﬁcity to recognize the saccharide portion of
the peptide–polysaccharide conjugate, which is presented to it by
MHC-II. The recognition allows development of the saccharide-
speciﬁc T cell memory, which is independent of the peptide portion
of the conjugate carrier (Fig. 1).
Carrier priming refers to the improved antibody response to a
carbohydrate portion of a glycoconjugate vaccine when an indi-
vidual has been previously primed with the carrier protein as
compared to those that have not. There are three commonly used
carrier proteins in the conjugate vaccine industry: tetanus toxoid
(TT), diphtheria toxoid (DT) and cross reacting material of diphthe-
ria toxin with amino acid 197 substitution (CRM197) [8]. Since the
carrier protein is most likely to be TT or DT-like, carrier priming
may occur upon prior exposure to a TT or DT-containing vac-
cine such as diphtheria, tetanus and pertussis vaccine (DTP). It
is believed that priming with the carrier molecule enhances the
response to conjugate vaccines by increasing the number of carrier-
speciﬁc T lymphocytes, which can provide the necessary “help”
for the expansion and differentiation of polysaccharide speciﬁc B-
lymphocytes [9,10]. The increase in memory cells after priming
means that the acquired secondary response is faster and greater
[11]. In many settings, enhancement of the response is observed.
However, suppression may  occur, particularly when the conjugate
contains a low ratio of hapten to carrier [12,13]. There are two  prob-
lems associated with the use of carrier molecules. The ﬁrst problem
is related to the structure of the MHC  molecule; only one pep-
tide is allowed to bind in its heterodimeric groove which creates
a competitive setting [14]. The second problem is epitope-speciﬁc
suppression, which is an anti-carrier antibody induced by previ-
ous immunization with the carrier alone. Carrier induced epitopic
suppression (CIES) is the interference with the antibody response
to a hapten coupled to a carrier protein among recipients previ-
ously immunized with that speciﬁc carrier protein. The interference
is thought to arise from competition between peptides or cap-
sular polysaccharides bound to homologous carrier proteins for
a limited number of carrier speciﬁc primed helper T cells. As a
result, there will be an increase in the antibody response to the
carrier and a decrease in the response to conjugated peptides or
polysaccharides [15]. In this respect, an ideal carrier would be a
molecule that is unable to induce a signiﬁcant antibody response to
itself.
This  review summarizes the available data on carrier prim-
ing and epitopic suppression. The objectives of this paper are
to (a) consolidate the data related to carrier priming enhance-
ment in conjugated vaccines, (b) identify gaps in knowledge as
well as contradictory ﬁndings of carrier suppression in this area
research and (c) conceptualize ways by which this phenomenon
can be utilized to strengthen vaccination schedules, particularly in
resource-depleted sectors of the world.
2. Methods
A  review of contemporary literature was conducted to identify
relevant studies describing carrier priming leading to the enhanced
immunogenicity of related conjugate vaccines in animal studies,
human children and adults. Inclusion criteria for the inclusion of
scientiﬁc literature were immunological studies on carrier prim-
ing in animal and human models, molecular studies investigating
the mechanisms of conjugate vaccines and review articles on vac-
cine interactions. Searches were completed in Ovid MEDLINE from
(1928 to September 2013), Pub Med  (1928 to September 2013) and
Embase (1928 to September 2013) The Cochrane Library databases
– Cochrane Database of Systematic Reviews. Both database-speciﬁc
controlled vocabulary and general free text terms were used to
maximize retrieval. The primary controlled vocabulary terms used
were carrier priming, conjugate vaccine, H. inﬂuenza type b, N.
meningitidis serogroup C and S. pneumoniae. Hand searching of key
article reference lists was also used to locate additional relevant
articles. A copy of the search strategy used is available if required
upon application to authors.
3.  Results
3.1. Animal studies
Carrier  priming has been shown to enhance the immunogenic-
ity of conjugate vaccines in several trials in animals [16–22]. For
example, mice with pre-existing carrier immunity to (TT) had an
enhanced polysaccharide-speciﬁc antibody response when pneu-
mococcal conjugate vaccine (PCV) and meningococcal conjugate
vaccine (MenCV), utilizing TT carrier, were given (Table 1) [16]. A
dose-dependent relationship of the priming agent to the antibodies
produced against the polysaccharide molecule of the conjugate vac-
cine was also observed. The study showed that pre-immunization
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Table  1
Carrier priming in animal models.
Animal Interaction Immune response to
polysaccharide  antigen
of  the conjugate vaccine
Reference
Mice TT → PCV-TT ↑ [1]
TT → MenCV-TT ↑
Rabbits DT → HibV-CRM197 ↑ [2]
TT → HibV-TT ↑
→, Sequential administration; ↑, enhanced immune response; TT, tetanus tox-
oid; DT, diphtheria toxoid; PCV-TT, pneumococcal conjugate vaccine conjugated to
tetanus toxoid; MenCV-TT, meningococcal conjugate vaccine conjugated to tetanus
toxoid; HibV-CRM197, Haemophilus inﬂuenzae type b vaccine conjugated to cross-
reacting  material 197; HibV-TT, Haemophilus inﬂuenzae type b vaccine conjugated
to  tetanus toxoid.
with low doses of TT (0.025–0.25 g) enhanced the antibody
response to PCV-TT and MenCV-TT. However, high dose of prim-
ing with TT (25 g), had a suppressing effect [16]. Furthermore,
pre-clinical experiments have shown that rabbits primed with DT
enhanced the anti-polyribosyl ribitol phosphate (PRP) response
after one dose of H. inﬂuenzae type b vaccine conjugated to CRM197
(HibV-CRM197) as compared to those rabbits that were not primed
with DT [18]. Interestingly, CRM197 has shown ability to boost
immunity against diphtheria in mice and it is suggested to be a
promising vaccine candidate and potential alternative to conven-
tional DT vaccines, particularly as a boosting antigen [22].
3.2.  Human studies
3.2.1.  Studies involving children
3.2.1.1. HibV. Several studies have demonstrated that one dose of
HibV-TT may  be immunogenic if TT was given beforehand (Table 2)
[23–27]. Data from a randomized controlled trial (RCT) in human
infants suggest that there may  be a need for vaccination with DT
in order to maximize anti-PRP antibody responses to the HibV-
CRM197 [28]. In infants immunized with HibV-DT, a better immune
response was observed when the vaccine was administered one
month following their 1st routine immunization with the DTP
vaccine than when the two vaccines were given concomitantly
[29]. Kurikka et al. [30] showed that TT priming induced a greater
response to HibV capsular polysaccharide after the ﬁrst, second and
third dose of HibV-TT. Granoff et al. [23] demonstrated in their RCT
that priming infants at one month of age with DT and TT led to an
improved antibody response to PRP in their respective conjugate
vaccines; a two to three fold higher geometric mean concentra-
tion (GMC) of anti-PRP antibody was reported after two or three
doses as compared to the control group. Parke et al. [24] found
that the immunogenicity of the HibV-TT in infants vaccinated at
3, 5 and 7 months of age preceded by DTP vaccination at 2, 4 and
6 months of age was higher in more than one-third of the chil-
dren aged 3 months. In contrast, a lower anti-PRP antibody was
observed in infants who were simultaneously vaccinated with DTP
and HibV-TT [24]. A Venezuelan study showed that infants immu-
nized with HibV-TT at 2, 4 and 6 months preceded 1 week earlier
by DTP vaccination, had an exceptionally higher anti-PRP antibody,
while a study in Nashville, USA had a comparatively lower immune
response when infants received concomitant HibV-TT and DTP
immunisations (but genetic and environmental differences were
not controlled for) [27,31]. A RCT comparing a two-dose priming
schedule of HibV-TT administered at 4 and 6 months of age with
the regular three-dose schedule given at 2, 4 and 6 months of age
showed that the two-dose regime, with prior exposure to DTP,
elicited both higher anti-PRP antibody levels and a greater per-
centage of infants achieving protective levels of antibody against
PRP. The study is suggestive that DTP given at two  months of age
primed  for a better antibody response against PRP [32]. Anderson
and co-workers found that concomitant immunization of infants
with HibV-DT and DTP was  less efﬁcient in inducing PRP antibod-
ies than if the injection of the conjugate was  delayed for 1 month
after the routine vaccinations. However, this could be at least par-
tially related to the fact that the children were one month older at
the time of challenge [33,34]. In a RCT in Niger, infants given DTP  at
6 weeks of age followed by HibV-TT at 10 and 14 weeks had greater
anti-PRP antibody levels than infants given a three dose schedule
of concomitant HibV-TT with DTP at 6, 10 and 14 weeks of age. The
GMC  following the ﬁrst dose of HibV-TT administered at 10 weeks
of age was (2.40 g/ml), more than double and signiﬁcantly higher
than the GMC  of the 6 weeks dose of HibV-TT [35]. Although some
of the differences reported may  reﬂect improved immune response
in infants vaccinated at an older age, the more pronounced immune
response may  also reﬂect carrier priming with TT four weeks prior
to the administration of HibV-TT. Additional studies revealed that
infants primed with DTP at 1 month of age and then given DTP
plus HibV-TT at 2, 4 and 6 months of age had higher antibody
responses (GMC 11.5 g/ml) than infants who were not so primed
[36]. In Brazil, where DTP was  given at 2, 4 and 6 months of age, a
study showed that a truncated schedule of HibV-TT given at 3 and 5
months was  highly immunogenic. The GMC of PRP was remarkably
high at 6 months of age (27.42 g/ml). The excellent immunogenic-
ity was attributed to prior immunization with DTP [37]. A study
by Booy et al. [38] investigated the potential effects of prior vac-
cination with TT on the effectiveness of a single dose of HibV-TT
during the time when a HibV catch-up program was  initiated for
UK infants. Vaccine efﬁcacy was estimated by comparing rates of
Hib disease in those who had been vaccinated with rates predicted
by age adjustment of disease rate prior to the introduction of HibV-
TT to the UK vaccination schedule. The study demonstrated that
the effectiveness of HibV-TT appeared to be appreciably improved
when infants were primed with TT through the receipt of DTP
before the ﬁrst HibV-TT dose. Young infants aged 3–11 months, who
received their ﬁrst dose of HibV-TT after TT vaccination, appeared
to have high levels of protection from one week after their ﬁrst
dose of HibV-TT. Moreover, convalescent antibody levels against
PRP in infants who  developed invasive Hib disease, despite having
one dose of HibV-TT, were signiﬁcantly higher if greater TT priming
had occurred.
However, contrary to the above ﬁndings, Lieberman et al. [39] in
their RCT could not show an enhancement of the response to HibV-
TT when given with (hepatitis B, DTP, and oral polio vaccines) at
2, 4 and 6 months of age, after neonatal TT and DT priming. This
probably reﬂects immaturity of the neonatal immune system.
It  has been demonstrated that mothers immunized with TT had
infants who did not respond well to the ﬁrst dose of DTP  com-
pared to the infants of non-immunized mothers [40]. Booy et al.
[41] found that early immunization schedule of DTP resulted in a
signiﬁcantly lower immune response than a later one, which sug-
gest that with an accelerated schedule, maternal antibodies can
have an inhibitory effect on the responses to immunization against
tetanus and pertussis. However, the inhibitory effects of passively
acquired maternal TT antibodies on the antibody response to HibV-
TT was demonstrated in a RCT [42], such effects were not seen if
infants were primed with TT one month prior to immunization with
HibV-TT in other observational studies [25,43,44].
3.2.1.2. PCV. There are several RCTs comparing different immu-
nization schedules for PCV in infants in terms of timing and number
of doses. One RCT demonstrated that the responses to 7-valent PCV
(PCV7-CRM197) were consistent whether it was  given concurrently
or sequentially after diphtheria, tetanus and acellular pertussis vac-
cine (DTaP) [45]. Another RCT compared three primary doses of
PCV7-CRM197 at 2, 4 and 6 months against two doses at 4 and 6
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Table 2
Carrier priming in infants, children and adolescents.
Vaccine Age group Interaction Immune response to polysaccharide
antigen of the conjugate vaccine
Reference
HibV Infant DTP → HibV-TT ↑ [3–9]†
TT  → HibV-TT ↑ [10,11]*
DTP  → HibV-DT ↑ [12]
Passive maternally acquired TT → HibV-TT ↓ [13,14]†
Neonate TT → HibV-TT No difference [15]*
PCV  Infants DTwP → PCV11-DT ↑ [16]*
DTwP → PCV11-TT ↑
DTaP → PCV13- CRM197 ↑ [17]*
DTaP  → PCV7- CRM197 Variable according to serotype [18]*
DTaP  → PCV7- CRM197 No difference [19]*
MenCV Adolescents (11–18 years) Td → MenCV4-DT ↓ [20]*
Tdap  → MenCV4-DT No difference [21]*
Tdap  → MenCV4-CRM197 No difference [22]*
TT  → MenCV-TT ↓ [23]*
DT  → MenCV-CRM197 No difference
→,  sequential administration; ↑, enhanced immune response; ↓, suppressed immune response; *, randomized controlled trial; †,  Refs. [3–5,14] are randomized controlled
trials;  Td, tetanus and diphtheria toxoid adsorbed vaccine; TT, tetanus toxoid; DT, diphtheria toxoid; DTP, diphtheria, tetanus and pertussis vaccine; DTwP, diphtheria, tetanus
and  whole-cell pertussis vaccine; DTaP, diphtheria, tetanus and acellular pertussis vaccine; Tdap, combined tetanus, reduced diphtheria and acellular pertussis vaccine,
HibV,  Haemophilus inﬂuenzae type b conjugate vaccine; HibV-TT, Haemophilus inﬂuenzae type b vaccine conjugated to tetanus toxoid; HibV-DT, Haemophilus inﬂuenzae b
vaccine  conjugated to diphtheria toxoid; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate
vaccine;  PCV11, 11-valent pneumococcal conjugate vaccine; PCV-TT, pneumococcal conjugate vaccine conjugated to tetanus toxoid; PCV-DT, pneumococcal conjugate
vaccine conjugated to diphtheria toxoid; PCV-CRM197, pneumococcal conjugate vaccine conjugated to cross-reacting material 197; MenCV, meningococcal conjugate vaccine;
Men4CV, 4-valent meningococcal conjugate vaccine; MenCV-DT, meningococcal conjugate vaccine conjugated to diphtheria toxoid; MenCV-TT, meningococcal conjugate
vaccine conjugated to tetanus toxoid; MenCV-CRM197, Meningococcal conjugate vaccine conjugated to cross-reacting material 197.
months. After completion of primary series, those given just two
doses that were primed by a previous dose of DTaP, achieved similar
GMC for serotypes 4, 9V, and 19F but a signiﬁcantly lower pro-
portion of subjects with IgG concentrations (≥0.35 g/mL) against
serotypes 6B, 14, 18 C, and 23F in the primed arm [46]. Spijker-
man  et al. [47] in their RCT included a comparison group of infants
who received a 13-valent PCV (PCV13-CRM197) at 3 and 5 months
and primed by previous exposure to DTaP. This group was  com-
pared with three other groups where PCV13-CRM197 was  given at
2, 3 and 4 months; 2 and 4 months; and 2, 4 and 6 months; with-
out prior exposure to DTaP. One month after the primary series
they found that the 3–5 schedule group was superior to the 2–3–4
and 2–4 schedules for 5 and 11 serotypes respectively. The 3–5
schedule with only 2 primed doses via DTaP, was also similar to a
2–4–6 months schedule, with lower IgG levels only for serotypes
6A, 6B, and 23F. Consistently, in a trial conducted the Philippines,
a single dose of the 11-valent PCV (PCV11-DT) given at 18 weeks
of age elicited a similar concentration of functionally active anti-
bodies against pneumococcal serotypes, to that of the three-dose
schedule where PCV11-DT was given at 6, 10 and 14 weeks of age
concomitantly with diphtheria, tetanus and whole-cell pertussis
vaccine (DTwP). It was plausible that the highly immunogenic sin-
gle dose of PCV11-DT was  achieved in this study through carrier
priming with DT via three antecedent doses of DTwP [48].
3.2.1.3. MenCV. In a RCT involving UK preschool and schoolchil-
dren aged 1–17 years, it was found that the immunogenicity
of MenCV-TT was reduced by prior administration of tetanus
containing vaccine. However, antibody levels were still well
above the lower threshold for protection [49]. When the con-
current administration of 4-valent MenCV (MenCV4-DT) with
combined tetanus, reduced diphtheria and acellular pertussis vac-
cine (Tdap) was compared against consecutive administration
in adolescents, the results were controversial; one RCT study
reported non-inferiority and similar immune response in both
methods [50], while another RCT reported that the propor-
tion of participants with adequate immune response against the
MenCV4-DT was higher when MenCV4-DT vaccine was given con-
comitantly with tetanus and diphtheria toxoid adsorbed vaccine
(Td) than when given one month following Td [51]. Two RCTs
reported that when conjugated with CRM197, prior or simultane-
ous administration of a diphtheria-containing vaccine did not affect
the immune response to MenCV4-CRM197 [49,52]. Nevertheless,
administering MenCV-CRM197 has shown to enhance subsequent
diphtheria immunogenicity upon administering it before DTP
[53].
3.2.2. Studies involving adults
3.2.2.1. HibV. Barington et al. [54,55] documented that adults
immunized with HibV-DT had a high immune response that
correlated positively with pre-vaccination levels of anti-DT. Fur-
thermore, they reported a high level of carrier immunity that
was associated with early peaking of the PRP-speciﬁc antibodies
(Table 3). This however contrasts with the team’s another RCT
where pre-immunization with the relevant carrier protein reduced
the subsequent PRP antibody level. Surprisingly, Barington et al.
[56] found that pre-immunization with DT signiﬁcantly reduced
consequent response to the carrier portion of the other conjugate
(HibV-DT and then HibV-TT).
3.2.2.2. PCV. After administering PCV7-CRM197 to adults aged
50–80 year in a RCT study in the UK, one possible explanation
given for the observed higher antibody levels in males compared to
females, was  the greater priming effect in males who were found
in a previous serosurvey in the UK to have higher titers of diphthe-
ria antibodies [57]. This was consistent with Shelly and colleagues’
RCT, which found that adults with high anti-diphtheria antibody
level had a higher antibody level to polysaccharide antigens in the
PCV7-CRM197 after vaccination, than their counterparts who  had
a lower diphtheria antibody level. They hypothesized that indi-
viduals with a more recent exposure to diphtheria vaccine might
respond better to vaccines conjugated to CRM197. Interestingly,
immunization with PCV-CRM197 in this study resulted in a 2-fold
rise in antibody level to DT indicating that the priming effect may
work in both directions [58]. A similar ﬁnding was documented by
Olander et al. [59] when PCV11-DT/TT induced signiﬁcant booster
responses in both adults and toddlers to tetanus and diphtheria
carrier proteins. The routine diphtheria and tetanus vaccinations
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Table  3
Carrier priming in adults.
Vaccine Interaction Immune response to polysaccharide antigen of the conjugate vaccine Reference
HibV DT → HibV-DT ↑ [24]
TT  → HibV-TT ↓  [25]*
DT  → HibV-DT ↓
PCV  Pre-existing anti-diphtheria toxin antibodies → PCV7-CRM197 ↑ [26]*
Pre-existing  anti-diphtheria toxin antibodies → PCV5-CRM197 ↑ [27]*
Malaria  TT → Malaria-TT ↓ [28]
hCGV  TT → hCGV-TT ↑ [29]
→, Sequential administration; ↑, enhanced immune response; ↓, suppressed immune response; *, randomized controlled trial; HibV, Haemophilus inﬂuenzae type b conjugate
vaccine;  TT, tetanus toxoid; HibV-TT, Haemophilus inﬂuenzae type b vaccine conjugated to tetanus toxoid; DT, diphtheria toxoid; HibV-DT, Haemophilus inﬂuenzae type b vaccine
conjugated  to diphtheria toxoid; PCV, pneumococcal conjugate vaccine; PCV7-CRM197, 7-valent pneumococcal conjugate vaccine conjugated to cross-reacting material 197;
PCV5-CRM197, 5-valent pneumococcal conjugate vaccine conjugated to cross-reacting material 197; Malaria-TT = Malaria sporozoite peptide vaccine conjugated to Tetanus
toxoid; hCGV, human chorionic gonadotropin vaccine; hCGV-TT, human chorionic gonadotropin vaccine conjugated to tetanus toxoid.
had primed adults and children to respond to the carrier proteins
of the PCV11-DT/TT. It was clear that carrier proteins are capable
of both priming and boosting children and adults.
3.2.2.3. Other conjugate vaccines. We  found no study addressing
the carrier priming effect of MenCV in adults. However, in addition
to PCV and HibV, there were some other uncommonly used conju-
gate vaccines such as malaria and human chorionic gonadotropin
(hCG) vaccines, these have shown some controversial carrier prim-
ing effect among adults [60,61]. For example, prior vaccination with
tetanus and later receiving a vaccine consisting of malaria sporo-
zoite conjugated to tetanus showed suppression of the antimalaria
antibody. However, a trial in non-malarious areas and mostly naive
to TT showed a notable IgM response to the sporozoite antigen [60].
In a clinical trial evaluating the hCG-based birth-control vaccine
conjugated to TT, it was found that prior immunity to the carriers
did not result in epitopic suppression of anti-hCG responses; On the
contrary, there was an enhancement of anti-hCG antibodies upon
previous immunization with TT [61].
4. Discussion
In this review, we found evidence of carrier priming in HibV
and PCV in both animal and human models in different age groups.
However, MenCV data were inconclusive.
4.1. Evidence from animal studies
In animal models, studies on immune interference and immuno-
genicity of conjugate vaccines were complex and sometimes
conﬂicting [62]. In mice, priming with DT and TT enhanced succes-
sive immune response against the antigens of MenCV-TT/PCV-TT
[16]. It was suggested that the rapid increase in anti-hapten afﬁnity
in these mice was a result of pre-existence of anti-carrier antibod-
ies in serum that contributed to opsonisation and elimination of
the antigen [63]. However, high doses of carrier priming inhibited
a conjugate-induced anti-polysaccharide antibody response [16].
This was consistent in rabbits where suppression was reported in
experiments in which very large amounts of carrier were used for
priming and high anti-carrier antibody level was  achieved. Pas-
sive transfer of large amounts of anti-carrier antibody has been
shown to inhibit the response to a hapten–carrier conjugate [21].
The contradictory results in animals can perhaps be explained on
the basis that carrier-speciﬁc T helper cells remaining after the
priming injection increases anti-hapten response, whereas anti-
carrier antibody remaining after the priming injection can decrease
the anti-hapten response. If the helper cell effect dominates, the
net effect on the anti-hapten response is enhanced, whereas the
reverse may  be true if the antibody component dominates [64].
Therefore,  the ideal carrier would be a small sized carrier that
induces a higher antibody response to the hapten rather than
itself.
4.2. Evidence from human studies
4.2.1. Studies involving children
4.2.1.1. HibV. The immunological phenomenon of carrier priming
has been largely observed in HibV utilizing TT or DT carriers. Infants
who were exposed to TT or DT, followed by immunization with a
HibV-TT/DT, demonstrated a higher PRP antibody production upon
ﬁrst exposure to the vaccine and in subsequent boosters of the vac-
cines compared to infants who  were not primed. Immunogenicity
studies investigating the use of HibV in Brazil, Venezuela, Chile and
Niger have indicated that carrier priming with TT through adminis-
tration of DTP may  have enhanced subsequent immunogenicity of
HibV-TT. They have consistently shown that the concentration of
antibody produced against HibV was  signiﬁcantly higher in infants
primed with DTP [27,35,37,65]. Campagne et al. [35] highlighted
that two  dose schedules of PRP-T should be given serious consid-
eration, particularly if their reduced cost would be economically
advantageous in resource-stricken areas of the world. A reduction
in the number of doses required is likely to decrease the cost and
increase vaccination coverage [66]. However, an anecdotal ﬁnding
by Knufet al. [67] conversely demonstrated that a prior vaccina-
tion with pertussis acellular antigen (aP) in the neonatal period,
resulted in a subsequent reduction in seroprotection rates and anti-
body GMCs for HibV seven months after the three primary doses
of the infanrix hexa vaccine: DTaP with inactivated polio vaccine,
hepatitis B vaccine and HibV-TT (DTaP-IPV-HBV/HibV-TT). It was
hypothesized that the T-cells generated from the pertussis vaccine
superseded the T helper cells required for HibV-TT resulting in a
negative bystander effect.
In addition to carrier priming, there is another explanation for
the enhanced immunity in infants receiving consecutive admin-
istration compared to coadministration of HibV with DTP, that is
the children were one month older in the former group [33]. The
maturity of the immune system is another important factor that
should be considered as it has been shown that neonatal immu-
nization with the carrier proteins of the HibV did not result in
earlier or higher Hib antibody responses, which was attributed to
the immaturity of their immune system [39].
There has been only one study providing evidence that accel-
erated immunity via carrier priming reduces the incidence of the
disease which the conjugate vaccine targets. A study by Booy
et al. [38] investigated the efﬁcacy of HibV in the UK by com-
paring observed rates infants affected by Hib in those who have
been vaccinated with rates predicted by age adjustment of dis-
ease rates prior to the introduction of the vaccine. The effect of
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priming with TT through the receipt of DTP on disease inci-
dence was also investigated. The study showed that the efﬁcacy
of HibV-TT was demonstrably enhanced when TT was given prior
to HibV-TT. Infants aged 3–11 months, who received their ﬁrst dose
of PRP-T after DTP vaccination, appeared to have high levels of pro-
tection from one week after their ﬁrst dose of PRP-TT vaccine. The
demonstration that priming with TT leading to protection by HibV-
TT after just one dose, if conﬁrmed, may  inﬂuence the decision of
the carrier type, the timing and the order of immunization sched-
ules. This might allow the administration of fewer doses of vaccine
or smaller amounts of antigen resulting in substantial savings in
public health resources [27]. With respect to previously acquired
maternal antibodies, it was demonstrated that maternally acquired
TT antibodies present at the time of immunization with HibV-TT
suppressed the response to the polysaccharide part of HibV-TT in
a dose-dependent manner. This inhibition is B cell determinant-
speciﬁc, depends on the ratio between maternal antibody titers at
the time of immunization and the dose of vaccine antigen [68].
The  high levels of pre-existing maternal antibodies at the time
of vaccination bind to vaccine epitopes and mask them to infant B-
lymphocytes, thus reducing further immune responses. This effect
was not overcome by coadministration of TT but was overcome by
active priming with TT one month earlier [69].
Precise timing to introduce a vaccine is very important as con-
jugate vaccines are T-dependent antigens and can be effective from
the ﬁrst month [70]. Infants should be immunized early enough to
protect them at age of risk, yet if immunization is done too early,
maternal antibodies can interfere with the generation of active
immunity [43]. Therefore, these conﬂicting factors must be consid-
ered when national immunization plans are made. An ideal time to
start an immunization therefore would be the time when mater-
nal antibodies no longer inhibit the response, but have not yet
decreased below a protective level.
4.2.1.2. PCV. Various PCV immunization schedules have been
examined looking for the best result. Although these studies were
not primarily designed to detect a carrier priming effect, some
of them did have schedules with incidental pre-exposure to DTP
before the ﬁrst dose of PCV in their comparisons. One study showed
no evidence of improved immune response to PCV7 in those primed
by DTaP [45] whereas another showed some variable effect accord-
ing to the serotype [46]. However, a recent study by Spijkerman
et al. [47] with two-dose schedule of PCV13 at 3 and 5 months
primed with previous DTaP, proved to yield higher antibody con-
centrations for 5 serotypes compared to a three-dose schedule
at 2, 3 and 4 months, and higher antibody concentrations for 11
serotypes compared to a 2 and 4 months schedule. Nevertheless,
this might also be attributed to the fact that the 2, 3 and 4 months
schedule had a less appropriate interval between doses in addition
to the maturity of the 3 and 5 months schedule over the 2 and 5
months schedule. In the Philippines, one single dose PCV11 admin-
istrated to infants after DTwP reported similar antibody response
to three unprimed doses of PCV11. This ﬁnding is an important
one for countries with ﬁnancial constraints and high pneumococ-
cal disease burden [48]. The less-expensive alternative regimens
such as a 1- or 2-dose schedule of PCV could greatly beneﬁt chil-
dren in developing countries where the mortality and morbidity
from pneumococcal diseases remain high [71].
4.2.1.3. MenCV. In adolescents, MenCV4-DT coadministration with
Tdap was similar [50,52] or higher [51] in immunogenicity than
the sequential administration after Tdap. Further studies revealed
reduced immune response to MenCV-TT after the administration
of TT [49], this thought to be due to the expansion of carrier-
speciﬁc B cells (TT in this case) and subsequent intramolecular
antigenic competition between polysaccharide and tetanus
epitopes.  Increased amounts of carrier protein may  interfere with
immunologic priming with other conjugate vaccines [72]. Inter-
estingly, baseline diphtheria antibodies were signiﬁcantly higher
in children given four previous doses of MenCV-CRM197 indicating
that carrier priming can work in both directions [53].
4.2.2.  Studies involving adults
4.2.2.1. HibV. Carrier priming to HibV in adults demonstrated
some contradictory results by Barington et al. [54–56]. Two  stud-
ies showed that prior administration of DT enhanced immune
response to subsequent HibV-DT [55]. The investigators suggested
that carrier-speciﬁc antibodies correlated with the numbers of
carrier-speciﬁc helper T cells, which in turn increased the B cell
response against the polysaccharide component of the conjugate
vaccine [54]. In contrast, another study reported that the immu-
nization of human adults with HibV-TT previously immunized with
HibV-DT, or vice versa, did not elicit an additional increase in the
immune response to HibV [56]. The suppression was  non-epitope
speciﬁc as a result of reduced formation of anti-carrier antibodies
or by improved competition between carrier-speciﬁc and hapten-
speciﬁc B cells for the conjugate .The suppression is proposed to
be abrogated or even changed to enhancement if the amount of
carrier used for priming was  reduced to a level causing a low anti-
body response to the carrier [73]. Increasing the number of haptens
attached to the carrier molecule is also suggested to eliminate the
tendency to suppression [12].
4.2.2.2. PCV. With the scarcity of studies examining the carrier
priming effect in PCV in adults, there is evidence that the carrier
proteins are capable of both priming and boosting in adults as well
as children [59]. However, with considering that the inclusion of
pneumococcal serotypes in the conjugate vaccine is evolving from
11 to 13, and possibly 23 in the future, it should be noted that
an increase in the number of serotypes included in the vaccine,
would result in an increase in the total polysaccharide content
and, consequently, the amount of carrier protein. This should not
affect protection induced by this vaccine but may  be important in
combining conjugate vaccines using the same carrier proteins [74].
There are no data about carrier priming in MenCV in adults.
However, other conjugate vaccines such as malaria and hCG vac-
cine showed inconsistent evidences of a carrier priming effect. In
humans, CIES resulting from pre-immunization with TT has been
postulated to be responsible for a decrease in the response to a
malaria peptide-TT conjugate vaccine. It was observed that while
signiﬁcant epitopic suppression occurred at a lower dose of hapten
antigen, the suppression became progressively less signiﬁcant with
increasing vaccine dose, and ﬁnally disappeared or even reversed
into immune enhancement at a very high vaccine dose [60].
5.  Key considerations
• Increasing  epitope density of the carrier protein was found to
reduce  the competition between carrier-speciﬁc and hapten-
speciﬁc  B cells resulting in reduction of epitopic suppression.
However, this phenomenon was contradictory in some cases [61]
and  suggested to be dose-dependent and hard to predict [60].
• Low  ratio of hapten to carrier results in CIES.
• Carrier  overload may  induce immune suppression in primed indi-
viduals  [75].
• An  ideal carrier would be a molecule that induces a low antibody
response  to itself and high antibody response to the hapten [14].
In general, maximizing protection of infants with as few vaccine
doses as possible would deﬁnitely increase the general acceptabil-
ity of the vaccines and support broader coverage without increasing
vaccination costs. Clearly, prior immunity to the carrier protein has
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potentials to improve the immunogenicity of conjugate vaccines as
demonstrated in a variety of animal and human clinical trials. This
has implications for the future use of conjugate vaccines. Poten-
tially, the carrier priming effect can be utilized to optimize vaccine
schedules by administering DTP before (as opposed to with) other
conjugate vaccines; such a schedule would reduce the number of
doses and costs required to achieve adequate protection.
Conﬂicts of interest
Robert  Booy has received funding from Baxter, CSL, GSK, Merck,
Novartis, Pﬁzer, Roche, and Sanoﬁ Pasteur for the conduct of spon-
sored research, travel to present at conferences or consultancy
work; all funding received is directed to research accounts at The
Children’s Hospital at Westmead.
Iman Ridda is supported by Australian National Health and Med-
ical Research Council Early Career Fellowship (630739) and has
received funding for investigator-initiated research from GSK and
for consultation from Merck.
The other authors have declared no conﬂict of interest in relation
to this work.
References
[1] Watt JP, Wolfson LJ, O’Brien KL, Henkle E, Deloria-Knoll M,  McCall N, et al.
Burden of disease caused by Haemophilus inﬂuenzae type b in children younger
than 5 years: global estimates. Lancet 2009;374(September (9693)):903–11
[PubMed PMID: 19748399. Epub 2009/09/15.eng].
[2]  O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M,  McCall N, et al.
Burden of disease caused by Streptococcus pneumoniae in children younger
than 5 years: global estimates. Lancet 2009;374(September (9693)):893–902
[PubMed PMID: 19748398. Epub 2009/09/15.eng].
[3]  Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME.  Effectiveness
of meningococcal serogroup C conjugate vaccine 4 years after introduc-
tion. Lancet 2004;364(July (9431)):365–7 [PubMed PMID: 15276396. Epub
2004/07/28.eng].
[4] Finn A, Heath P. Conjugate vaccines. Arch Dis Child 2005;90(July (7)):667–9
[PubMed PMID: 15970605. Pubmed Central PMCID: PMC1720496.English].
[5] Avery OT, Goebel WF.  Chemo-immunological studies on conjugated
carbohydrate–proteins: II. Immunological speciﬁcity of synthetic
sugar–protein  antigen. J Exp Med  1929;50(September (4)):533–50 [PubMed
PMID: 19869645. Pubmed Central PMCID: 2131643. Epub 1929/09/30.eng].
[6] Rappuoli R, De Gregorio E. A sweet T cell response. Nat Med  2011;17(December
(12)):1551–2 [PubMed PMID: 22146455. Epub 2011/12/08.eng].
[7] Avci FY, Li X, Tsuji M,  Kasper DL. A mechanism for glycoconjugate vaccine acti-
vation of the adaptive immune system and its implications for vaccine design.
Nat Med  2011;17(12):1602–9.
[8] Lee LH, Blake MS.  Effect of increased CRM197 carrier protein dose on meningo-
coccal C bactericidal antibody response. Clin Vaccine Immunol 2012;19(April
(4)):551–6.
[9]  Kurikka S. Priming with diphtheria–tetanus–pertussis vaccine enhances the
response to the Haemophilus inﬂuenzae type b tetanus conjugate vaccine in
infancy. Vaccine 1996;14(September (13)):1239–42 [PubMed PMID: 8961512.
Epub 1996/09/01.eng].
[10] Granoff DM,  Holmes SJ, Osterholm MT,  McHugh JE, Lucas AH, Anderson EL, et al.
Induction of immunologic memory in infants primed with Haemophilus inﬂuen-
zae type b conjugate vaccines. J Infect Dis 1993;168(September (3)):663–71
[PubMed PMID: 8354908. Epub 1993/09/01.eng].
[11]  Delves PJ, Martin SJ, Burton DR, Roitt IM.  Roitt’s essential immunology. West
Sussex, UK: Wiley-Blackwell; 2011.
[12]  Schutze MP.  Carrier-induced epitopic suppression is initiated through clonal
dominance. J Immunol 1989;142(8):2635.
[13] Schutze MP,  Leclerc C, Jolivet M,  Audibert F, Chedid L. Carrier-induced epi-
topic suppression, a major issue for future synthetic vaccines. J Immunol
1985;135(4):2319–22.
[14]  Giudice GD. New carriers and adjuvants in the development of vaccines. Curr
Opin Immunol 1992;4(4):454–9.
[15] Pöllabauer EM,  Petermann R, Ehrlich HJ. The inﬂuence of carrier protein on the
immunogenicity of simultaneously administered conjugate vaccines in infants.
Vaccine 2009;27(11):1674–9.
[16] Peeters CC, Tenbergen-Meekes AM, Poolman JT, Beurret M, Zegers BJ, Rijkers
GT. Effect of carrier priming on immunogenicity of saccharide–protein conju-
gate vaccines. Infect Immun 1991;59(October (10)):3504–10 [PubMed PMID:
1894357. Pubmed Central PMCID: 258913].
[17]  Schneerson R, Robbins JB, Chu C, Sutton A, Vann W,  Vickers JC, et al.
Serum antibody responses of juvenile and infant rhesus monkeys injected
with Haemophilus inﬂuenzae type b and pneumococcus type 6A capsu-
lar polysaccharide–protein conjugates. Infect Immun 1984;45(September
(3)):582–91 [PubMed PMID: 6332076. Pubmed Central PMCID: 263334. Epub
1984/09/01.eng].
[18]  Anderson P. Antibody responses to Haemophilus inﬂuenzae type b and diphthe-
ria toxin induced by conjugates of oligosaccharides of the type b capsule with
the nontoxic protein CRM197. Infect Immun 1983;39(January (1)):233–8.
[19] Vella PP, Ellis RW.  Immunogenicity of Haemophilus inﬂuenzae type b conju-
gate vaccines in infant rhesus monkeys. Pediatr Res 1991;29(January (1)):10–3
[PubMed PMID: 2000253. Epub 1991/01/01.eng].
[20]  Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization,
and immunogenicity of Haemophilus inﬂuenzae type b polysaccharide–protein
conjugates. J Exp Med  1980;152(August (2)):361–76 [PubMed PMID: 6967514.
Pubmed Central PMCID: 2185954. Epub 1980/08/01.eng].
[21]  Katz DH, Paul WE,  Goidl EA, Benacerraf B. Carrier function in anti-hapten
immune responses I. Enhancement of primary and secondary anti-hapten
antibody responses by carrier preimmunization. J Exp Med  1970;132(August
(2)):261–82 [PubMed PMID: 4101344. Pubmed Central PMCID: 2138738.].
[22] Stickings P, Peyre M,  Coombes L, Muller S, Rappuoli R, Del Giudice G, et al.
Transcutaneous immunization with cross-reacting material CRM197 of diph-
theria toxin boosts functional antibody levels in mice primed parenterally
with adsorbed diphtheria toxoid vaccine. Infect Immun 2008;76(April (4)):
1766–73.
[23]  Granoff DM,  Holmes SJ, Belshe RB, Osterholm MT, McHugh JE, Anderson
EL. Effect of carrier protein priming on antibody responses to Haemophilus
inﬂuenzae type b conjugate vaccines in infants. JAMA 1994;272(October
(14)):1116–21  [PubMed PMID: 7933324].
[24]  Parke Jr JC, Schneerson R, Reimer C, Black C, Welfare S, Bryla D, et al. Clinical
and immunologic responses to Haemophilus inﬂuenzae type b-tetanus toxoid
conjugate vaccine in infants injected at 3, 5, 7, and 18 months of age. J Pediatr
1991;118(2):184–90.
[25]  Barington T, Gyhrs A, Kristensen K, Heilmann C. Opposite effects of actively
and passively acquired immunity to the carrier on responses of human
infants to a Haemophilus inﬂuenzae type b conjugate vaccine. Infect Immun
1994;62(January (1)):9–14 [PubMed PMID: 8262653. Pubmed Central PMCID:
186060. Epub 1994/01/01.eng].
[26] Kayhty H, Eskola J, Peltola H, Ronnberg PR, Kela E, Karanko V, et al. Anti-
body responses to four Haemophilus inﬂuenzae type b conjugate vaccines.
Am J Dis Child 1991;145(February (2)):223–7 [PubMed PMID: 1994693. Epub
1991/02/01.eng].
[27]  Castillo de Febres O, Decker M,  Estopinan M,  Bordones G, Edwards K. Enhanced
antibody response in Venezuelan infants immunized with Haemophilus
inﬂuenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J
1994;13(7):635.
[28]  Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity
to the carrier protein on antibody responses to Haemophilus inﬂuenzae type b
conjugate vaccines. Vaccine 1993;Suppl. 1:S46–51.
[29]  Kurikka S. Priming with diphtheria–tetanus–pertussis vaccine enhances the
response to the Haemophilus inﬂuenzae type b tetanus conjugate vaccine in
infancy. Vaccine 1996;14(13):1239–42.
[30] Kurikka S, Käyhty H, Saarinen L, Rönnberg P-R, Eskola J, Mäkelä PH. Immuno-
logic priming by one dose of Haemophilus inﬂuenzae type b conjugate vaccine
in infancy. J Infect Dis 1995;172(5):1268–72.
[31] Decker MD, Edwards KM,  Bradley R, Palmer P. Comparative trial in
infants of four conjugate Haemophilus inﬂuenzae type b vaccines. J Pediatr
1992;120(2(Part 1)):184–9.
[32] Lagos R, Valenzuela MT,  Levine OS, Losonsky GA, Erazo A, Wasserman
SS, et al. Economisation of vaccination against Haemophilus inﬂuenzae type
b: a randomised trial of immunogenicity of fractional-dose and two-dose
regimens. Lancet 1998;351(May (9114)):1472–6 [PubMed PMID: 9605803.
Epub/05/30.eng].
[33] Anderson P, Pichichero M,  Edwards K, Porch CR, Insel R. Priming and induction
of Haemophilus inﬂuenzae type b capsular antibodies in early infancy by Dpo20,
an oligosaccharide-protein conjugate vaccine. J Pediatr 1987;111(5):644–50.
[34] Anderson P, Pichichero M,  Insel R. Immunogens consisting of oligosaccharides
from the capsule of Haemophilus inﬂuenzae type b coupled to diphtheria toxoid
or the toxin protein CRM197. J Clin Invest 1985;76(1):52.
[35]  Campagne G, Garba A, Schuchat A, Boulanger D, Plikaytis BD, Ousseini M,
et al. Response to conjugate Haemophilus inﬂuenzae B vaccine among infants in
Niamey Niger. Am J Trop Med  Hyg 1998;59(November (5)):837–42.
[36] Granoff OM,  Holmes SJ, Belshe RB. The effect of carrier priming on the anticap-
sular (PRP) antibody responses to Haemophilus inﬂuenzae type b (Hib) conjugate
vaccines. Pediatr Res 1993;169A:33 [Abstract].
[37]  Guimarães T, Cereda RF, Bianchin PJ, Nagao AT, Sampaio MC,  Mendonc¸ a JS.
Antibody response to Haemophilus inﬂuenzae type b tetanus conjugate vaccine
with two doses given at 3 and 5 months of age. Int J Infect Dis 2002;6(2):113–7.
[38] Booy R, Heath PT, Slack MPE, Begg N, Richard Moxon E. Vaccine failures after
primary immunisation with Haemophilus inﬂuenzae type-b conjugate vaccine
without booster. Lancet 1997;349(9060):1197–202.
[39] Lieberman JM,  Greenberg DP, Wong VK, Partridge S, Chang SJ, Chiu CY, et al.
Effect of neonatal immunization with diphtheria and tetanus toxoids on anti-
body responses to Haemophilus inﬂuenzae type b conjugate vaccines. J Pediatr
1995;126(February (2)):198–205 [PubMed PMID: 6657844].
[40] Sangpetchsong V, Impat A, Dhiensiri K, Podhipak A. Effect of passive immunity
to tetanus in DTP vaccinated infants. Southeast Asian J Trop Med  Public Health
1985;16(1):117.
[41]  Booy R, Taylor S, Tudor-Williams G, Moxon ER, Aitken SJM, Grifﬁths
H, et al. Immunogenicity of combined diphtheria, tetanus, and pertussis
24
Author's personal copy
1430 K. Pobre et al. / Vaccine 32 (2014) 1423–1430
vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet
1992;339(8792):507–10.
[42] Mulholland K, Suara RO, Siber G, Roberton D, Jaffar S, N’Jie J, et al. Maternal
immunization with Haemophilus inﬂuenzae type b polysaccharide–tetanus pro-
tein conjugate vaccine in the Gambia. JAMA 1996;275(15):1182–8 [PubMed
PMID: 8609686. Epub/04/17.eng].
[43] Sarvas H, Kurikka S, Seppälä IJT, Mäkelä PH, Mäkelä O. Maternal antibodies
partly inhibit an active antibody response to routine tetanus toxoid immu-
nization in infants. J Infect Dis 1992;165(5):977–9.
[44]  Claesson BA, Schneerson R, Robbins JB, Johansson J, Lagergard T, Taranger J,
et al. Protective levels of serum antibodies stimulated in infants by two  injec-
tions of Haemophilus inﬂuenzae type b capsular polysaccharide–tetanus toxoid
conjugate. J Pediatr 1989;114(1):97–100.
[45] Scheifele DW,  Halperin SA, Smith B, Ochnio J, Meloff K, Duarte-Monteiro D.
Assessment of the compatibility of co-administered 7-valent pneumococcal
conjugate DTaP, IPV/PRP-T Hib and hepatitis B vaccines in infants 2–7 months
of age. Vaccine 2006;24(12):2057–64.
[46] Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens
of the conjugated 7-valent pneumococcal vaccine: a randomized controlled
trial. Pediatr Infect Dis J 2010;29(8):756–62.
[47] Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, et al. Immunogenicity of
13-valent pneumococcal conjugate vaccine administered according to 4 dif-
ferent primary immunization schedules in infants: a randomized clinical trial.
JAMA 2013;310(9):930–7.
[48] Lucero MG, Puumalainen T, Ugpo JM,  Williams G, Käyhty H, Nohynek H. Similar
antibody concentrations in ﬁlipino infants at age 9 months, after 1 or 3 doses
of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vac-
cine: a randomized controlled trial. J Infect Dis 2004;189(11):2077–84.
[49] Burrage M,  Robinson A, Borrow R, Andrews N, Southern J, Findlow J, et al. Effect
of vaccination with carrier protein on response to meningococcal C conjugate
vaccines and value of different immunoassays as predictors of protection. Infect
Immun  2002;70(September (9)):4946–54.
[50]  Weston WM,  Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity
of co-administered tetanus–diphtheria–acellular pertussis (Tdap) and tetrava-
lent meningococcal conjugate (MCV4) vaccines compared to their separate
administration. Vaccine 2011;29(5):1017–22.
[51] Food Drug Administration. Menactra® full prescribing information 2011;
2011 http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/
approvedproducts/ucm70.pdf.1311
[52]  Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, et al. Safety
and immunogenicity of one dose of MenACWY-CRM, an investigational
quadrivalent meningococcal glycoconjugate vaccine, when administered to
adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vac-
cine 2010;28(18):3171–9.
[53] McVernon J, MacLennan J, Clutterbuck E, Buttery J, Moxon ER. Effect of infant
immunisation with meningococcus serogroup C–CRM197 conjugate vaccine on
diphtheria immunity and reactogenicity in pre-school aged children. Vaccine
2003;21(19–20):2573–9.
[54]  Barington T, Kristensen K, Henrichsen J, Heilmann C. Inﬂuence of prevac-
cination immunity on the human B-lymphocyte response to a Haemophilus
inﬂuenzae type b conjugate vaccine. Infect Immun  1991;59(3):1057–64.
[55] Barington T, Sparholt S, Juul L, Heilmann C. A simpliﬁcation of the enzyme-
linked immunospot technique increased sensitivity for cells secreting IgG
antibodies to Haemophilus inﬂuenzae type b capsular polysaccharide. J Immunol
Methods 1992;156(2):191–8.
[56] Barington T, Skettrup M,  Juul L, Heilmann C. Non-epitope-speciﬁc suppression
of the antibody response to Haemophilus inﬂuenzae type b conjugate vaccines by
preimmunization with vaccine components. Infect Immun 1993;61(2):432–8.
[57] Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al.
The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-
valent polysaccharide vaccine in adults aged 50–80 years. Clin Infect Dis
2009;49(9):1318–25.
[58]  Shelly MA,  Pichichero ME,  Treanor JJ. Low baseline antibody level to diphtheria
is associated with poor response to conjugated pneumococcal vaccine in adults.
Scand J Infect Dis 2001;33(7):542–4.
[59] Ölander R-M, Wuorimaa T, Käyhty H, Leroy O, Dagan R, Eskola J. Booster
response to the tetanus and diphtheria toxoid carriers of 11-valent pneumo-
coccal conjugate vaccine in adults and toddlers. Vaccine 2001;20(3):336–41.
[60] Di John D, Wasserman SS, Torres JR, Cortesia MJ,  Murillo J, Losonsky GA,
et al. Effect of priming with carrier on response to conjugate vaccine. Lancet
1989;2(December (8677)):1415–8 [PubMed PMID: 499 2480].
[61] Shah S, Raghupathy R, Singh O, Talwar GP, Sodhi A. Prior immunity to a carrier
enhances antibody responses to hCG in recipients of an hCG-carrier conjugate
vaccine. Vaccine 1999;17(23–24):3116–23.
[62] Knuf M,  Kowalzik F, Kieninger D. Comparative effects of carrier proteins on
vaccine-induced immune response. Vaccine 2011;29(31):4881–90.
[63] Hurme M,  Kontiainen S, Seppälä IJT, Mäkelä O. Afﬁnity and Ig classes
of anti-hapten antibodies in carrier-preimmunized rats. Eur J Immunol
1973;3(4):191–5.
[64] Ishizaka K. Reaginic antibody formation in the mouse II. Enhancement and sup-
pression of anti-hapten antibody formation by priming with carrier. J Immunol
1973;110(4):1067.
[65] Lagos R, Valenzuela MT,  Levine OS, Losonsky GA, Erazo A, Wasserman SS, et al.
Economisation of vaccination against Haemophilus inﬂuenzae type b: a ran-
domised trial of immunogenicity of fractional-dose and two-dose regimens.
Lancet 1998;351(9114):1472–6.
[66] Booy R. Getting Hib vaccine to those who need it. Lancet
1998;351(9114):1446–7.
[67]  Knuf M,  Schmitt H-J, Wolter J, Schuerman L, Jacquet J-M, Kieninger D, et al.
Neonatal vaccination with an acellular pertussis vaccine accelerates the acqui-
sition of pertussis antibodies in infants. J Pediatr 2008;152(5):655–60.
[68] Siegrist C-A. Mechanisms by which maternal antibodies inﬂuence infant vac-
cine responses: review of hypotheses and deﬁnition of main determinants.
Vaccine 2003;21(24):3406–12.
[69] Barington T, Gyhrs A, Kristensen K, Heilmann C. Opposite effects of actively
and passively acquired immunity to the carrier on responses of human
infants to a Haemophilus inﬂuenzae type b conjugate vaccine. Infect Immun
1994;62(1):9–14.
[70]  Kurikka S, Käyhty H, Peltola H, Saarinen L, Eskola J, Mäkelä PH.  Neonatal immu-
nization: response to Haemophilus inﬂuenzae type b-tetanus toxoid conjugate
vaccine. Pediatrics 1995;95(6):815–22.
[71] O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M,  McCall N, et al.
Burden of disease caused by Streptococcus pneumoniae in children younger than
5  years: global estimates. Lancet 2009;374(9693):893–902.
[72]  Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, et al. Meningococ-
cal serogroup C conjugate vaccine is immunogenic in infancy and primes for
memory. J Infect Dis 1999;179(6):1569–72.
[73] Sarvas H, MÄKelÄ O, Toivanen P, Toivanen A. Effect of carrier preimmu-
nization on the anti-hapten response in the chicken. Scand J Immunol
1974;3(4):455–60.
[74] Ahman H. Streptococcus pneumoniae capsular polysaccharide–diphtheria tox-
oid conjugate vaccine is immunogenic in early infancy and able to induce
immunologic memory. Pediatr Infect Dis J 1998;17(3):211–6.
[75]  Baraldo K, Mori E, Bartoloni A, Petracca R, Giannozzi A, Norelli F, et al. N19
polyepitope as a carrier for enhanced immunogenicity and protective efﬁcacy
of meningococcal conjugate vaccines. Infect Immun 2004;72(8):4884–7.
25
  
1.5.2 Publication #2; commentary: 
Tashani M, Rashid H, Mulholland K, Booy R. Carrier priming to 
improve pneumococcal disease control and reduce the 
international program’s cost in children. Pneumonia. 
2016;8:16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26
PneumoniaTashani et al. Pneumonia  (2016) 8:16 DOI 10.1186/s41479-016-0016-8COMMENTARY Open AccessCarrier priming to improve pneumococcal
disease control and reduce the
international program’s cost in children
Mohamed Tashani1,2,3* , Harunor Rashid1,2,3,4, Kim Mulholland5,6 and Robert Booy1,2,3,4,7Abstract
Pneumococcal conjugate vaccine (PCV) has the potential to interact with other vaccines containing diphtheria
toxin-like antigens (such as those found in the DTP vaccine) upon sequential administration. This is attributed to
the similarity of the diphtheria toxoid antigen to the carrier protein used to make PCV, (known as cross reactive
material [CRM]) to diphtheria toxin 197 or CRM197. The interaction could lead to enhanced immunogenicity of PCV
as a result of a phenomenon called carrier priming, whereby DTP is given some weeks before the first dose of PCV.
This phenomenon could be implemented in the immunisation schedule in developing countries and among
vulnerable populations to enhance the immunogenicity of PCV, reduce the number of doses required, and produce
a more cost-effective immunisation program in developing countries.
Keywords: Pneumococcal conjugate vaccine, Carrier primingMain text
Streptococcus pneumoniae is a leading cause of pneumo-
nia and death in children worldwide [1]. It is estimated
that 14.5 million episodes of serious pneumococcal
disease occur each year in children aged less than five
years, resulting in at least 500,00 deaths, almost all of
which occur in low- and middle-income countries [2].
Vaccination has proved very successful in the control of
pneumococcal disease in many developing countries and
there is growing evidence for herd protection. For
example, in The Gambia, infant vaccination has reduced
vaccine-type pneumococcal carriage not only among
vaccinated children but also among non-vaccinated
older children and adults, indicating a substantial herd
effect [3]. However, not all countries have introduced
vaccination of infants as implementation is limited by
the high cost of the vaccine [4]. The cost of one dose of
pneumococcal conjugate vaccine (PCV) can be very high
in developed countries (> $100) [5]. The best subsidised
price for resource-poor countries has been brought* Correspondence: mohamed.tashani@health.nsw.gov.au
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27down to $3 · 30 per dose [6], which is comparable to the
cost of all other pediatric vaccines combined (HepB,
BCG, OPV, DPT-Hib, and Measles) [7]. Therefore, there
is intense interest in reducing the cost of vaccination
against pneumococcal disease in young children through
eg. shorter schedules of one or two doses instead of
three doses [8].
The use of the 3 + 0 schedule is supported by
randomised controlled clinical trials for prevention of
pneumonia and invasive pneumococcal disease (IPD)
in developing countries [9], and has been recom-
mended by WHO. However, after more than a decade
of using PCV in many developed countries, evidence
consistently demonstrates strong herd immunity; most
vaccine-type pneumococcal disease is close to elimin-
ation in children irrespective of individual vaccination
status [10]. Consequently, a “1 + 1” schedule (where a
booster dose is given in second year of life) has been
promoted for use in developing countries where the im-
munisation program is mature (implemented for few
years) and vaccine-type carriage is largely eliminated in
the community [11]. In such mature vaccine programmes,
individual protection may not be required because the
probability of exposure to vaccine-type infection has
become very low [10]. Therefore, a “1 + 1” schedule couldle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Tashani et al. Pneumonia  (2016) 8:16 Page 2 of 3be sufficient to maintain disease control, and at a consid-
erably reduced cost [8]. Long-term protection against IPD
by PCV depends on a combination of persistence of
protective serum antibody levels, immunological memory,
and herd immunity [12]. Additionally, and importantly,
we suggest consideration of the use of carrier priming to
enhance the immunogenicity, especially of the first PCV
dose. Carrier priming is defined as an improved antibody
response to a carbohydrate portion of a glycoconjugate
vaccine because an individual has been previously primed
with the carrier protein [13].
The 13-valent PCV utilises carrier protein cross-
reacting material 197 (CRM197) of diphtheria toxin,
which is antigenically similar to the diphtheria toxin in
DTP. It is believed that priming via the carrier molecule
enhances the response to conjugate vaccines by increas-
ing the number of carrier-specific T lymphocytes; these
can provide the necessary support for the expansion and
differentiation of polysaccharide specific B lymphocytes
[14]. Several studies have found that prior receipt of
tetanus/diphtheria containing vaccine such as DTP in
infants who are then administered conjugate vaccine can
lead to rapid and earlier onset of clinical protection
against the disease [15-17]. In developing countries, the
risk of IPD peaks in the first few months of life and the
current vaccine schedule is 6, 10 and 14 weeks. We
propose evaluation of a schedule that offers the first PCV
at ten weeks of age after prior administration of DTP
vaccine at six weeks to take advantage of carrier priming
[16]. If adequate priming occurs, a reduced schedule
(where first PCV is given after DTP) may be sufficient and
more cost-effective, particularly for resource poor settings
with mature immunisation programs.
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Key points of Publication #1 and #2:
Publications#1 & #2 together represent a thorough review of the current literature
with regards to the interaction between DTP/Tdap vaccine and conjugate vaccine
given sequentially. It appears that this interaction could result in an enhancement of
the immunogenicity of PCV given to young children. All the available PCVs (PCV7,
PCV11 and PCV13) were studied demonstrating favourable responses upon prior
exposure to DTP/Tdap. However, in adults, only a limited number of studies have
explored this interaction and only in PCV7 whereas no adult studies explored the
effect in PCV13 and MCV. Therefore, I have embarked on two RCTs to explore this
effect in adult travellers.
While preparing for these RCTs and as a background preparation I conducted a series
of surveys among Australian Hajj pilgrims measuring the uptake of pneumococcal
vaccine and investigated pilgrims’ KAP towards Hajj-associated respiratory infections
and vaccines against the infections.
The following Publication #3 addresses the uptake of the pneumococcal vaccine
among Australian Hajj pilgrims.
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Abstract: The uptake of the pneumococcal vaccine is suboptimal in Australia and remains unknown among Australian 
Hajj pilgrims, many of whom are eligible because of age or underlying disease and at particular risk because of travel and 
activities at Hajj. Pneumococcal vaccination uptake was examined over three consecutive years (2011 to 2013) through 
anonymous self-administered cross sectional surveys among Australian pilgrims who assembled in Mina valley, Mecca, 
Saudi Arabia. Respectively, 158, 513 and 219 pilgrims were recruited in 2011, 2012 and 2013; their mean ages were 43.8 
(SD±13), 43 (SD±13.5) and 42.6 (SD±12.3) years; males accounted for 67 (42.4%), 325 (63.4%) and 172 (78.5%). Pneu-
mococcal vaccine uptake rates were 28.5% (45/158), 28.7% (147/513) and 14.2% (31/219); among the pilgrims with ‘at 
risk’ conditions the pneumococcal vaccine uptake rates were 15 (30.6%), 43 (45.3%) and 9 (29%) respectively. According 
to our surveys, the pneumococcal vaccine uptake among Australian pilgrims is low. Further research is needed to explore 
the reasons through a validated study. 
Keywords: Hajj, Mecca, Pneumococcal vaccine, vaccination coverage. 
1. INTRODUCTION 
 Increasing immunisation coverage is one of the strategic 
objectives of the Australian National Immunisation Program. 
For pneumococcal vaccine, uptake is low overall and until now, 
unknown for Hajj pilgrims, many of whom are in the category 
for whom it is recommended. In Australia, pneumococcal 
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vaccine is recommended for people ‘at-risk’ with severe 
complications, defined as those aged ≥65 years old and/or 
people with pre-existing medical conditions such as chronic 
lung, heart, liver, kidney, neuromuscular, metabolic or im-
mune-compromising conditions Box (1). 
 
Box. (1). Pneumococcal vaccine indications for adults, accord-
ing to the Australian Department of Health and Ageing:  
§ Indigenous and non-indigenous adults (18-64 years) with 
one of the following conditions 
• Chronic lung disease (including asthma) 
• Chronic heart disease 
• Chronic renal disease 
• Diabetes mellitus 
• Alcoholism 
• Immunodeficiency states 
• Tobacco smoker 
• Hyposplenism, asplenia, splenic dysfunction, sickle 
cell disease 
• Chronic liver disease (including cirrhosis) 
§ All non-indigenous adults aged ≥65 years – every 5 years if 
high risk 
§ Indigenous adults aged ≥50 years- repeated after 5 years 
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 Hajj is one of the five basic pillars of Islam and is the 
largest annual mass gathering in the world that attracts 2-3 
million pilgrims every year. Excessive crowding, heat, dust, 
physical exhaustion and shared accommodation during Hajj 
intensify the transmission of respiratory infections. Pneumo-
nia accounts for a third of the reasons for hospitalisation to 
Saudi hospitals during the Hajj season [1-3] with Streptococ-
cus pneumoniae as one of leading organisms isolated from 
patients admitted in Meccan hospitals and intensive care 
units [4-6]. S pneumoniae is a virulent Gram-positive coccus, 
often carried asymptomatically in the nasopharynx of hu-
mans, including by Hajj pilgrims [7]. It can also cause inva-
sive disease such as bacteraemia, pneumonia, bronchitis, and 
meningitis [8]. All age groups can be affected by invasive  
S. pneumoniae disease, but it predominantly affects the ex-
tremes of age, especially the elderly. Taking into account 
that a considerable proportion of Hajj pilgrims are elderly 
and have pre-existing medical conditions [9, 10], and that the 
rate of antimicrobial resistance to S. pneumoniae is rising in 
the developing world, including the Gulf Cooperation Coun-
cil (GCC) region [5, 6, 11], a prevention strategy with vacci-
nation may be the most cost-effective approach to health 
systems [12].  
 Pneumococcal vaccines are designed to cover the sero-
types most frequently associated with severe pneumococcal 
disease. Currently over 90 capsular antigenic types (sero-
types) have been recognised, each of which may elicit type-
specific immunity in the host [13]. Therefore, measures such 
as vaccination, to prevent the disease and reduce the carriage 
rates seem wise, particularly with supporting evidence that 
pneumococcal polysaccharide vaccine (PPV23) covers the 
most common pneumococcal serotypes in KSA [11, 14]. 
Evidence from observational studies indicates that pneumo-
coccal vaccine protects both healthy adults against pneumo-
nia and bacteraemia and high-risk groups against bacterae-
mia hospitalisation, and death, with direct medical cost sav-
ings [15, 16]. The PPV23 is recommended in most devel-
oped countries for the elderly adults, but the uptake is usu-
ally suboptimal [17-19]. Moreover, while some vaccines are 
either compulsory or recommended to Hajj pilgrims by the 
Saudi Ministry of Health, vaccination against pneumococcal 
disease is not [20]. Therefore, the uptake of pneumococcal 
vaccine among Hajj pilgrims is still poor.  
 Despite clear recommendations, there are no available 
comprehensive data on the uptake of pneumococcal vaccine 
among Australian Hajj pilgrims or other travellers. In an 
effort to investigate the pneumococcal vaccine uptake, we 
surveyed a group of Australian pilgrims over three consecu-
tive years. 
2. METHOD 
 A cross sectional, anonymous self-administered survey 
was distributed to Australian pilgrims who assembled in 
Mina valley (an important Hajj location at the outskirts of 
Mecca), as well as accommodation facilities in Makkah city, 
Saudi Arabia. Hajj dates are based on the lunar calendar and 
annually are 10-11 days earlier than the previous year. Pil-
grims were recruited to the studies on the morning or after-
noon of the first day of their stay in Mina (corresponding to 
the 4th of November 2011, 25th of October 2012 and 13th 
October 2013). All were assigned to numbered tents and 
those staying in ‘Australian’ tents were recruited serially. 
One month before the commencement of Hajj, the Hajj tour 
group leaders were provided with detailed information about 
the study to encourage participation in the survey. The re-
search team consisted of both research doctors and volunteer 
trained medical students, with equal numbers of males and 
females, who explained the survey individually to the poten-
tial participants. The tour group guides arranged broadcasts 
about the study in English and Arabic. For those pilgrims 
who could not complete the questionnaires or preferred not 
to do so themselves, volunteer researchers recorded dictated 
answers. The inclusion criteria were: adult pilgrims aged ≥18 
years with Australian citizenship with or without pre-
existing medical condition. Demographic and personal data 
(date of birth, gender, country of birth), history of pre-
existing medical conditions, vaccination histories, medica-
tion use and pneumococcal vaccination history were col-
lected. Questionnaires were collected within 30 minutes. 
Data were compiled into a Microsoft Excel 2013 spread-
sheet. Statistical Package for the Social Sciences (SPSS) 
version 19 software program (SPSS, Inc., Chicago, IL, USA) 
was used to carry out descriptive data analyses. Categorical 
variables were compared by using the Chi-square test. A p 
value ≤0. 05 was considered statistically significant. Ethical 
approval had been obtained for the study from Hunter New 
England Human Research Ethics Committee (11/SCHN/162) 
and the Saudi Arabian Ministry of Health (reference: 
KACST: H-01-R-012). 
3. RESULTS 
 The total number of pilgrims recruited in the three years 
was 954, 64 were excluded as they were non-Australians or 
omitted essential information, such as pneumococcal vacci-
nation status Fig. (1). We approached 164, 552 and 238 pil-
grims in the years 2001, 2012 and 2013 respectively. 
3.1. Vaccine uptake in 2011 
 Table 1 shows for the 158 pilgrims recruited mean age 
was 43.8 (SD±13) years (5 did not reveal their ages) and 67 
(42.4%) were males. Most of the pilgrims were from New 
South Wales 93 (59%); 19 (12%) were from Victoria; 19 
(12%). Thirty five (33.5%) of the pilgrims originated from 
the Indian subcontinent, 52 (33%) were of Middle Eastern 
origin and the rest were mainly from Africa.  
 Fifty five (23.2%) were at least 50 years old and 18 (35.3%) 
of them had received pneumococcal vaccine Table 2. Seven 
(4.4%) were more than 65, two (28.6 %) of whom had had 
the recommended pneumococcal vaccine. 
 Thirty two (20%) reported an underlying medical condi-
tion that requires vaccination (11 with heart disease, 14 with 
chronic lung disease, 13 with diabetes, one with kidney dis-
ease, two with a neurological condition, one with liver dis-
ease and one on immunosuppression therapy, some with 
more than one of these), of whom 11 (34.5%) received their 
recommended pneumococcal vaccine. Nineteen (12%) were 
current smokers, five (26.3%) of whom had had the recom-
mended pneumococcal vaccine.  
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Fig. (1). Flow diagram showing recruitment of participants. 
 
 Overall pneumococcal vaccine uptake was 45 (28.5%), 
with 15 (30.6%) reporting established risk factors. Uptake 
was significantly higher (P= 0.03) in females 32 (35.2%) 
than males 13 (19.5%). 
3.2. Vaccine uptake in 2012 
 As summarised in Table 1, 513 pilgrims participated, 
with mean age 43 (SD±13.5) years (29 did not report their 
age) and 325 (63.4%) male (18 did not provide gender). 
Most of the pilgrims were from New South Wales 209 
(40.7%) and nearly as many, 186 (36.3%), were from Victo-
ria. One hundred fifty four of pilgrims were aged ≥ 50 years, 
34 (22%) of whom had received pneumococcal vaccine. 
Seventy eight (15.2%) reported an underlying medical condi-
tion requiring vaccination (13 with heart disease, 11 with 
lung disease, 59 with diabetes mellitus, six with kidney dis-
ease, one with liver disease and 2 on immunosuppression 
therapy) of whom 35 (45%) had received pneumococcal 
vaccine. Of 33 (6.4%) pilgrims aged ≥65 years, 16 (48.5%) 
had had pneumococcal vaccine. Overall 147(28.7%) reported 
pneumococcal vaccination and 133 (26%) answered “not 
sure”. Of these 43 (45.3%) reported risk factors.  
3.3. Vaccine uptake in 2013 
 As in Table 1, 238 were recruited, the mean age of re-
sponders was 42.6 (SD±12. 3) years (14 did not report their 
age) and 172 (78.5%) of them were males (14 did not pro-
vide gender). Seventy (32%) were aged more than 50 years 
of age, 10 (14.3%) of whom had received pneumococcal 
vaccine. Twenty seven (12.3%) reported an underlying 
medical condition (nine with heart disease, four with lung 
disease, 14 with diabetes mellitus, two with kidney disease 
and one with neurological disease), of whom eight (29.6%) 
had received the recommended pneumococcal vaccine. 
Seven (3.2%) pilgrims were more than 65 years, two 
(28.6%) of whom had had the recommended pneumococcal 
vaccine.  
 The overall pneumococcal vaccine uptake was 13 
(14.2%). Seventy one (32.4%) were “not sure” of their 
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pneumococcal vaccine status. For the ‘at-risk’ category, nine 
(29%) had received the vaccine. 
3.3. Summary findings for period 2011-2013  
 Over the three years surveyed, 223 (25%) reported that 
they had received pneumococcal vaccine. For the ‘at-risk’ 
category, uptake was 67 (38.3%) and 135 (14.4%) reported 
having received the vaccine in the five years before their 
Hajj pilgrimage. 
 There was no significant disparity in the proportion of 
pilgrims receiving the vaccine in the years 2011 and 2012. 
However, vaccine uptake in 2013 was significantly lower (P 
<0.01) than in 2011 and 2012. The data show a decreasing 
trend in pneumococcal vaccine uptake (P<0.001) over the 
three year survey of Australian Hajj pilgrims. All of the 224 
pilgrims who had had pneumococcal vaccine had also re-
ceived flu vaccine, with strong correlation between both vac-
cine uptakes. A logistic regression model showed moderate 
evidence (P=0.02) of an interaction between gender and year 
in vaccine uptake. 
4. DISCUSSION 
 To our knowledge, this is the first Australian study to 
explore the pneumococcal vaccine uptake among Australian 
Hajj travelers. Despite the importance of the vaccine and 
predominance of pneumococcal disease among pilgrims, 
pneumococcal vaccine uptake among Australian pilgrims has 
been low. Generally, pneumococcal vaccine uptake in other 
(non-Australian) countries was variable according to the risk 
category and funding program. For instance, one small 
Dutch study in 2012 revealed that of at risk (splenectomised 
travellers) 10 (47.5%) received their recommended pneumo-
coccal vaccine [21]. Other studies from the Netherland 
showed that splenectomised individuals pneumococcal cov-
erage varied between 64% and 85% [22, 23]. Two studies in 
the UK found that despite being part of the national immuni-
sation programme, uptake of pneumococcal vaccine in cer-
tain ‘at risk groups’ in the United Kingdom only ranged from 
13% to 69% [17, 24]; strict coordination and audit can im-
prove uptake [25, 26]. Of note, after the introduction of 
pneumococcal vaccine through a publicly funded national 
program in Australia in 2005, a 5 years survey among Aus-
Table 1. Demographic and characteristic features of the study participants. 
  Number of participants 
in 2011 
Number of participants 
in 2012 
Number of participants 
in 2013 
  n (%) n (%) n (%) 
Gender*         
  Male 67 (42.4) 325 (63.4) 172 (78.5) 
  Female 91 (57.6) 170 (33.1) 33 (15.1) 
  No Answer 0 18 (3.5) 14 (6.4) 
Age category**      
  <50 102 (64.5) 330 (64.3) 135 (61.6) 
  ≥ 50 51 (23.2) 154 (30) 70 (32) 
  < 65 146 (92.4) 451 (88) 198 (90.4) 
  ≥ 65 7 (4.4) 33 (6.4) 7 (3.2) 
State      
  NSW 93 (58.9) 209 (40.7) 17 (7.8) 
  Others including VIC (and no answer) 65 (41) 304 (59.3) 202 (92.3) 
Participants with 
chronic diseases 
     
  DM 13 (8.2) 59 (11.5) 14 (6.4) 
  Chronic heart disease 11 (7) 12 (2.3) 9 (4.1) 
  Chronic renal disease 1 (0.6) 6 (1.2) 2 (0.9) 
  Chronic lung disease 14 (9) 11 (2) 4 (1.8) 
  Chronic neurological disease 2 (1.3) 0 1 (0.5) 
*Gender was not known for 18 subjects in 2012 and 14 in 2013. 
**Age was not known for 5, 29 and 14 subjects in 2011, 2012 and 2013 respectively. 
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tralian aged 65 years or more showed that coverage for eld-
erly people has been consistently high for influenza vaccine 
(75%), but less so for pneumococcal vaccine (50-60%) [18, 
19, 27], even for hospitalised elderly (52.6%) [28], appar-
ently because of greater awareness of the annual influenza 
vaccination program.  
 The vaccine uptake among at risk Australian Hajj pil-
grims of 38.3%, varies from other countries. For example, it 
was found that 67.4% of at risk Iranian pilgrims had their 
recommended pneumococcal vaccine in 2005, while the 
overall uptake rates among general Iranian pilgrims in 2004 
and 2005 were 2.5% and 8.9% respectively [29]. In one UK 
study in 2005, the overall uptake was 5% (15% in at-risk 
Hajj pilgrims) [30]. In the year 2010 in France, the pneumo-
coccal vaccine uptake among pilgrims was 1.7% (including 
6.7% among at risk) and 5% in those with risk factors for 
pneumococcal infection in 2011 [31, 32]. However, in the 
previous year (2009), the uptake of pneumococcal vaccine 
among French Hajj pilgrims was higher up to 31.4% [33], 
which perhaps reflects heightened awareness after the out-
break of the pandemic influenza 2009. Among French pil-
grims, pneumococcal vaccine uptake has continued to be 
greater than for Australian pilgrims in our study. In 2013 
vaccine uptake was 35.9% and 47.8% among ‘at-risk’ 
French pilgrims [7]. Another random survey of Hajj pilgrims 
from 22 countries (included 46 Australians) at Saudi Arabian 
Airport entry and exit during Hajj 2013 showed low uptake 
of 4.4% pneumococcal vaccine (1.5% in those over 65 years 
old and 27.3% in those with diabetes) [34]. 
 Our survey demonstrated that pneumococcal vaccine 
uptake was significantly lower in the year 2013, possibly 
because more pilgrims that year were male Fig. (2). since 
men are less proactive in health matters, especially in seek-
ing preventative and pre-travel advice [35]. A Dutch study of 
Hajj pilgrims found independent factors for meningococcal 
vaccine acceptance were being female, of younger age, and 
with pre-existing health problems [36]. 
 Pneumococcal vaccine uptake by Australians is unsatis-
factory, irrespective of Hajj pilgrimage as a risk factor. The 
cost of the vaccine is one of the possible reasons for poor 
vaccine uptake in general travellers [37]; for Hajj, it has been 
also postulated that the absence of funding and the lack of 
Table 2. Pneumococcal vaccine uptake among Australian Hajj pilgrims in 2011-13. 
   n/N (% of the total  
category in 2011) 
n/N (% of the total  
category in 2012) 
n/N (% of the total  
category in 2013) 
Gender*         
  Male 13/67 (19.4) 100/325 (30.8) 22/172 (12.8) 
  Female 32/91 (35.2) 43/170 (25.3) 7/33 (21.2) 
  No Answer NA 4/18 (22.2) 2/14 (14.3) 
Age category      
  <50 24/102 (23.5) 87/330 (26.4) 17/135 (12.6) 
  ≥ 50 18/51 (35.3) 55/154 (35.7) 10/70 (14.3) 
  < 65 40/146 (27.4) 126/451 (28) 25/198 (12.6) 
  ≥ 65 2/7 (28.6) 16/33 (48.5) 2/7 (28.6) 
State      
  NSW 29/93 (31.2) 64/209 (30.6) 0 
  Others including VIC and “No answer” 16/61 (26.2) 80/298 (26.8) 31/201 (15.4) 
Participants with 
chronic diseases 
     
  DM 7/13 (53.8) 30/59 (50.8) 5/14 (35.7) 
  Chronic heart disease 6/11 (54.4) 3/12 (25) 4/9 (44.4) 
  Chronic lung disease 3/14 (21.4) 4/11 (36.4) 0/4 
  Chronic renal disease 0/1 4/6 (66.7) 0/2 
At risk***   15/49 (30.6) 43/95 (45.3) 9/31 (29) 
*Gender was not known for 18 subjects in 2012 and 14 in 2013. 
**Age was not known for 5, 29 and 14 subjects in 2011, 2012 and 2013 respectively. 
***defined as those aged ≥65 years old and/or smoker and/or subject with pre-existing medical conditions such as chronic lung, heart, liver, kidney, neuromuscular, metabolic or 
immune-compromising conditions. 
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general awareness about pneumococcal diseases and the vac-
cine options are contributing factors to the poor uptake [6]. 
For example, despite the great similarity and overlap of the 
indications of influenza and pneumococcal vaccines. It has 
been shown that the influenza vaccine uptake among Austra-
lian Hajj pilgrims was satisfactory (up to 89% in 2012) ow-
ing to the combined recommendation of Saudi Arabian Gov-
ernment, travel agents and Hajj group leaders [16]. 
 In the past two years, a novel corona virus named Middle 
East Respiratory Syndrome Coronavirus (MERS-CoV) has 
emerged in the Middle East region with its epicentre in Saudi 
Arabia. The virus affects lung parenchyma and can result in 
severe complications in those who have chronic comorbid-
ities with a high mortality rate (42%) [38]. The current rec-
ommendation for ‘at risk’ pilgrims is to postpone their pil-
grimage [34]. Accordingly, it would be also sensible to rec-
ommend pneumococcal vaccine to all Hajj pilgrims with at 
risk condition in order to protect from MERS-CoV with sec-
ondary bacterial infection. This should be supported by im-
proved education and awareness campaigns, for both the 
pilgrims and those who care for their health [6]. It has been 
proven that education can result in remarkable improvements 
in the knowledge and behaviour of pilgrims [39] and or/other 
at-risk groups [21]. In addition, primary care practice teams 
that received an educational outreach visit demonstrated a 
significantly greater improvement in uptake in high-risk 
groups for pneumococcal vaccine [40]. General practices and 
travel clinics need further encouragement to offer pneumo-
coccal vaccine to at-risk pilgrims before they embark.  
 In attempt to prevent the transmission of infectious dis-
eases at Hajj, the Saudi health authorities annually publish 
health advice for the pilgrims regarding the required and 
recommended vaccines for Hajj in addition to other preven-
tative measures such as hand hygiene and facemask usage 
[41, 42]. However, these recommendations so far have not 
included the pneumococcal vaccine. Consensus recommen-
dation is needed from local and international travel/Hajj/ 
health authorities regarding pneumococcal vaccine for the 
older pilgrims or pilgrims with chronic medical condition 
[36]. One strength of our study is that it focused specifically 
on the uptake of pneumococcal vaccine among Australian 
pilgrims. A limitation is the fact that self-reported pneumo-
coccal vaccination status may be unreliable [43] with issues 
regarding sensitivity [44] and specificity [45]. The survey 
did not distinguish between conjugate and polysaccharide 
vaccines. Recent assessments indicate that conjugate vaccine 
may offer some advantage over the polysaccharide in adults 
and may become the vaccine of choice for Hajj pilgrims if 
supported by the authorities [46]. Despite being more expen-
sive, conjugate vaccine could be a cost-saving strategy in the 
context of a mass vaccination program [47]. Another limita-
tion was the disproportionate number of male pilgrims in 
2013. Nevertheless, further research is needed to explore the 
reasons for the poor uptake and to assess impact of new 
measures to improve uptake. 
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Fig. (2). Pneumococcal vaccine uptake by gender among Australian Hajj pilgrims in the years 2011-13. 
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Key points of publication #3:
This part of the thesis (Publication# 3) presented the outcome of a survey exploring
the pneumococcal vaccine uptake among Hajj pilgrims. Apparently, the uptake was
suboptimal even among ‘at-risk’ populations who are in most need for it for their
travel.
However, the sensitivity of the survey may have been lower than what was expected
and the main limitation of the study finding is that I could not differentiate in the
survey whether the pilgrims had the conjugate or polysaccharide vaccine because
the participants were not able to distinguish between them. Nevertheless, a year
after, and in collaboration with other colleagues in the Hajj research team, we
carried on investigating the uptake of the pneumococcal conjugate vaccine where
we found it reached up to 41% (54).
In this thesis, I proceeded with examining the Hajj pilgrims’ KAP about the
respiratory infections including pneumococcal infection.
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 2.1.2 Publication #4; letter: 
Tashani M, Alfelali M, Barasheed O, Fatema FN, Alqahtani A, Rashid H, 
et al. Australian Hajj pilgrims' knowledge about MERS-CoV and other 
respiratory infections. Virol Sin. 2014;29:318-20. 
 
 
Overview of publications #4: 
Because the vaccine uptake was poor, I wanted to explore further aspects in relation to this 
issue. The following publication, #4 in this thesis, assesses the Hajj pilgrims’ understanding 
about various travel-related infections, their severity and mode of transmission.  
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LETTER
Australian Hajj pilgrims’ knowledge about MERS-CoV and other 
respiratory infections
Dear Editor,
With the intense crowding in mass gatherings such 
as Hajj, there is a high risk of acquisition of airborne 
in-fections with the potential for its transmission in the 
pilgrims’ country of origin (Memish Z A, et al., 2014). 
The risk of importing serious infections from Hajj 
has escalated since the emergence of the Middle East 
respiratory syndrome coronavirus (MERS-CoV) in Saudi 
Arabia and other neighbouring countries from September 
2012.
Active surveillance of Hajj pilgrims in 2012 and 2013 
failed to detect occurrence of MERS-CoV among Hajj 
pilgrims (Rashid H, et al., 2013; Gautret P, et al., 2014). 
However, MERS-CoV infection has been reported in 
several Umrah (minor pilgrimage) visitors to Makkah 
and Madinah who have travelled to UK, Malaysia and 
the Netherlands indicating that there is a potential for 
worldwide spread of MERS-CoV (HPA UK Novel Coro-
navirus Investigation team, 2013;  Premila Devi J, et al., 
2014; Kraaij-Dirkzwager M, et al., 2014). 
To reduce the risk of infectious disease transmission 
at Hajj, the Saudi Ministry of Health (MoH) publishes 
annual recommendations for Hajjis with advice for 
elderly adults ≥65, pregnant women, children, and 
those with pre-existing medical conditions preferably to 
postpone Hajj but whoever attends to maintain optimum 
preventive measures. However, many pilgrims may not 
be aware of MERS-CoV and other infection diseases 
in Saudi Arabia. For instance, a study among French 
pilgrims showed that only 64.7% of them were aware of 
MERS-CoV (Gautret P, et al., 2013). Nevertheless, sub-
sequently, there have been fresh sparks of MERS-CoV 
early this year with consequent wider media coverage; 
therefore, we conducted this survey to explore Australian 
pilgrims’ awareness of MERS-CoV and knowledge about 
the transmission of common respiratory infections. 
A cross sectional survey was conducted among Aus-
tralian pilgrims who were planning to attend the Hajj 
2014. The survey was conducted at Hajj vaccination 
clinic at the Children’s Hospital at Westmead, Sydney, 
from February to July 2014. Vaccinees were invited to 
participate in a questionnaire-based survey while they 
were waiting in the observation room, before or after 
the receipt of vaccines. Following a short briefing about 
the study, informed consent was obtained from each 
participant who agreed to join the survey; knowledge 
about respiratory infections was assessed using a 
13-point questionnaire. Pilgrims’ demographics, previous 
Hajj attendance and history of chronic medical conditions 
were also collected. Pilgrims completed the surveys 
themselves; however, research team members helped 
those who were unable to complete the questionnaires 
themselves. Ethics approval was obtained from Hunter 
New England Research Ethics Committee (HREC re-
ference number 13/05/3.05).
A convenience sample of 119 Australian pilgrims aged 
18-71 (mean 41 [±12.5]) years completed the question-
naires; 54 (45.5%) were male. Almost all of them were 
educated to a good standard (Table 1). Ninety seven 
(81.5%) pilgrims were a first time Hajj attendee and 18 
(15%) of them had at least one condition for which the 
Saudi MoH recommends postponement of Hajj. None 
of the female participants was pregnant (pregnancy was 
excluded as a vaccination requirement). Almost 70% 
respondents were originally from Asia-pacific (Table 
1) with English being the preferred language to receive 
medical information.
Two-thirds (n=80) of the respondents stated that they 
have access to all necessary medical information they 
needed (Table 2), yet a two-thirds of the participants were 
not aware of the ongoing MERS-CoV epidemic in Saudi 
Arabia. When asked if they had heard of novel corona 
virus outbreak in Saudi Arabia only 42 (35.3%) pilgrims 
responded that they had, while 71 (59.7%) declared that 
they had not, and the remaining 6 (5%) did not answer 
the question. This compares with 64.7% French Hajj pil-
grims in the previous year knowing about MERS-CoV 
circulation in Saudi Arabia (Gautret P, et al., 2013). 
Many pilgrims had misperception about the mode of 
transmission of common respiratory infections. For instance, 
42% respondents did not know how pneumococcal in-
fection is transmitted, and another 16%-18% did not 
know how influenza and pertussis are transmitted; this 
compares with 16.7% French pilgrims and 9% international 
pilgrims not knowing how acute respiratory infections (ARI) 
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are transmitted at Hajj (Gautret P, et al., 2009; Memish Z 
A, et al., 2012). On the contrary, respectively, 45 (37.8%), 
69 (58%) and 78 (65.5%) pilgrims gave correct answers 
that pneumococci, influenza and pertussis transmit via 
air, while 7 (5.9%), 15 (12.6%) and 3 (2.5%) pilgrims 
respectively stated that the respective infectious agents 
spread through drinking water (Table 3); interestingly 
some respondents also believed that the infections can 
spread through a shaving razor.
When asked about their risk perception concerning 
the seriousness of pneumococcal disease, influenza 
and pertussis, only 31%–45% pilgrims believed that 
the diseases were serious, while about 11% pilgrims 
supposed that influenza was not serious (Table 2). Re-
garding the trustworthiness of the source of health 
information, most respondents (90%) opined that the 
general practitioner (GP) was the most trustworthy so-
urce of the medical information whereas to the large 
majority, television and internet were not reliable re-
sources.
The lack of knowledge among Hajj pilgrims about 
potentially serious infectious hazards at Hajj indicates 
that health authorities in the pilgrims’ countries of origin 
should take a more active role in sharing the health 
Table 2. Pilgrims’ perception about respiratory infections and source of medical information
Table 3. Pilgrims’ knowledge about the mode of transmission of common respiratory infections
 
Strongly 
agree
n (%)
Agree
n (%)
Don't 
know
n (%)
Disagree
n (%)
No answer
n (%)
Strongly 
disagree
n (%)
  Pneumococcal infection  is a serious disease   54 (45.4)   41 (34.5)   15 (12.6) 0   9 (7.6) _
  Pertussis is a serious disease   53 (44.5)   50 (42.0)   9 (7.6) 0   7 (5.9) _
  Influenza is a serious disease   37 (31.1)   54 (45.4)   8 (6.7) 13 (10.9)   7 (5.9) _
  There is a high risk of catching pneumococcal    
  infection at Hajj
  35 (29.4)   43 (36.1)   31 (26.1) 2 (1.7)   8 (6.7) _
  There is a high risk of catching influenza at Hajj   39 (32.8)   50 (42)   21 (17.6) 1 (0.8)   8 (6.7) _
  There is a high risk of catching pertussis at Hajj   31 (26.1)   47 (39.5)   25 (21.0) 5 (4.2)   11 (9.2) _
  I have access to all medical information that I 
  need
  20 (16.8)   60 (50.4)   17 (14.3) 9 (7.6)   13 (10.9) 0
  I trust medical information from television   4 (3.4)   51 (42.9)   17 (14.3) 32 (26.9)   12 (10.1) 3 (2.5)
  I trust medical information from internet   3 (2.5)   41 (34.5)   31 (26.1) 31 (26.1)   10 (8.4) 3 (2.5)
  I trust medical information from GP   46 (38.7)   60 (50.4)   4 (3.4) 0    9 (7.6) 0
 Vehicle
Mode of transmission 
of pneumococci
n (%)
Mode of transmission of 
influenza
Mode of transmission of 
pertussis
n (%) n (%)
      Air 45 (37.8) 69 (58) 78 (65.5)
      Drinking water 7 (5.9) 15 (12.6) 3 (2.5)
     Shaving razors 1 (0.8) 3 (2.5) 1 (0.8)
     Food 0 0 6 (5)
     Don't know 50 (42.0) 19 (16) 21 (17.6)
     No answer 16 (13.4) 13 (10.9) 10 (8.4)
 Highest level 
of education
n (%) 
Pilgrims’ country 
of birth
n (%)
Preferred language to receive 
medical information
n (%)
  University (Bachelor)  42 (35.3)            Indonesia    29 (24.4)                     English 83 (69.7)
  High school  28 (23.5)            Pakistan    27 (22.7)                     Arabic 15 (12.6)
  TAFE Diploma*  19 (16)            Australia    20 (16.8)                     Indonesian 11 (9.2)
  Master  18 (15.1)            Lebanon    18 (15.1)                     No answer 5 (4.2)
  Other  12 (8.2)            Bangladesh    11 (9.2)                     Urdu 4 (3.4)
             Other    14 (11.8)                     Persian 1 (0.8)
* TAFE Diploma=Technical and Further Education Diploma
Table 1. Pilgrims’ level of education, country of birth and preferred language
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recommendations and guidelines published by Saudi 
MoH with travellers. Health education programs at the 
entry points in Saudi Arabia have been shown to improve 
pilgrims’ knowledge (Turkestani A, et al., 2013), and 
publicizing of health messages (eg, posters, roadside 
electronic notices) at Hajj was associated with higher 
compliance to protective measures and shorter duration 
of respiratory illness (Balaban V, et al., 2012). Healthcare 
workers, particularly GPs, can play an important role 
in making Hajj pilgrims aware of the ongoing global 
and regional outbreaks (Turkestani A, et al., 2013). 
International health authorities like World Health 
Organization (WHO), US Centers for Disease Control 
and Prevention (CDC), and Department of Health, 
Australia (DoHA) could take a lead in disseminating the 
health information. This is more important in the current 
context of the 2014 Ebola outbreak in the Muslim co-
untries in West Africa that send pilgrims on Hajj (Memish 
Z A, et al, 2014).
Other studies conducted by our colleagues showed that 
tour group leaders are highly influential in promoting 
vaccination (Barasheed O, et al., 2014), but a limitation 
of this survey is that we did not explore the role of 
the tour operators in making the pilgrims aware of the 
outbreaks. Small sample size is another limitation of this 
study and therefore the findings cannot be generalised 
to all Australian pilgrims. Addressing this limitation and 
to better quantify the knowledge, attitude and practice 
of Australian Hajj pilgrims about health hazards at Hajj 
and their prevention, we are undertaking a larger survey 
during and after the Hajj 2014. The survey will explore 
pilgrims’ understanding about the source of transmission, 
preventive and therapeutic options of MERS-CoV and 
other respiratory infections.
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Key points of Publication #4:
The letter demonstrated a lack of proper knowledge among Hajj pilgrims. For instance, 42% of
them did not know how pneumococcal infection is transmitted and some (6%) thought it is
transmitted through drinking water. The low vaccine uptake coupled with this poor
understanding about respiratory infections, inspired me to undertake a KAP survey to detect
the barriers against vaccines of serious bacterial infections (Neisseria meningitidis, and
Streptococcus pneumoniae) both of which would be included in my proposed RTC.
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 2.1.3 Publication #5; KAP survey:  
Tashani M, Alfelali M, Azeem MI, Fatema FN, Barasheed O, Alqahtani 
AS, et al. Barriers of vaccinations against serious bacterial infections 
among Australian Hajj pilgrims. Postgrad Med. 2016;128:541-7. 
 
Publication overview: 
This paper will present the result of a KAP survey addressing the barriers to vaccinations 
against serious bacterial infections (e.g. pneumococcal, diphtheria, pertussis and tetanus). 
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ABSTRACT
Objectives: Vaccination against serious bacterial infections is recommended for Hajj pilgrims. Although
the uptake of mandatory vaccines among Hajj pilgrims is acceptable, the uptake of other recommended
vaccines remains suboptimal. In this study, we have explored the barriers to vaccination against serious
bacterial infections among Australian Hajj pilgrims.
Methods: Travellers aged 18 years and older planning to attend Hajj in the years 2014 and 2015 were
surveyed at the immunization clinic of the Children’s Hospital at Westmead, Sydney, Australia. A
questionnaire-based survey was conducted to explore pilgrims’ vaccination histories for their previous
visits to Mecca, the reasons for non-receipt of vaccination, and to assess knowledge about the
transmission of infections.
Results: A total of 300 participants aged 18-76 (median 41) years completed the survey. Most (233
[77.7%]) were born outside Australia. Overall, 113 (37.7%) had performed pilgrimage in the past; 19
(16.8%) of them reported receiving pneumococcal vaccine and 16 (14.1%) diphtheria, tetanus and
pertussis (DTP) vaccine. Lack of awareness about the availability of the vaccines was the main reason for
non-receipt of pneumococcal and DTP vaccines (respectively 41.1% and 44.7%). Most pilgrims (266
[88.7%]) believed that travel vaccines are necessary before embarking on a journey; however, some
expressed concerns about adverse reactions (156 [52.0%]), cost (114 [38.0%]), and permissibility of the
vaccine according to their religion (6 [2.0%]). Respectively, 187 (62.3%), 145 (48.3%) and 86 (28.7%)
respondents did not correctly know how meningococcal and pneumococcal diseases and pertussis
transmit. Nevertheless, most (256 [85.3%]) indicated that they trust their family doctor for medical
information and most (203 [67.7%]) preferred to receive the medical information in English.
Conclusion: The uptake of recommended vaccines against serious bacterial infections among
Australian Hajj pilgrims is low. Lack of awareness about the availability of vaccines, misperceptions
surrounding the safety of vaccines and high cost are key barriers of uptake.
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Introduction
Australia aims to maintain a high level of vaccination coverage
nationally and has one of the most comprehensive publicly
funded immunization programs for children and ‘at-risk’ popu-
lations in the world [1]. Despite this achievement, the uptake
of a few vaccines among certain ‘at-risk’ groups/vulnerable
population remains low, which may increase the risk of trans-
mission of vaccine-preventable infections [1]; additionally, tra-
vel-associated infections can be imported by unvaccinated
people and may be introduced in vulnerable pockets.
Australia is a multicultural country and welcomes a large
number of international travelers who, especially if unvacci-
nated, may pose the risk of importing travel-associated
infections [2]. Therefore, a number of vaccines are recom-
mended for both arriving and departing travelers [3]. Each
year, several thousand Australian pilgrims attend Hajj pilgrim-
age, an assembly of 2–3 million people in Mecca, Saudi Arabia,
considered to be the largest annual mass gathering on the
planet. To protect against serious infectious diseases, Hajj
attendees are required to receive several vaccines before
embarking on their journey. The Saudi authority mandates a
quadrivalent meningococcal vaccine for all Hajj pilgrims and
strongly recommends a few other vaccines such as polio,
yellow fever, influenza, diphtheria, tetanus, and pertussis
(DTP), mumps, measles, and rubella (MMR) vaccines [4].
Additionally, independent experts recommend pneumococcal
vaccine for Hajj pilgrims particularly for those who are highly
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susceptible to the infection [5]. Pneumococcal vaccine is also
recommended in Australia for people with certain high-risk
medical conditions, elderly (≥65 years of age) and of aborigi-
nal ethnicity [1]. However, while the uptake of the mandatory
vaccine is generally ensured [6], and the uptake of influenza
vaccine is improving [7], the uptake of other recommended
vaccines such as pneumococcal, DTP, and MMR vaccines is
poor or suboptimal [8–12].
A few studies have examined the uptake of recommended
Hajj vaccines, and explored barriers to, and facilitators of
vaccinations (e.g. of influenza vaccine). However, very limited
studies have specifically examined the uptake of vaccinations
against serious bacterial infections.
Therefore, we have conducted this survey to evaluate the
uptake of pneumococcal and DTP vaccines among Australian
Hajj pilgrims, to explore barriers to those vaccinations and
examine the travelers’ understanding about the severity and
mode of transmission of serious bacterial infections.
Method
Study participants
This was a cross-sectional survey conducted among Australian
Hajj pilgrims, before embarking their journey, aged 18 years
and older, in Greater Sydney, New South Wales (NSW), over two
consecutive years in 2014 and 2015. Travelers who were parti-
cipating in the Hajj 2014 season were recruited over a period of
20 weeks, from February to June; whereas the recruitment of
2015 lasted for 30 weeks from February to August. This study
was done in parallel to an ongoing randomized controlled trial
(RCT) that examines immunological interactions between vac-
cinations against serious bacterial infections.
We have ongoing parallel work with Hajj pilgrims and we
have lists of tour operators whom we contacted through our
network in order to make a request that they refer their clients to
our immunization clinic at the Children’s Hospital at Westmead,
NSW, Australia to take part in the RCT as well as in the survey.
Questionnaire administration and design
The trial subjects were invited to participate voluntarily in this
questionnaire-based survey while they were waiting in the
observation room before the receipt of their vaccines. After a
short briefing about the study, informed consent was
obtained from each participant who agreed to join the survey.
Participants completed the single-choice questions them-
selves on the questionnaires; however, research team mem-
bers helped those who were unable to complete the
questionnaires themselves by recording the dictated answers.
The first part of the questionnaire contained the participants’
demographic details including country of birth, age, gender,
and level of education. The second part contained medical
histories, including preexisting medical conditions, previous
Hajj or Umrah pilgrimages and receipt of pneumococcal and
DTP vaccinations prior to their previous visits to Mecca.
Participant was considered ‘at-risk’ if he/she had one of the
following conditions according to the Australian immunization
handbook: chronic lung disease (including asthma), chronic
heart disease, chronic renal disease, diabetes mellitus, alcohol-
ism, immunodeficiency states, tobacco smoker, hyposplenism,
asplenia, splenic dysfunction, sickle cell disease, chronic liver
disease (including cirrhosis), and all nonindigenous adults
aged ≥65 years [1]. No question was asked about the uptake
of vaccination for the recruitment years’ Hajj trip as vaccina-
tions against meningococcal and pneumococcal conjugate
vaccines and DTP were actively offered as part of the RCT.
Since meningococcal vaccine is a mandatory requirement for
Hajj visa, no question was asked about its uptake for the
previous pilgrimage; other surveys involving pilgrims from
Australia and other developed countries have confirmed that
all travelers receive this mandatory vaccine [6,12]. The third
part evaluated the knowledge of the pilgrims about infections
that are commonly transmitted at Hajj and the respondent
attitudes toward vaccinations against those infections. The
later was constructed as 5-point Likert scale from strongly
disagree to strongly agree. The questionnaire ended with an
open question that asked if the pilgrims had any concern,
myth, or doubt surrounding vaccinations, or heard a rumor
or opinion against vaccination. Answers of concerns about
vaccination were structured into two themes: concerns regard-
ing significant complications of vaccination, and concerns
regarding permissibility of the vaccine components according
to Islamic faith, in other words ‘Halal status.’
Data collection and analysis
The data were entered into an excel spreadsheet. Analysis was
performed using SPSS V22 statistical software (SPSS, Chicago,
IL, USA). The results were analyzed descriptively predomi-
nantly by presenting as frequency distributions.
Ethics consideration
This study was reviewed and approved by the Hunter New
England Human Research Ethics Committee (HNEHREC
Reference number: 13/05/15/3.05).
Results
From more than 14 different Hajj travel agents in Greater
Sydney, 304 pilgrims were approached and 300 of them
(response rate 98.7%) agreed to participate in the study. The
participants were aged 18–76 (median 41) years, and 148
(49.3%) were female, none of them was pregnant (pregnancy
was excluded as a vaccination requirement). Most of the
respondents (262 [87.3%]) were educated up to a good stan-
dard (high school or above); about one-third of the partici-
pants (97 [32.3%]) belonged to the middle-income category
($400–1249 per week). Only 67 (22.3%) respondents reported
to be born in Australia while the others were born overseas
(Table 1). English was reported to be the preferred language
to receive medical information for most participants (203
[67.7%]) followed by Arabic (42 [14.0%]) and other languages
(Table 1). Forty five (15.0%) of the participants suffered from at
least ‘one risk’ condition, including age ≥65 years, for which
pneumococcal vaccine is recommended. About a third (97
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[32.3%]) reported to have regular contact with children aged
under 2 years of age.
The majority (187 [62.3%]) indicated that this was their first
pilgrimage to Mecca, the remaining 113 (37.7%) respondents
performed Hajj previously in the past 10 years. Upon ques-
tioning the latter 113 about vaccinations for their previous
pilgrimage, respectively, 19 (16.8%) and 16 (14%) of them
admitted receiving pneumococcal and DTP vaccines
(Table 2). Only one (9.0%) pilgrim from 11 previous Hajj
goers in the ‘at-risk’ category reported receiving pneumococ-
cal vaccine for the previous Hajj visit.
The lack of awareness about the availability or existence of
the vaccine was the single most common reason for nonre-
ceipt of pneumococcal (41.1%) and DTP (44.7%) vaccines,
respectively, followed by reliance on natural immunity (5.4%
for pneumococcal vaccine and 7.1% for DTP vaccine), the
other reasons have been summarized in Table 2.
When asked about their perception regarding the impor-
tance of receiving vaccine before travel, most pilgrims either
strongly agreed (162 [54.0%]) or just agreed (104 [34.7%]) that
the vaccines are necessary; only 33 (11.3%) considered that
vaccines do not provide immunity against infectious disease
(Table 3). With regards to their risk perception concerning the
severity of meningococcal disease, pneumonia, and pertussis,
respectively 54.0%, 45.0%, and 42.7% pilgrims strongly agreed
that the infections were serious. Upon reviewing the
responses to an open-ended question on concerns, myths, or
rumors surrounding vaccination, 40 (13.3%) pilgrims stated to
have heard of rumors: 34 (11.4%) stated that development of
significant complication as a result of vaccination was a con-
cern, but the perceived magnitude of the reported complica-
tion varied widely from a flu-like illness through autism to
fatality, while the other 6 (2.0%) pilgrims expressed concern
about the permissibility of vaccine on religious ground (e.g.
having ‘non-Halal’ or religiously non-permissible elements
within the vaccine).
Only over a third of the participants (102 [34.0%]) knew
correctly that most travel vaccines are not funded by the
Australian Government and are paid out of pocket, whereas
55 (18.3%) thought that the Hajj vaccines are either fully or
partly subsidized by government (regardless of their risk sta-
tus), while the remaining 144 (48.0%) pilgrims either did not
know or skipped that question.
Pilgrims’ knowledge about the modes of transmission of
common respiratory infections has been summarized in
Table 4; most of the time, respondents failed to identify the
correct modality of transmission of infections. This is despite
the fact that about two-thirds of them (189 [63.0%]) claimed
to have access to required medical information.
Regarding the trustworthiness of the source of health infor-
mation, most respondents (205 [68.3%]) opined that the gen-
eral practitioner (GP) was the most trustworthy source of the
medical information, whereas over one-third of them indi-
cated that television and internet were reliable resources
(Table 3).
Discussion
This survey demonstrates that the uptake of recommended
vaccines against serious bacterial infections among Australian
pilgrims is suboptimal. The survey has additionally pointed to
some key problems and barriers to vaccination, identified
misconceptions and myths surrounding vaccination and
explored gaps in travelers’ knowledge of the modes of trans-
mission of serious bacterial infections.
In this survey, we have demonstrated that pneumococcal
vaccine uptake among Australian pilgrims for their previous
pilgrimage was poor (16.8%). This compares well with other
local and international surveys (Table 5). Concerning DTP vac-
cine uptake among our participants who previously visited
Mecca for pilgrimage, only 16 (5.3%) of our participants
reported receiving it; this compares with another independent
survey involving Australian pilgrims in 2014 which showed
that 30.0% pilgrims received DTP [12] (Table 5). We have
noted that many pilgrims missed out the opportunity to
receive some important vaccines such as pneumococcal vac-
cine either due to the dearth of awareness about the existence
(41.0%) of vaccine (even among ‘at-risk’ pilgrims who could
get it for free) or not being a Hajj visa requirement. This lack of
awareness was similar to that of another survey among
Australians pilgrims in 2014 where more than half of the
pilgrims (56.0%) declined to have any knowledge about the
Table 1. Participants’ demographic characteristics (N = 300).
n (%)
Age (years)
Median (range) 41 (18–76)
Mean (SD) 41.27 (±12.18)
Sex
Male 152 (50.7)
Female 148 (49.3)
Country of birth
Australia 67 (22.3)
Indonesia 55 (18.3)
Lebanon 50 (16.7)
Pakistan 47 (15.7)
Bangladesh 25 (8.3)
Other 41 (13.6)
Not answered 15 (5.0)
Pilgrims with ‘at-risk condition’ 45 (15)
Education level
Doctorate 4 (1.33)
Master 44 (14.7)
TAFEa Diploma 54 (18.0)
University (Bachelor) 95 (31.7)
High school 69 (23.0)
Primary school 12 (4.0)
Other 5 (1.7)
No education 3 (1.0)
No answer 14 (4.7)
Preferred language to receive
medical information
English 203 (67.7)
Arabic 42 (14.0)
Bahasa 29 (9.7)
Urdu 12 (4.0)
No answer 12 (4.0)
Persian/Farsi 2 (0.7)
Income per week Low (Nil–$399/0) 44 (14.7)
Middle ($400–1249) 97 (32.3)
High ($1250–>2000) 35 (11.7)
Preferred not to
disclose
124 (41.3)
Regular contact with children
<2 years
97 (32.3)
aTechnical and further education institute for vocational tertiary education.
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vaccines [12]. Likewise, a qualitative survey among Australian
hospitalized elderly in 2007 found that many respondents
simply were not aware of the existence of the vaccine [13].
Cost of vaccine was identified to be an additional barrier.
About 38.0% of our respondents expressed concerns about
the high cost of the vaccine. Current travel vaccines are not
affordable for all Hajj travelers (for instance, a dose of pneu-
mococcal vaccine cost the pilgrims about $100 per head). A
French study has shown that offering pneumococcal vaccine
as out of pocket purchase, resulted in a lower (41.0%)
Table 2. Barriers against the uptake of some recommended vaccines among previous pilgrimage (Hajj/Umrah) performers (N = 113).
n (%) (95% CI, lower limit–
upper limit)
Pilgrims who admitted receiving pneumococcal vaccine in previous pilgrimage 19 (16.8) (0.1–0.25)
Pilgrims who did not remember their pneumococcal vaccination status for the
previous pilgrimage
38 (33.6) (0.25–0.43)
Pilgrims who declined receiving pneumococcal vaccine in previous pilgrimage 56 (49.5) (0.4–0.59)
Reasons for nonreceipt
Not aware about it 23 (41.0) (0.28–0.55)
Reliance on natural
immunity
3 (5.4) (0.01–0.15)
Was not required 3 (5.4) (0.01–0.15)
‘I don’t think it’s
important’
3 (5.4) (0.01–0.15)
Busy 1 (1.8) (0.00–0.09)
No answer 23 (41.0) (0.28–0.55)
Pilgrims who admitted receiving DTPa vaccine in previous pilgrimage Hajj 16 (14.1) (0.08–0.22)
Pilgrims who did not remember their DTP vaccination status for the previous
pilgrimage
41 (36.3) (0.27–0.46)
Pilgrims who declined receiving DTP vaccine in previous pilgrimage 56 (49.5) (0.4–0.59)
Reasons for nonreceipt
Was not aware
about it
25 (44.6) (0.31–0.58)
Reliance on natural
immunity
4 (7.1) (0.02–0.17)
Was not required 4 (7.1) (0.02–0.17)
‘I don’t think it’s
important’
3 (5.3) (0.01–0.15)
Busy 2 (3.5) (0.00–0.12)
No answer 18 (32.1) (0.2–0.46)
aDiphtheria, tetanus, and pertussis.
Table 3. Pilgrims’ perception about respiratory infections and trusted source of medical information.
Strongly agree Agree Don’t know Disagree Strongly disagree
n (%) n (%) n (%) n (%) n (%)
Vaccination is necessary before travel 162 (54.0) 104 (34.7) 31 (10.3) 2 (0.7) 1 (0.3)
I have access to all medical info to make vaccine decision 48 (16.0) 141 (47.0) 82 (27.3) 27 (9.0) 2 (0.7)
I prefer to take multiple vaccines at the same time 23 (7.7) 96 (32.0) 88 (29.3) 82 (27.3) 11 (3.7)
Concern about the cost of vaccines 13 (4.3) 101 (33.7) 50 (16.7) 108 (36.0) 28 (9.3)
Concern about side effects of vaccines 21 (7.0) 135 (45.0) 55 (18.3) 75 (25.0) 14 (4.7)
Too many vaccines may weaken the immune system 13 (4.3) 48 (16.0) 152 (50.7) 74 (24.7) 13 (4.3)
Vaccine does not help the development immune system 3 (1.0) 31 (10.3) 60 (20.0) 144 (48.0) 62 (20.7)
Meningitis is serious disease 162 (54.0) 80 (26.7) 56 (18.7) 1 (0.3) 1 (0.3)
Pneumonia is serious disease 135 (45.0) 102 (34.0) 62 (20.7) 1 (0.3) 0 (0.0)
Pertussis is serious disease 128 (42.7) 118 (39.3) 49 (16.3) 5 (1.7) 0 (0.0)
There is a high risk of meningitis at catching Hajj 96 (32.0) 107 (35.7) 90 (30.0) 6 (2.0) 1 (0.3)
There is a high risk of catching pneumonia at Hajj 91 (30.3) 110 (36.7) 92 (30.7) 0 (0.0) 7 (2.3)
There is a high risk of catching Pertussis at Hajj 66 (22.0) 139 (46.3) 80 (26.7) 14 (4.7) 1 (0.3)
I trust medical information received from TVa 10 (3.3) 104 (34.7) 86 (28.7) 86 (28.7) 14 (4.7)
I trust medical information received from internet 12 (4.0) 82 (27.3) 108 (36.0) 85 (28.3) 13 (4.3)
I trust medical information received from GPb 106 (35.3) 150 (50.0) 41 (13.7) 2 (0.7) 1 (0.3)
aTelevision.
bGeneral practitioner.
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acceptance rate [9]. Some of our participants had humble
income and national insurance policy does not cover the
cost of Hajj (and/or) other travel immunization, thus paying
out of pocket is considered a hindrance against the uptake of
travel vaccines [14]. National policies should consider subsidiz-
ing travel vaccines depending on travel destination and
affordability of the traveler.
The lack of awareness about DTP vaccine was also reported
by 44.7% of our respondents. This is unsurprising, as there is a
lack of awareness about DTP vaccine among the general
Australian population. For instance, a 2011 survey among
hospitalized adult patients in Australian showed that only
9.6% had received the pertussis vaccination in the preceding
5 years and 79.4% had no knowledge of pertussis adult boos-
ter dose [24]. In the year 2005, diphtheria and tetanus vaccina-
tion rate among elderly French Hajj pilgrims was lower
compared to their younger counterparts [23]; in the subse-
quent year, diphtheria and tetanus vaccine uptake was noted
to be significantly higher among French citizens with higher
educational level and better fluency in French [10]. The 9-year-
long survey involving Dutch pilgrims showed that only one
quarter of pilgrims accepted the diphtheria and tetanus
Table 4. Australian Hajj pilgrims’ knowledge about the mode of transmission of travel-related infections.
Food n (%) Drinking water n (%) Shaving razors n (%) Air n (%) Don’t know n (%) No answer n (%)
Meningococci disease 31 (10.3) 21 (7.0) 13 (4.3) 67 (22.3) 143 (47.7) 25 (8.3)
Pneumococci disease 6 (2.0) 13 (4.3) 8 (2.7) 121 (40.3) 118 (39.3) 34 (11.3)
Pertussis disease 19 (6.3) 10 (3.3) 2 (0.7) 195 (65.0) 55 (18.3) 19 (6.3)
Influenza disease 23 (7.7) 14 (4.7) 4 (1.3) 188 (62.7) 46 (15.3) 25 (8.3)
Food poison disease 237 (79.0) 4 (1.3) 1 (0.3) 1 (0.3) 33 (11.0) 24 (8.0)
HIV/AIDSa disease 4 (1.3) 1 (0.3) 208 (69.3) 0 (0.0) 59 (19.7) 28 (9.3)
Hepatitis A disease 53 (17.7) 22 (7.3) 77 (25.7) 11 (3.7) 112 (37.3) 25 (8.3)
Hepatitis B and C disease 40 (13.3) 16 (5.3) 92 (30.7) 9 (3.0) 120 (40.0) 23 (7.7)
aHuman immunodeficiency virus/Acquired immunodeficiency syndrome.
Table 5. Summary of reported pneumococcal and DTPa vaccines uptake rates in Australia and other countries.
Study Vaccines studied
Country of the
participants Year Population
Vaccine
coverage (%) Notes
Tashani et al. [11] Pneumococcal vaccine Australia 2011 Hajj
pilgrims
28.5 Among ‘at-risk’ group, the uptake was 30.6%
2012 28.7 Among ‘at-risk’ group, the uptake was 45.3%
2013 14.2 Among ‘at-risk’ group, the uptake was 29.0%
Hull et al. [15] 2006 ‘At-risk’
elderly
61.0 A year after it began to be funded by the
government
2011 ‘At-risk’
elderly
60.0
Gautret et al. [16] France 2009 Hajj
pilgrims
31.4
Gautret et al. [17] 2010 Hajj
pilgrims
1.7 Vaccine rates among >65 years without
chronic diseases 1.3%,
>65 years with chronic diseases 2% and
<65 years with chronic diseases 3.4%
Benkouiten et al. [18] 2012 Hajj
pilgrims
35.9 Retrospective study for the past 5 years.
Showed 22% uptake among ‘at-risk’
Benkouiten et al. [19] 2013 Hajj
pilgrims
51.2 Retrospective study for the past 5 years
Meysamie et al. [20] Iran 2004 Hajj
pilgrims
2.5
2005 Hajj
pilgrims
8.9
Shafi et al. [21] UK 2005 Hajj
pilgrims
5.0 Among ‘at-risk’ group the uptake was 15.0%
Hashim et al. [22] Malaysia 2013 Hajj
pilgrims
59.4
Alqahtani et al. [12] DTP Australia 2014 Hajj
pilgrims
30.0 Many pilgrims from Greater Sydney have
received the vaccine for free as part of our
RCT conducted at the same time
Gautret et al. [23] Tetanus vaccine France 2005 Hajj
pilgrims
22.6 Vaccination rate decreased with age
Diphtheria vaccine 2005 Hajj
pilgrims
16.1
Pertussis 2005 Hajj
pilgrims
10.6
Gautret et al. [10] Tetanus vaccine 2006 Hajj
pilgrims
18.0
Diphtheria vaccine 2006 Hajj
pilgrims
14.7
Keles et al. [8] Diphtheria and tetanus
vaccines
Holland 2001–
2009
Hajj
pilgrims
24.0 9-Year retrospective survey. Independent
factors for acceptance were being female,
of younger age, and being less healthy
aDiphtheria, tetanus and pertussis.
bRandomized controlled trial.
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vaccine and the uptake was better in females, younger indivi-
duals, and in those who were less healthy. On the contrary
high cost of vaccine, language barrier, and the fact that the
vaccine was not a Hajj visa requirement were notable barriers
of vaccination [8]. The latter corroborates with our findings
that approximately 7.1% of the respondents avoided the vac-
cine for not being a visa requirement.
It is generally believed that a major determining factor of
vaccination is a physician’s recommendation [25], even
when the patient is hesitant [26]. The majority of our
respondents admitted that they trust medical information
received from their GP more than mass media (e.g. TV or
Internet), and this is consistent with the attitude of
Australian hospitalized adult patients [13]. It is therefore
sensible to reinforce this trust by providing continuous
medical education to the GPs on health risks of mass gath-
erings. To improve the trust in the local doctors in Australia,
GPs should be aware of Muslim community beliefs and
attitude in order to address them [27]. For example, our
open-ended question about vaccine myths/concerns/rumors
has revealed that there are wide concerns about the safety
issue and, more importantly, the vaccine permissibility in
Islamic faith (‘Halal’ status). Similar concerns based on reli-
gious grounds have resulted in vaccine refusal in selected
communities leading to the reemergence of infection diseases
such as polio in several countries [28–30]. In Indonesia, vac-
cines require Halal labeling [5]. In Australia, such issue has
been resolved by a decree from religious jurists that the
complements of a vaccine once go through an irreversible
chemical change become permissible in Islam [31]. It is note-
worthy that the myth surrounding vaccines’ link to Autism still
persists and has been stated by 3 (1.0%) of our participants;
similar rumors were reported by some Australian hospitalized
elderly adults in Australia in 2007 [13].
In addition to the role of GPs, literature suggests that the
travel agents and Hajj tour group leaders are key promoters of
vaccination [32–34]; consequently, educating travel agents to
inform their clients of the importance of receiving recom-
mended vaccines before travel might improve vaccine uptake.
Of note, minority (22.3%) of our participants were born in
Australia; however, yet a majority of them (67.7%) preferred to
receive health information in English. Elsewhere, it was sug-
gested that offering non-Western migrants more written and
oral information in their own language would result in a
higher compliance [27,35]. Our survey revealed that respon-
dents’ risk perception and knowledge about modes of trans-
mission of several bacterial infections were not so accurate,
which suggests that there is a need for advocating health
education for Hajj pilgrims. It is observed that lower vaccina-
tion rate is typically linked to low perception of disease sever-
ity [36]. However, despite high perception of meningococcal
and pneumococcal diseases and pertussis as serious infec-
tions, and high risk of transmission of those infections at
Hajj, at least 18.0% of our respondents did not know precisely
how the diseases are transmitted; this compares with 16.7%
French pilgrims and 9.0% international pilgrims not knowing
how acute respiratory infections are transmitted [37,38].
A strength of our survey is that it is the first study to focus
on the uptake and barriers of vaccination against serious
bacterial infections among Australian Hajj pilgrims. However,
the moderate sample size is a limitation of our survey, and the
responses were subject to recall bias as self-reporting of pneu-
mococcal vaccine has not been shown to be reliable [39,40];
also we could not validate vaccination history by checking
vaccine certificates or other records since most people do
not carry them and this is not yet systematically registered.
Another limitation is that some participants omitted certain
questions on vaccine uptake, and the reasons for this were not
explored. Also some authorities may not consider ‘lack of
awareness’ per se as a real barrier to a vaccination. Whether
or not a participant is aware of a vaccine is probably depen-
dent on other factors such as educational level, employment,
income, receipt of pre-travel advice, etc., but this was not
explored further in this analysis primarily to avoid overexploi-
tation of this small survey. The survey did not include ques-
tions about common travel vaccine such as typhoid and we
did not explore the trustworthiness of tour Hajj operators as a
source of medical information. Additionally, the survey did not
distinguish between conjugate and polysaccharide vaccines as
we would not expect the participants to distinguish them.
However, because the conjugate vaccines provide additional
benefits of reducing pharyngeal carriage and provide robust
and longer lasting immunity without the risk of hyporespon-
siveness on repeated administration, they, alone or comple-
mentary to polysaccharide, are increasingly becoming popular
[5,18]. This raises the concern of potential interaction of the
mandatory meningococcal vaccine with the pneumococcal
conjugate vaccine or with DTP vaccine due to the resem-
blance of vaccine antigens with carrier proteins [41].
Unpublished data among Australian pilgrims demonstrated
that DTP has a negative impact on pneumococcal conjugate
vaccine upon coadministration, and this negative impact
becomes profound upon sequential administration.
Conclusion
Our survey among Australian Hajj pilgrims has demonstrated
lack of awareness of the availability of vaccine as an important
barrier of vaccination. Pilgrims had poor knowledge about the
transmission modes of serious bacterial infections. Primary-
care providers can play an important role in promoting recom-
mended vaccines and addressing the barriers of vaccination.
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Key points of Publications #5:
This part of the project demonstrated that there were several misconceptions
surrounding the vaccines. Uniformly for all the vaccines, lack of awareness was the
single most important barrier, followed by a belief reliance on natural immunity.
Some people did not know or could agree that vaccination is necessary before travel.
Over one third of the pilgrims did not know about or had access to appropriate
medical information. Interestingly, however, about 40% preferred to take multiple
vaccines at the same time. These surveys unearthed important knowledge gaps that
vaccine uptake is suboptimal and that people are keen to take multiple vaccines
together, which may raise concerns of potential interactions.
Therefore, in the subsequent section of this thesis, I shall explore in infants and
adults and I started with exploring by available Australian data, whether the children
are protected by exploring the issue of interaction in infants and then adults.
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 2.2.1 Publication #6; retrospective data analysis: 
 Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. 
Potential carrier priming effect in Australian infants after 7-
valent pneumococcal conjugate vaccine introduction. World J 
Clin Pediatr. 2016;5:311-8. 
 
Overview of Publication #6: 
After assessing the vaccine uptake, exploring the knowledge and addressing the 
barriers to optimum vaccine uptake, the following section of the thesis will 
investigate the issue of multiple vaccine interactions in vulnerable populations in 
order to explore any possible interference and to potentially find positive 
interactions that could contribute in reducing the conjugate vaccine costs.  
In the following paper (Publication #6) , I have accessed the Australian National 
Notifiable Diseases Surveillance System (NNDSS) and conducted a retrospective data 
analysis that explores evidence of clinical protection in infants as a result of carrier 
priming which occurs with conjugate vaccine after exposure to DTP vaccine. 
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in infants after one dose of 7-valent pneumococcal 
conjugate vaccine (7vPCV) owing to carrier priming. 
METHODS: Using Australian National Notifiable 
Diseases Surveillance System data, we conducted a 
descriptive analysis of cases of vaccine type invasive 
pneumococcal disease (VT-IPD) during “catch-up” years, 
when 7vPCV was carrier primed by prior administration 
of DTPa vaccine. We compared the number of VT-IPD 
cases occurring 2-9 wk after a single dose of 7vPCV 
(carrier primed), with those < 2 wk post vaccination, 
when no protection from 7vPCV was expected yet. 
Further comparison was conducted to compare the 
occurrence of VT-IPD cases vs  non-VT-IPD cases after a 
single carrier-primed dose of 7vPCV.
RESULTS: We found four VT-IPD cases occurring < 
2 wk after one carrier primed dose of 7vPCV while 
only one case occurred 2-9 wk later. Upon further 
comparison with the non-VT-IPD cases that occurred 
after one carrier primed dose of 7vPCV, two cases were 
detected within 2 wk, whereas seven occurred within 
2-9 wk later; suggesting a substantial level of protection 
from VT-IPD occurring from 2 wk after carrier-primed 
dose of 7vPCV.
CONCLUSION: This data suggest that infants may 
benefit from just one dose of 7vPCV, likely through 
enhanced immunity from carrier priming effect. If this 
is proven, an adjusted 2-dose schedule (where the 
first dose of PCV is not given until after DTPa) may be 
sufficient and more cost-effective.
Key words: Carrier priming; Conjugate vaccine; Infant; 
Invasive pneumococcal disease
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: With the inclusion of newer conjugate vaccines 
with higher number of serotypes in the immunisation 
schedule, literature suggests that prior immunisation 
with tetanus/diphtheria-containing vaccines could 
enhance the immunogenicity of subsequently admi-
nistered glycoconjugate vaccine, a phenomenon known 
as “carrier priming”. This analysis provides evidence of 
substantial clinical protection ensued after one dose 
of 7-valent pneumococcal conjugate vaccine as result 
of carrier priming. This phenomenon could be imple-
mented to enhance the immunogenicity of conjugate 
vaccines among vulnerable populations such as infants 
in resource-poor settings, travellers, immigrants and 
refugees.
Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. 
Potential carrier priming effect in Australian infants after 7­valent 
pneumococcal conjugate vaccine introduction. World J Clin 
Pediatr 2016; 5(3): 311­318  Available from: URL: http://www.
wjgnet.com/2219­2808/full/v5/i3/311.htm  DOI: http://dx.doi.
org/10.5409/wjcp.v5.i3.311
INTRODUCTION
Streptococcus pneumoniae (SPn) is responsible for 
33% of childhood mortalities due to pneumonia 
worldwide[1]. Invasive pneumococcal disease (IPD) is 
caused by SPn and is defined as an infection confirmed 
by the isolation of pneumococci from a normally sterile 
body site, such as the blood stream and cerebrospinal 
fluid whereas non-invasive disease includes otitis 
media, sinusitis and bronchitis[2]. The incidence of IPD 
is often used as a measure of pneumococcal disease 
burden[3]. The 7-valent pneumococcal conjugate vaccine 
(7vPCV) was introduced to the Australian National 
Immunisation Program (NIP) for vaccination against 
SPn for medically at-risk and Indigenous children in 
2001 and for all children from January 2005[4]. The 
dosage schedule used was three doses at 2, 4 and 6 
mo of age along with other vaccines such as diphtheria, 
tetanus and acellular pertussis (DTPa). A concurrent 
catch up vaccination program was implemented for two 
years targeting children up to two years of age, many 
of whom would have received DTPa vaccine prior to 
their first catch up dose of 7vPCV. The use of the 3 + 0 
schedule is strongly supported by a systematic review 
of several randomized controlled clinical trials (RCTs) of 
pneumonia and IPD in developing country settings[5]. 
A 3-dose 2-4-6 mo schedule result in the optimum 
antibody levels after the primary series for many 
serotypes. However, interestingly, the 2-dose 3-5 mo 
schedule demonstrated higher antibody levels for five 
serotypes than the 3-dose schedule (at 2-3-4 mo) and 
equivalent antibody responses for serotypes 6B and 23F 
suggesting that the optimal timing of doses is perhaps 
more important than the number of doses[6]. 
The PCV is currently available in less than 60% of 
countries across the world[7] as the cost of the vaccine is 
an important barrier. Affordability of the vaccine could be 
improved through adoption of schedules with reduced 
doses by taking the advantage of a phenomenon called 
“carrier priming” when PCV is administered after DTPa 
vaccination[8]. Carrier priming is defined as an enhanced 
antibody response to a glycoconjugate vaccine when an 
individual has been previously primed with the carrier 
protein[9].
PCVs utilise carrier proteins such as tetanus toxoid, 
diphtheria toxoid or cross-reacting material 197 of 
diphtheria toxin. It is apparent that there is a high 
resemblance between these carrier proteins and the 
contents of DTPa vaccine. The carrier priming effect is 
attributed to the development of carrier-specific T-cells 
in response to a preceding immunisation with a vaccine 
(such as DTPa) that contains antigens similar to the 
carrier proteins in conjugate vaccines; this has been 
demonstrated in various studies[8].
The catch-up vaccination program implemented 
in 2005 accompanying the introduction of universal 
7vPCV vaccination program in Australia provides a 
unique opportunity to examine the potential protective 
effect of carrier priming on IPD. We hypothesise that 
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due to the effect of carrier priming, the number of 
vaccine type-IPD (VT-IPD) cases 2-9 wk following the 
administration of the first dose of 7vPCV (through catch 
up program in those children primed with previous dose 
of DTPa), would be less frequent than that of the VT-
IPD cases within the first two weeks post-vaccination 
(where no protection is expected yet). In this analysis, 
we compared the number of IPD occurring after the 
2nd week post-vaccination until the 9th week (the time 
of the next dose) to that occurring two weeks post-
vaccination. 
MATERIALS AND METHODS
Data source and case definition
We conducted a retrospective descriptive analysis by 
obtaining data from the National Notifiable Diseases 
Surveillance System (NNDSS), Australia. IPD has been 
a notifiable disease in Australia since the year 2001. 
Laboratories, medical practitioners and allied health 
providers are required to report IPD cases to the health 
authorities. De-identified data on notified cases are 
reported by authorities electronically to NNDSS.
A case of IPD is defined as an identification of SPn 
through culture or nucleic acid testing from any normally 
sterile body site. The onset date is considered as the 
date of diagnosis. Demographic and clinical information 
including Indigenous status, age, vaccination status and 
serotype of the isolated pneumococci were collected 
from each case of IPD. According to the Australian NIP, 
all cases ≥ 2 mo old were presumed to receive dose 
one of DTPa. The VT-IDP was defined as the isolation 
of one of the serotypes contained in 7vPCV (4, 6B, 9V, 
14, 18C, 19F and 23F). Isolation of other serotypes was 
defined as non-vaccine type-IPD (NVT-IDP). Eligibility 
criteria of IPD cases for analysis were non-Indigenous, 
infant (aged ≤ 12 mo) of both genders with no 
documented underlying pre-existing medical conditions.
We undertook the following comparisons: (1) the first 
analysis in this paper compares the number of VT-IPD 
within two weeks after a single carrier primed dose of 
7vPCV with that occurred during 2-9 wk; (2) the second 
analysis compares the number of VT-IPD cases vs NVT-
IPD cases after a single carrier primed dose of 7vPCV 
during and two weeks after vaccination; (3) the third 
analysis compares the number of VT-IPD cases after a 
single carrier primed dose of 7vPCV with the number of 
VT-IPD cases after non-carrier-primed dose of 7vPCV 
during and two weeks after vaccination; and (4) the final 
analysis explores herd immunity after the introduction of 
7vPCV to assess the herd effect during the transitional 
period (when most of the analysed cases occurred). 
Herd immunity was explored by detecting numbers of 
VT-IPD among infants < 2 mo before, during and after 
the introduction of 7vPCV.
Ethics approval
Permission to access NNDSS data for the study was 
granted by the data custodian Communicable Disease 
Network Australia of the Australian Department of 
Health. Australian Capital Territory Health Human 
Research Ethics Committee approval was obtained 
as a prerequisite for data access (Reference number 
ETHLR.13.318).
Statistical analysis
Statistical Package for the Social Sciences (SPSS) 
version 22 software program (SPSS, Inc., Chicago, IL, 
United States) was used to carry out descriptive data 
analyses. Categorical variables were compared by using 
the one-sided fisher’s exact test. A P value ≤ 0.05 was 
considered statistically significant. 
RESULTS
A total of 23632 IPD cases were identified and scanned 
for study eligibility. The number of cases included in 
the study was 184 among non-Indigenous Australian 
children who developed IPD after at least one dose 
of 7vPCV and were born between 1st January 2001 
(when 7vPCV became available in the private market) 
until 31st December 2006 (when the 7vPCV catch up 
program ended). Of these, 108 (58.7%) were males. 
The majority of cases were from New South Wales 
[61 (33.2%)], Victoria [50 (27.2%)] and Queensland 
[42 (22.3%)]. Serotype was determined in 174 cases 
(94.5%). Final analysis in this study included 22 IPD 
cases with median ages as shown in Figure 1.
While examining a carrier-priming protective effect 
after one dose of 7vPCV, we found that four VT-IPD 
cases (serotypes: 23F, 4, 14 and 19F) occurred within 
two weeks after one carrier primed dose of 7vPCV. 
We did not expect the vaccine to work effectively for 
two weeks; we found that only one case (serotype 
19F) occurred 2-9 wk later (Figure 2), indicating that 
one carrier primed dose could provide a substantial 
protection after two weeks.
Further analysis revealed that two NVT-IPD cases 
(serotypes: 6C and 22F) occurred within two weeks 
after the first carrier primed dose of 7vPCV whereas 
seven NVT-IPD cases (serotypes: 35B, 38 and five 
10A) were reported 2-9 wk after vaccination (Figure 
3). Compared to the number of VT-IPD cases after the 
carrier primed dose, this suggests a protective effect (P 
= 0.06) against VT-IPD occurring after only one carrier 
primed dose (Table 1).
Upon further comparison with the non-carrier 
primed VT-IPD cases, two VT-IPD cases (serotypes: 18C 
and 14) occurred within two weeks after the first dose 
of 7vPCV while six VT-IPD cases (serotypes: 18C, 14, 
23F, 6B and two 19F) occurred 2-9 wk after vaccination 
(Figure 4); which although not quite significant, may 
indicate that protection ensued (P = 0.08) (Table 2). 
However, age would be a confounder in the latter 
comparison as the primed cases were older with 
possibly more mature immunity. 
Considering the fact that most of the cases included 
in our analysis took place during the transitional years 
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no significant protection to young infants in the absence 
of carrier priming effect[14]. 
Our limited data suggested that herd protection 
in infants was not prominent in the first two years of 
vaccine introduction which is not surprising as the impact 
on carriage takes some years, and the proportion of 
infants and children that were vaccinated was still 
low[15].
PCV is highly effective, but it is also one of the most 
expensive vaccines on the routine paediatric schedule, 
at about USD $100/dose[16]. Among Australian children 
< 5 years of age there were approximately 700 cases 
of IPD and 16 associated deaths in the year prior to 
universal 7vPCV introduction. In 5 years of 7vPCV use 
IPD due to VT declined by 97% and total IPD by 68% 
in these children[17]. The percentage of the world’s birth 
cohort living in countries with PCV in their NIPs rose 
from 1% in 2000 to 58% in 2014[7]. This suggests that 
efforts to increase PCV use globally are succeeding; 
of 2005-2006, we explored herd immunity during this 
transitional period to evaluate its effect. The trends 
shown in Table 3 and Figure 5 demonstrate little 
evidence of clinical protection (herd immunity) among 
young infants aged < 2 mo (before first vaccine dose). 
This suggests that herd immunity was unlikely to have 
contributed to the protection of young infants against 
IPD during observation period of our study. Therefore, 
the explanation for protection is likely to be the direct 
effect of one PCV dose enhanced by prior carrier priming.
DISCUSSION 
Our analysis suggests that infants may receive some 
protection even from a single dose of 7vPCV if conjugate 
vaccines are offered after DTPa vaccination; this could 
be attributed to enhanced protection through a carrier 
priming effect even after one dose of vaccine. This is 
consistent with other incidental findings among infants, 
adults and even in animal models where prior exposure 
to DTPa or one of its components was shown to en-
hance the immunogenicity of subsequent PCV[6,10-13]. 
There is evidence from other settings that children who 
had not carrier primed would still be susceptible to IPD 
at 2-8 wk after one dose of 7vPCV (unpublished Danish 
IPD data, Z Harboe personal communication). It has 
been shown elsewhere that one dose of 7vPCV provides 
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Two weeks after 
carrier primed dose of 
7vPCV
2-9 wk after 
carrier primed 
dose of 7vPCV
  Number of VT-IPD cases � 1
  Number of NVT-IPD cases 2 7
  1P �alue  0.06
Table 1  Contingency table comparing the numbers of vaccine 
type invasive pneumococcal disease and non-vaccine type 
invasive pneumococcal disease cases 9 wk after single carrier 
primed dose of the 7-valent pneumococcal conjugate vaccine 
among non-Indigenous Australian infants (2001-2006)
1One-sided fisher’s exact test. 7�PCV: 7-�alent pneumococcal conjugate 
�accine; VT-IPD: Vaccine type in�asi�e pneumococcal disease; NVT-IPD: 
Non-�accine type in�asi�e pneumococcal disease.
Two weeks after 
dose of 7vPCV
2-9 wk after dose of 
7vPCV
  Number of VT-IPD cases 
  after carrier primed 7�PCV 
� 1
  Number of VT-IPD cases 
  after non-carrier primed 
  7�PCV 
2 6
  1P �alue 0.08
Table 2  Contingency table comparing the numbers of 
vaccine type invasive pneumococcal disease cases 9 wk after 
carrier primed and non-carrier primed dose of the 7-valent 
pneumococcal conjugate vaccine among non-Indigenous 
Australian infants (2001-2006)
1One-sided fisher’s exact test. 7�PCV: 7-�alent pneumococcal conjugate 
�accine; VT-IPD: Vaccine type in�asi�e pneumococcal disease.
IPD cases obtained from 
NNDSS between 2001 and 
2013
(n  = 23632)
Cases that occurred after at least 
one 7vPCV dose between 2001 
and 2006 (n = 184)
Cases 1eligible for 
the final analysis
(n  = 22)
Ineligible 
excluded cases 
(n  =162)
5 carrier primed 
VT-IPD cases (Median 
age 8.3 mo)
8 non-carrier primed 
VT-IPD cases
(Median age 2.2 mo)
9 carrier primed 
NVT-IPD cases
(Median age 5.9 mo)
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Figure 1  Flowchart showing the selection process of analysed cases and 
their median ages. 1Australian non-Indigenous immunocompetent infants with 
receipt of first dose of 7vPCV after diphtheria, tetanus and acellular pertussis 
vaccine. NNDSS: National Notifiable Diseases Surveillance System; 7vPCV: 
7-valent pneumococcal conjugate vaccine; VT-IPD: Vaccine type invasive 
pneumococcal disease; NVT-IPD: Non-vaccine type invasive pneumococcal 
disease.
Tashani M et al . Carrier priming effect in Australian infants
61
however, important gaps in PCV introduction remain, 
notably in the World Health Organization South-East 
Asia Region that includes several countries with large 
birth cohorts but limited financial capacities to purchase 
these costly vaccines[18].
The implication of carrier priming raises hope for 
developing countries where IPD is still a major cause of 
morbidity and mortality[19,20]. The serotypes in the current 
PCV formulations account for 49%-88% of deaths in 
Africa, Asia and Latin America where IPD morbidity 
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Year 2001-2002 2003-2004 2005-2006 2007-2008 2009-2010
Age < 2 
mo
2 mo-< 
4 mo
4 mo-< 
6 mo 
< 2 
mo
2 
mo-< 
4 mo
4 
mo-< 
6 mo
< 2 
mo
2 
mo-< 
4 mo
4 
mo-< 
6 mo
< 2 
mo
2 mo-< 
4 mo
4 mo-< 
6 mo
< 2 
mo
2 
mo-< 
4 mo
4 
mo-< 
6 mo
  VT-IPD Vaccinated 0   1   0   0   2   0   0 7 2 1 0   0   0 1   �
Not 
�accinated
7 1� 26   7 1� 37 12 2 0 3 2   1   1 2   0
  NVT-IPD Vaccinated 0   0   0   0   0   0   0 5 8 2 � 1�   2 8 18
Not 
�accinated 
8   7 13 1�   6 13 13 3 3 7 3   5 1� 3   �
Table 3  Invasive pneumococcal disease cases among non-Indigenous Australian children < 6 mo (2001-2010)
VT-IPD: Vaccine type in�asi�e pneumococcal disease; NVT-IPD: Non-�accine type in�asi�e pneumococcal disease.
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Figure 2  Number of vaccine type invasive pneumococcal disease cases 9 wk after a single carrier primed dose of the 7-valent pneumococcal conjugate 
vaccine among non-Indigenous Australian infants (2001-2006). VT-IPD: Vaccine type invasive pneumococcal disease.
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Figure 3  Number of vaccine type invasive pneumococcal disease compared to non-vaccine type invasive pneumococcal disease cases 9 wk after single 
carrier primed dose of 7-valent pneumococcal conjugate vaccine among non-Indigenous Australian infants (2001-2006). IPD: Invasive pneumococcal 
disease; VT: Vaccine type; NVT: Non VT.
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and mortality are the highest, yet many children do not 
have access to these vaccines[21]. Achieving sufficient 
immunity against pneumococcal disease in spite of 
sparing a dose of vaccine could be of great value to 
these countries.
Simply minimizing the number of doses of PCV would 
not likely to be beneficial unless the carrier priming effect 
is also harnessed. A study in Fiji by Russell et al[22,23] was 
conducted to explore the immunogenicity of the reduced 
dose schedule of 7vPCV in order to determine optimal 
pneumococcal vaccination strategy for poor settings. 
They found that the immunogenicity of three PCV doses 
is better than two doses with potentials for a two dose 
PCV primary series to offer similar protection as provided 
by three doses for most serotypes. They also noted that 
a significant protection from one dose of PCV would not 
continue for children throughout the highest risk period 
for IPD and an early booster at 6 or 9 mo of age (“1 + 
1” schedule) deserves a further investigation for use 
in the developing world[22,23]. However, in their variable 
schedules/methods, they only administered DTPa with 
the first dose of PCV, and missed the chance to examine 
the effect of carrier priming.
This paper sheds light on the need for further 
RCTs designed specifically to detect/provide conclusive 
evidence of the positive impact of carrier priming. If 
priming occurs, there is a possibility in the third world 
that if DTPa vaccine is given first, at anywhere between 
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Figure 4  Number of vaccine type invasive pneumococcal disease cases 9 wk after a single carrier primed dose of 7-valent pneumococcal conjugate 
vaccine compared to the vaccine type invasive pneumococcal disease cases after non-carrier primed single 7-valent pneumococcal conjugate vaccine 
dose among non-Indigenous Australian infants (2001-2006). IPD: Invasive pneumococcal disease; VT: Vaccine type.
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Figure 5  Number of vaccine type invasive pneumococcal disease cases among non-Indigenous Australian in children aged < 2 mo (2001-2010). VT-IPD: 
Vaccine type invasive pneumococcal disease.
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2 and 6 wk of age, a subsequent single dose of PCV 
may be at least partially protective, and a second dose 
4 wk later highly protective so that a third dose may 
not be required, either making a substantial saving in 
vaccine cost or allowing the third dose of PCV to be 
used at a more strategic time, e.g., between 9 and 12 
mo of age. We believe that this theory is applicable to 
other conjugate vaccines, e.g., Hib and meningococcal 
conjugate vaccines, irrespective of the carrier protein. 
Furthermore, carrier-priming phenomenon could be 
implemented to reinforce immunisation schedules in 
resource-poor settings. 
We are currently investigating this innovative 
concept of carrier priming by RCT among adult travellers 
to mass gathering, where we offer DTPa before, with 
and after conjugate vaccines to examine the effect.
A limitation of the study is that it is retrospective and 
observational with a limited number of cases included in 
the final analysis. Additionally, the exact dates of receipt 
of DTPa were not accessible as the NDDS system 
registers only the vaccines related to the disease, in 
this case PCV. However, the Australian surveillance data 
indicated that the coverage of DTPa was ≥ 90% during 
that time[24]. This is the first established descriptive 
analysis looking at clinical evidence of carrier priming for 
prevention of pneumococcal disease.
In conclusion, these data suggest a favourable 
level of evidence of the effectiveness of one dose of 
PCV; this could be attributed to enhanced immunity 
through a carrier priming effect. If priming really occurs, 
an adjusted 2-dose schedule (where the first PCV is 
given following DTPa) may be sufficient and more cost-
effective for vulnerable populations, particularly those 
that have used PCV for several years so that herd 
immunity is also operating. 
COMMENTS
Background
Conjugate vaccines such as pneumococcal conjugate vaccine (PCV) have a 
carrier protein to enhance its immunogenicity. These carrier proteins have some 
similar antigens to the contents of diphtheria, tetanus and pertussis vaccine 
(DTP). This similarity may bring a potential interaction between PCV and DTP. 
This occurs as upon administering DTP before PCV which leads to development 
of carrier-specific T-cells resulting in an enhance immunogenicity of PCV, a 
phenomenon called carrier priming.
Research frontiers
Invasive pneumococcal diseases carry substantial morbidity and mortality 
particularly in developing countries and among vulnerable populations. Currently, 
infants are required to receive at least three doses of (the expensive) PCV. In 
this analysis, the authors propose investigating the use of carrier priming to 
enhance the immunogenicity of PCV in order to spare one of the three doses.
Innovations and breakthroughs
Most studies exploring conjugate vaccine interactions, examine concurrent co-
administration. This unique analysis examines sequential administration and its 
effect on the protectiveness conjugate vaccines.
Applications 
If carrier priming used judicially to enhance the immunogenicity of PCV, an 
adjusted 2-dose schedule (where the first PCV is given after DTPa) may be 
sufficient and cost-effective. 
Terminology
Invasive pneumococcal disease (IPD): Infection confirmed by the isolation 
of pneumococci from a normally sterile body site, such as the blood stream, 
cerebrospinal fluid and joint fluid. Vaccine type invasive pneumococcal disease 
(VT-IPD): IPD caused by one of the pneumococcal serotype that is included in 
the pneumococcal vaccine. Non-vaccine type invasive pneumococcal disease 
(NVT-IPD): IPD caused by one of the pneumococcal serotype that is not included 
in the pneumococcal vaccine. Carrier priming: Enhanced antibody response to a 
glycoconjugate vaccine when an individual has been previously primed with the 
carrier protein. Carrier primed IPD case: IPD case that occurred after one dose 
of PCV that was administered at least one dose of DTP vaccine. Non-carrier 
primed VT-IPD cases: IPD case that occurred after one dose of PCV without 
previous exposure to at least one dose of DTP vaccine.
Peer-review
This is an interesting descriptive analysis investigating evidence for clinical 
protection in infants after one dose of the 7-valent PCV as a result of possible 
prior carrier priming from Tdap vaccine administration. It provides evidence for 
efficacy of reduced PCV schedule if administered following Tdap vaccination. 
This is valuable especially for developing countries as saving cost.
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Key point from Publication #6:
Following on from Publication #6 which showed evidence of clinical protection in
infants, attributed to carrier priming, the following three Publications #7-9 will
present the results of two RCTs designed specifically to investigate the effect of Tdap
vaccine when administered before, with or after two conjugate vaccines (PCV13 and
MCV4).
66
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Overview of Publications #7-9:
Hajj pilgrimage poses a high risk for several infectious diseases, therefore, Hajj
pilgrims are recommended to receive multiple vaccinations before they embark on
their journey. This ‘journey’ provided us with a precious opportunity to examine
conjugate vaccine interactions and to a good quality evidence on whether
administering Tdap vaccine will enhance or suppress the subsequent
immunogenicity of a given conjugate vaccine.
In the year 2014, the study participants received three vaccines (Tdap [Boostrix],
PCV13 [Prevnar13TM] and MCV4 [Menveo TM]) in three different orders as will be
demonstrated in detail in the following publications. It is noteworthy to highlight
that Prevnar13TM and MenveoTM both are conjugated to CRM197 carrier protein.
Therefore, in order to explore further possibilities, the 2015 trial (which had similar
design) we replaced MenveoTM with NimenrixTM which is conjugated to TT.
The immunogenicity results are presented as follows:
· Publication #7 will present the PCV13 and Tdap immunogenicity results for the
trial in 2014.
· Publication #8 will present the PCV13 immunogenicity results of the second trial
done in 2015.
· Publication #9 will present the MCV4 and Tdap immunogenicity results for the
year 2015.
The safety and reactogenicity of these vaccines were also assessed and the results
are presented in Publications #7 and 9.
The immunogenicity of PCV13 was measured by the pneumococcal
opsonophagocytic assay (OPA) and the immunogenicity of MCV4 was measured by
the rabbit serum bactericidal antibody (rSBA). The immunogenicity of diphtheria and
tetanus antibody was measured by enzyme linked immunosorbent assay (ELISA); this
was done to assess the reverse effect of the conjugate vaccines on diphtheria and
tetanus immunogenicity.
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a b s t r a c t
Sequential or co-administration of vaccines has potential to alter the immune response to any of the anti-
gens. Existing literature suggests that prior immunisation of tetanus/diphtheria-containing vaccines can
either enhance or suppress immune response to conjugate pneumococcal or meningococcal vaccines. We
examined this interaction among adult Australian travellers before attending the Hajj pilgrimage 2014.
We also investigated tolerability of these vaccines separately and concomitantly. We randomly assigned
each participant to one of three vaccination schedules. Group A received adult tetanus, diphtheria and
acellular pertussis vaccine (Tdap) 3–4 weeks before receiving CRM197-conjugated 13-valent pneumococ-
cal vaccine (PCV13) and CRM197-conjugated quadrivalent meningococcal vaccine (MCV4). Group B
received all three vaccines on one day. Group C received PCV13 and MCV4 3–4 weeks before Tdap.
Blood samples collected at baseline, each vaccination visit and 3–4 weeks after vaccination were tested
using the pneumococcal opsonophagocytic assay (OPA) and by ELISA for diphtheria and tetanus antibod-
ies. Funding for meningococcal serology was not available. Participants completed symptom diaries after
each vaccination. A total of 111 participants aged 18–64 (median 40) years were recruited. No statisti-
cally significant difference was detected across the three groups in achieving OPA titreP1:8 post vacci-
nation. However, compared to other groups, Group A had a statistically significant lower number of
subjects achieving P4-fold rise in serotype 3, and also significantly lower geometric mean titres
(GMTs) to six (of 13) pneumococcal serotypes (3, 5, 18C, 4, 19A and 9V). Group C (given prior PCV13
and MVC4) had statistically significant higher pre-Tdap geometric mean concentration (GMC) of anti-
diphtheria IgG; however, there was no difference across the three groups following Tdap. Anti-tetanus
IgG GMCs were similar across the groups before and after Tdap. No serious adverse events were reported.
In conclusion, Tdap vaccination 3–4 weeks before concomitant administration of PCV13 and MCV4 signif-
icantly reduced the antibody response to six of the 13 pneumococcal serotypes in adults.
The trial is registered at the Australian New Zealand Clinical Trials Registry (ANZCTR):
ACTRN12613000536763.
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1. Introduction
Immunisation with glycoconjugate vaccines has had a substan-
tial impact on public health in terms of controlling infections
caused by Haemophilus influenzae, Streptococcus pneumoniae and
Neisseria meningitides [1]. The polysaccharide capsule of these
organisms is a virulent factor. Conjugation of the capsular polysac-
charide to a carrier protein converts the otherwise T-cell indepen-
dent immune response to the polysaccharide to a T-cell dependent
immune response [2]. Most carrier proteins currently used in mar-
keted polysaccharide conjugate vaccines are: tetanus toxoid (TT),
diphtheria toxoid (DT) or a cross-reactive mutant form of diphthe-
ria toxin (CRM197). The number of glycoconjugate vaccines and
their valency continues to grow and their integration in routine
infant immunisation schedules has prompted concerns about
potential immunological interactions between carrier proteins
and components of other routine vaccines compromising their
effectiveness [3,4]. The immunogenicity of glycoconjugate vaccines
depends on various extrinsic and intrinsic factors including the age
of vaccinee, the size of the antigen, the type of protein carrier and
the combination of vaccine antigens co-administered [2,5]. For
example, for CRM197, which is antigenically similar to the diph-
theria toxoid present in the DTP (diphtheria, tetanus and pertussis)
vaccines, it was found that prior or concurrent exposure to DTP
may either enhance or suppress the immunogenicity of polysac-
charide vaccines conjugated to CRM197. This was explained vari-
ously as because of bystander effect, carrier-induced epitopic
suppression (CIES) or carrier priming effect [6].
Based upon a critical appraisal of existing evidence, however,
neither carrier protein type nor the magnitude of its dose
adequately predict the observed interferences [4]. Thus, co-
administration (or successive administration) of conjugate vacci-
nes may have positive or negative effects on their immunogenicity,
but the interaction has not been formally explored through a con-
trolled study and predictors of vaccine interactions are still lacking
[4]. Therefore, we designed this randomised controlled trial (RCT)
to evaluate the immunogenicity of the 13-valent pneumococcal
conjugate vaccine (PCV13) and the 4-valent meningococcal conju-
gate vaccine (MCV4) administered to adults aged 18–64 years
together either before, with, or after adult tetanus, diphtheria
and acellular pertussis (Tdap) vaccine. The vaccinees were adult
Australian pilgrims planning to attend Hajj pilgrimage in Saudi
Arabia in 2014.
A recent tetravalent meningococcal vaccine is a mandatory
part of the Hajj visa requirements; and PCV13 and Tdap vaccine
are recommended for Hajj pilgrims. Therefore, Hajj pilgrimage
provided a unique opportunity to explore the effects Tdap
coadministration versus sequential administration upon antibody
responses to PCV13 and MCV4 polysaccharide glycoconjugate
vaccines.
2. Method
2.1. Study design
This was an open label RCT conducted at The Children’s Hospital
at Westmead (CHW), Sydney, Australia from the 1st February to
28th of June 2014.
2.2. The study objectives are
2.2.1. To examine if Tdap primes (or suppresses) the immune
response to one or more of the components of PCV13 when
administered 3–4 weeks before or concomitantly compared
with 3–4 weeks after the PCV13.
2.2.2. To examine if PCV13 and MCV4 prime (or suppress) the
immune response to diphtheria or tetanus antigens when
administered 3–4 weeks before or concomitantly compared
with 3–4 weeks after Tdap.
2.2.3. To assess the safety/reactogenicity and tolerability of PCV13,
MCV4 and Tdap when administered concomitantly or
separately.
In this paper we present the data relevant to antibodies against
pneumococcal, diphtheria and tetanus antigens. The meningococ-
cal antibody results will be presented in a separate paper when
the results are available.
2.3. Participants
The prospective pilgrims aged 18–64-years were recruited from
Greater Sydney, New South Wales (NSW) through travel agents.
Hajj tour operators referred their clients to our clinic at CHW to
participate in the study.
2.4. Inclusion and exclusion criteria
2.4.1. Inclusion criteria
Eligible subjects were people aged 18–64 years who were able
to give informed consent in writing.
2.4.2. Exclusion criteria
Persons excluded from participation were those who, in the
past three years, had received any vaccine containing diphtheria,
tetanus, pertussis, meningococcal or pneumococcal antigens, or
who had contraindications to vaccination as listed in the NHMRC
Australian Immunisation Handbook 10th Edition [7].
2.5. Study groups
Each participant was randomly assigned according to computer
generated random numbers to any one of three study groups:
2.5.1. Group A: Initially received Tdap (left deltoid) followed
3–4 weeks later by coadministered PCV13 (right deltoid)
plus MCV4 (left deltoid).
2.5.2. Group B: Vaccinated simultaneously with Tdap (left deltoid)
plus PCV13 (upper right deltoid) plus MCV4 (lower right
deltoid) four centimetres apart.
2.5.3. Group C: Initially received PCV13 (right deltoid) plus MCV4
(left deltoid) followed 3–4 weeks later by Tdap (left deltoid).
All vaccines were injected intramuscularly and each subject
provided a 3–5 ml blood sample at each visit and 3–4 weeks after
the last vaccination (Fig. 1).
2.6. Subjects received
2.6.1. Tdap: Boostrix manufactured by GlaxoSmithKline.
2.6.2. PCV13: Prevnar13 conjugated to CRM197 and manufac-
tured by Pfizer.
2.6.3. MCV4: Menveo conjugated to CRM197 and manufactured
by Novartis.
2.7. Antibody assays
Blood samples were collected and stored at +2 and +8 C until
on the same day centrifuged and serumwas extracted, divided into
aliquots and stored at 80 C until transported frozen to Pfizer’s
laboratory at Pearl River, NY, USA for opsonophagocytic activity
(OPA) assays [8] for pneumococcus serotypes 1, 3, 4, 5, 6A, 6B,
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7F, 9V, 14, 18C, 19A, 19F and 23F; and to the Immunology labora-
tory of The Children’s Hospital at Westmead for diphtheria and
tetanus antibodies measured by ELISA.
For this study, antibody titres against pneumococcal antigens
were measured using OPA as it reflects the ability of anti-
pneumococcal antibodies to induce phagocytosis and killing [9].
OPA titre P1:8 are considered a surrogate measure of serotype
specific immunity P1:8 according to WHO recommendations
[10]. Fourfold rise in OPA titres was also calculated as secondary
endpoint. For diphtheria and tetanus, serum IgG levels, measured
by ELISA, above 0.1 IU/ml and 0.16 IU/ml respectively, were con-
sidered protective [11,12].
2.8. Assessment of safety, tolerability and reactogenicity
Participants were provided with a symptom diary, a digital
thermometer and a ruler to measure any redness or swelling at
the injection site. Each evening for seven days after each immuni-
sation, they recorded their axillary temperature, injection site reac-
tions (pain, redness, and swelling), solicited systemic adverse
events (AEs) (nausea or vomiting, diarrhoea, generalised weakness
and loss of appetite). Serious AEs were defined as AE that required
hospitalisation or persistent or significant disability or death.
Axillary temperature of P38 C was defined as a fever [13,14].
The symptoms were graded mild (no interference with daily
activities), moderate (some interference with daily activities) and
severe (significant; prevents daily activities).
2.9. Statistical analysis
Data were compiled into a Microsoft Excel 2013 spreadsheet
and then exported to Statistical Package for the Social Sciences
(SPSS) version 22 software program (SPSS, Inc., Chicago, IL, USA)
for analysis.
The outcome of principal interest was comparing the immune
responses to vaccines either administered concurrently or succes-
sively. Primary comparison among the three study groups was per-
formed by calculating geometric mean titre (GMT) of antibodies
and 95% confidence intervals by treatment group at each time
point for each antibody assayed by building a generalised linear
model. Log transformed antibody titres were analysed using
analysis of variance (ANOVA). Secondary comparison among the
three study groups involved binary logistic regression and Chi
square test (or Fishers exact test when expected cell count <5) to
compare the proportions of subjects achieved OPA titreP1:8 post
vaccination and seroresponders with P4-fold rise in OPA titres;
Assessed for eligibility (n=121) 
Excluded (n= 10) 
♦ Not meeting inclusion criteria (n= 10)
Group A (n= 37): 
♦ 4 13
Randomised (n=111) 
Enrolment 
Group B (n= 37): 
♦ Tdap+ 4 13
Group C (n= 37): 
♦  Tdap 
Visit 1 Blood draw  Tdap Blood draw 4+ 
13 
Blood draw 4+ 
13 
2 withdrawals: 
♦ 2 lost to follow-up 
2 withdrawals: 
♦ 1 lost to follow-up 
♦ 1 adverse event 
Visit 2 Blood draw 4 13  
(n= 35)
Blood draw 
(n= 35)
Visit 3 Not applicable
3-4 weeks 
Blood draw 
(n= 35)
Blood draw 
(n= 37)
3-4 weeks 
3-4 weeks 3-4 weeks 
3-4 weeks 
Withdrawal
Blood draw  Tdap 
(n= 37)
Fig. 1. Subject disposition flowchart. PCV13: 13-valent pneumococcal CRM197 conjugate vaccine; MCV4: quadrivalent meningococcal CRM197 conjugate vaccine; Tdap:
combined tetanus, reduced diphtheria and acellular pertussis vaccine; Group A: Tdap before PCV13 and MCV4; Group B: Tdap with PCV13 and MCV4; Group C: PCV13 and
MCV4 before Tdap.
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and 0.1 IU/ml and >0.16 IU/ml for anti-diphtheria and anti-tetanus
IgG post vaccination respectively. When the overall p-value was
significant, further univariate analysis was conducted between
two relevant study arms. Group C was the control group for the
OPA results and Group A was considered the control group for
the anti-tetanus and anti-diphtheria results.
The analysis of the reactogenicity and tolerability data were
evaluated descriptively, and summarised by the percentage and
number of subjects with events in each group.
2.10. Ethical aspects and trial registration
Informed consent was obtained from each participant. The
study was reviewed and approved by the Hunter New England
Research Ethics Committee (HREC reference number:
13/05/3.05), NSW, Australia. The study was conducted according
to the International Conference on Harmonisation (ICH) and Good
Clinical Practice (GCP) guidelines. The trial is registered at the
Australian New Zealand Clinical Trials Registry (ANZCTR):
ACTRN12613000536763.
3. Results
A total of 111 persons participated in the trial but ultimately
107 (96.4%) completed all study visits (four withdrew: three
because they could not comply with the study schedule and one
because of a non-serious AEs). The participants were aged 18–64
(median 40) years, 44.8% male. Demographic characteristics, coun-
tries of origin and chronic medical conditions are presented in
Table 1. There were no statistically significant differences in base-
line characteristics between groups.
3.1. OPA results
Generally, serotypes varied in immunogenicity. Table 2 details
by assigned group the numbers and proportions of seropositive
subjects (OPA titreP 1:8), subjects with P4-fold rise in OPA titre
and the GMT achieved for each pneumococcal serotype. There was
statistically insignificant difference across the three groups in
terms of achieving seropositive levelP1:8. With regard to achiev-
ingP4-fold rise in OPA titre, a difference between the groups was
found only for serotype 3 where Group A had a statistically lower
proportion compared to Group C. However, comparison of GMTs
across the three study groups showed that significantly (p < 0.05)
lower GMTs in Group A for six serotypes (3 [34.3], 5 [145], 18C
[1842], 4 [2260], 19A [890] and 9V [2425]) compared to group C
(Table 2). Additionally, six other serotypes (19F [2093], 1 [230],
14 [2295], 23F [3059], 7F [3108], and 6A [4860]) were (insignifi-
cantly) lower in Group A compared to Group C. There were no sig-
nificant differences between Groups B and C for all the 13
serotypes, but they were generally somewhat lower in Group B
than Group C for most of the serotypes; this pattern can be seen
in a schematic representation in Fig. 2.
Serotypes 6B and 6A were commonly reported among top four
serotypes achieving the highest OPA GMTs in all the three groups,
whereas serotypes 3, 5, 1 and 19F were commonly among the low-
est four serotypes in all three groups. The highest GMT reported
among all serotypes was 6B (9133) in Group C and the lowest
was 3 (34.3) in Group A.
3.2. Diphtheria and tetanus results
Before administering Tdap vaccine to any group, Group C, that
had only been exposed to PCV13 and MVC4 3–4 weeks before,
had a statistically significant higher proportion (94.6%, p < 0.01)
of subjects with anti-diphtheria IgG > 0.1 IU/ml (Table 3). However,
this significant difference among the three groups becomes dimin-
ished after Tdap vaccination, nevertheless, Group C retained the
highest proportion (100%) of subjects achieving protection level
(Fig. 3A). In a consistent pattern, the GMC of anti-diphtheria IgG
was statistically significantly higher (p < 0.01) in Group C (1.78,
95% CI [1.18–2.66]) before Tdap vaccination and the difference
becomes insignificant among the three study groups after vaccina-
tion (Table 3). On the other hand, anti-tetanus IgG did not have any
statistically significant difference among the three groups either
before or after Tdap vaccination in terms of GMCs or proportions
of protection (Table 3 and Fig. 3B).
Table 1
Subject demographics, counties of birth and chronic medical conditions.
Group A (n = 37) Group B (n = 37) Group C (n = 37)
Gender Males, n (%) 18 (51.4%) 15 (43%) 14 (38%)
Mean age Years (±S.D.) 38.6 (±11.2) 42.4 (±12.3) 42.2 (±11.5)
Country of birth
Australia 9 4 4
Indonesia 8 10 10
Pakistan 7 10 7
Lebanon 4 6 5
Bangladesh 3 3 4
New Zealand 0 0 1
Saudi Arabia 1 0 1
South Africa 1 0 0
Afghanistan 1 0 2
Egypt 1 1 1
Fiji Islands 0 2 1
Palestine 0 0 1
Syria 2 1 0
Chronic illness
Asthma 1 1 1
Chronic Bronchitis 0 1 0
Diabetes 2 4 2
Hypothyroid 1 0 0
Joint pain 0 1 0
Lactose Intolerance 0 1 0
Pituitary adenoma 1 0 0
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3.3. Reactogenicity results
Most local and systemic AEs reported within seven days of vac-
cine administration were mild to moderate in severity. In terms of
local AEs, they were generally similar across the study arms
(Table 4); however, proportions of local reactions (redness, swel-
ling and pain) were least reported after the administration of
MCV4 alone and after the administration Tdap alone. With regards
to systemic reactions, the most frequently reported were general
muscle aches and drowsiness (Table 4). The administration of Tdap
resulted in the least systemic AEs followed by the concomitant
administration of PCV13 andMCV4. Generally, the duration of local
and systemic reactions did not exceed seven days, and no serious
AEs were reported during the conduction of the trial.
4. Discussion
This study shows that antigens present in Tdap vaccine may
negatively interact with some serotypes of the CRM197-
conjugated PCV13. This may be due to the similarity of the carrier
protein CRM197 to diphtheria toxoid in Tdap. The study also
showed that the carrier protein CRM197 per se can induce substan-
tial immune response against diphtheria. To our knowledge this is
the first RCT in adults designed specifically to explore the occur-
rence of distinctive immunological phenomena such as carrier
priming, bystander effect or even CIES when conjugate vaccines
are administered before, with or after Tdap.
This study has shown that either concurrent or sequential
administration of Tdap and PCV13 resulted in a similar immune
Table 2
Proportions of seropositive subjects (OPA titre P1:8), proportions of subjects with P4-fold rise in OPA titre and OPA GMTs post vaccination for the 13 serotypes of PCV13,
3–4 weeks post-vaccination with PCV13 and MCV4 administered either before, concomitantly or sequentially to Tdap.
Serotype Group A (n = 35) Group B (n = 35) Group C (n = 37) Overall p-valuea
OPAP 1:8, n (%) [95% CI] OPAP 1:8, n (%) [95% CI] OPAP 1:8, n (%) [95% CI]
OPAP 4-fold, n (%) [95% CI] OPAP 4-fold, n (%) [95% CI] OPAP 4-fold, n (%) [95% CI]
OPA GMT (95% CI) OPA GMT (95% CI) OPA GMT (95% CI)
3 29 (87.9) [0.71–0.96] 32 (94.1) [0.8–0.99] 32 (94.1) [0.8–0.99] 0.59
14 (42.4) [0.25–0.6] 29 (85.3) [0.69–0.95] 25 (73.5) [0.56–0.87] <0.01b
34.3 (22–54) 78.8 (49.7–125) 65.5 (41.3–104) <0.01b
5 34 (100) [0.9–1] 33 (100) [0.9–1] 33 (100) [0.9–1] 1
28 (82.4) [0.65–0.93] 31 (94) [0.79–0.99] 32 (97) [0.51–0.84] 0.14
145 (73–287) 472 (271–822) 466 (262–829) <0.01b
18C 32 (97.1) [0.84–0.99] 33 (100) [0.9–1] 32 (100) [0.9–1] 1
30 (90.9) [0.95–0.98] 30 (90.9) [0.95–0.98] 26 (81.3) [0.63–0.92] 0.47
1842 (913–3715) 4861 (3550–6658) 6053 (4288–8543) <0.01b
4 33 (100) [0.9–1] 34 (100) [0.9–1] 34 (100) [0.9–1] 1
29 (82.9) [0.66–0.93] 28 (87.5) [0.71–0.96] 29 (93.5) [0.78–0.99] 0.47
2260 (1315–3882) 6394 (4277–9561) 4902 (7125–10,357) <0.01b
19A 34 (100) [0.9–1] 34 (100) [0.9–1] 33 (100) [0.9–1] 1
31 (91.2) [0.76–0.98] 32 (94.1) [0.8–0.99] 32 (97) [0.84–0.99] 0.87
890 (591–1340) 1568 (1032–2383) 1821 (1270–2614) 0.02b
9V 33 (100) [0.9–1] 32 (100) [0.9–1] 32 (100) [0.9–1] 1
23 (69.7) [0.51–0.84] 27 (84.4) [0.67–0.95] 24 (75) [0.56–0.88] 0.37
2425 (1605–3664) 6829 (4390–10,623) 4160 (2725–6350) <0.01c
19F 30 (100) [0.9–1] 31 (100) [0.9–1] 29 (100) [0.9–1] 1
23 (76.7) [0.57–0.9] 29 (93.5) [0.78–0.99] 26 (89.7) [0.72–0.97] 0.18
2093 (1159–3778) 3416 (2330–5008) 4146 (2846–6040) 0.06
1 34 (100) [0.9–1] 32 (97) [0.84–0.99] 33 (97) [0.84–0.99] 0.77
32 (94.1) [0.8–0.99] 32 (97) [0.84–0.99] 33 (97) [0.84–0.99] 1
230 (147–358) 446 (261–761) 383 (215–683) 0.1
14 33 (97.1) [0.84–0.99] 33 (100) [0.9–1] 32 (100) [0.9–1] 1
24 (70.6) [0.52–0.85] 18 (54.5) [0.36–0.72] 19 (59.4) [0.4–0.76] 0.37
2295 (1162–4534) 2687 (1808–3992) 3450 (2317–5136) 0.3
23F 34 (100) [0.9–1] 32 (97) [0.84–0.99] 32 (100) [0.9–1] 0.66
32 (94.1) [0.8–0.99] 32 (97) [0.84–0.99] 30 (93.8) [0.79–0.99] 0.87
3059 (2010–4655) 3974 (2535–6230) 4090 (2707–6182) 0.4
7F 34 (100) [0.9–1] 32 (97) [0.84–0.99] 33 (100) [0.9–1] 0.66
29 (85.3) [0.69–0.95] 27 (81.8) [0.64–0.93] 27 (81.8) [0.64–0.93] 0.7
3108 (2329–4148) 3853 (2906–5110) 4399 (3213–6000) 0.3
6A 34 (100) [0.9–1] 33 (97.1) [0.84–0.99] 33 (100) [0.9–1] 1
32 (94) [0.8–0.99] 29 (85.3) [0.69–0.95] 27 (81.8) [0.64–0.93] 0.66
4860 (3311–7133) 5703 (3574–9099) 5428 (3682–8003) 0.8
6B 35 (100) [0.9–1] 32 (100) [0.9–1] 33 (100) [0.9–1] 1
34 (97.1) [0.85–0.99] 29 (90.6) [0.75–0.98] 29 (87.9) [0.71–0.96] 0.34
5972 (4176–8539) 5607 (3579–8783) 9133 (5984–13,940) 0.1
OPA: opsonophagocytic activity; GMT: geometric mean titres; PCV13: 13-valent pneumococcal CRM197 conjugate vaccine; MCV4: quadrivalent meningococcal CRM197
conjugate vaccine; Tdap: combined tetanus, reduced diphtheria and acellular pertussis vaccine; Group A: Tdap before PCV13 and MCV4; Group B: Tdap with PCV13 and
MCV4; Group C: PCV13 and MCV4 before Tdap; CI: confidence interval.
a The overall p-value of the proportions of the three study groups was calculated by Fishers exact test (except for serotypes 14, 3, 7F and 9V by Chi square test) and for
GMTs by ANOVA test.
b p-value for Group A versus Group C < 0.01.
c p-value for Group A versus Group C = 0.03.
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response of OPA titre P1:8. Nevertheless, with regards to OPA
GTMs, this study has shown a statistically significant suppression
of almost half of its serotypes upon prior exposure to Tdap. The
general trend across all serotypes was for carrier induced suppres-
sion and this may be a power issue. Significant OPA GMT suppres-
sion was shown for six serotypes. It is known that the
immunogenicity of each serotype is different [15]. The suppression
in our study was more apparent in serotypes 3 and 5 which have
already proven to be the least immunogenic serotypes in other
adult studies [16]. It could be speculated that weak vaccine sero-
type immunogenicity correlates with susceptibility to suppression.
A numbers of trials have examined the effect of concomitant
administration of conjugate vaccines with Tdap, but there is a scar-
city of data on the effect of sequential administration. However,
unlike our study, a pre-clinical study in mice model demonstrated
that pre-existing immunity to TT subsequently enhanced the
immunity of TT-conjugated pneumococcal vaccine [17]. Further-
more, infant studies also revealed that prior receipt of DTP vaccine
enhanced the immunogenicity of PCV11-DT and PCV7/13-CRM197
[18–20]. Similar findings were also observed in adults where pre-
existing anti-diphtheria toxin antibodies enhanced immunogenic-
ity of PCV5-CRM197 [21,22]. These findings can be explained by
carrier priming phenomenon (also referred to as carrier-specific
enhancement of T-cell help) which is believed to occur as result
of increasing the number of carrier specific T lymphocytes that
can provide the necessary ‘‘help” for the expansion and differenti-
ation of polysaccharide specific B lymphocytes [23,24]. Neverthe-
less, many of the findings in these trials were incidental as the
trials were designed primarily to assess either the immunogenicity
of coadministration or evaluate variable immunisation schedules.
Conversely in our study among adults, we observed a negative
interaction when Tdap was coadministered with PCV13 and the
interaction became significant upon prior exposure to Tdap. Simi-
lar suppressive effect was noted in few other conjugate vaccines
such as Hib vaccine and meningococcal conjugate vaccine upon
prior exposure to a component of DTP vaccine [25–28]. This
10.00 
100.00 
1000.00 
10000.00 
100000.00 
Lo
g Serotype 1 
Serotype 14 
Serotype 18C*
Serotype 19A*
Serotype  19F Serotype 23F 
Serotype 3*
Serotype 4*
Serotype 5*
Serotype 6ASerotype 9V*
        Group A;              Group B;              Group C 
Serotype 6B
Serotype 7F
Fig. 2. GMTs and confidence intervals of OPA for all the PCV13 serotypes, 3–4 weeks post-vaccination with PCV13 and MCV4 administered either before, concomitantly or
sequentially to Tdap. GMT: geometric mean titres; OPA: opsonophagocytic activity; PCV13: 13-valent pneumococcal CRM197 conjugate vaccine; MCV4: quadrivalent
meningococcal CRM197 conjugate vaccine; Tdap: combined tetanus, reduced diphtheria and acellular pertussis vaccine; Group A: Tdap before PCV13 and MCV4; Group B:
Tdap with PCV13 and MCV4; Group C: PCV13 and MCV4 before Tdap; *: indicate statistically significant difference (p < 0.05).
Table 3
GMCs and proportions of subjects reaching antibody titresP1.0 IU/ml and >0.16 IU/ml for diphtheria and tetanus respectively, at baseline and 3–4 weeks post-vaccination with
Tdap administered either, before, concomitantly or sequentially to PCV13 and MCV4.
Group A (n = 35) Group B (n = 35) Group C (n = 37) Overall p-valuea
Subjects with anti-diphtheria IgG > 0.1 IU/ml [n (%)]
Pre Tdap 20 (60%) 26 (59%) 35 (94.6%) <0.01b
Post Tdap 34 (100%) 40 (95.2%) 37 (100%) 0.3
Subjects with anti-tetanus IgG > 0.16 IU/ml [n (%)]
Pre Tdap 21 (60%) 25 (57%) 26 (70%) 0.2
Post Tdap 32 (91.4%) 40 (91%) 36 (97.3%) 0.8
GMC of anti-diphtheria IgG [n (95% CI)]
Pre Tdap 0.27 (0.16–0.46) 0.23 (0.15–0.37) 1.78 (1.18–2.66) <0.01b
Post Tdap 1.78 (1.31–2.41) 1.94 (1.37–2.75) 2.39 (2–2.85) 0.3
GMC of anti-tetanus IgG [n (95% CI)]
Pre Tdap 0.46 (0.24–0.87) 0.33 (0.19–0.56) 0.59 (0.35–1) 0.3
Post Tdap 4.11 (2.81–6) 3 (2–4.5) 5 (3.6–6.5) 0.1
GMC: geometric mean concentration; PCV13: 13-valent pneumococcal CRM197 conjugate vaccine; MCV4: quadrivalent meningococcal CRM197 conjugate vaccine; Tdap:
combined tetanus, reduced diphtheria and acellular pertussis vaccine; Group A: Tdap before PCV13 and MCV4; Group B: Tdap with PCV13 and MCV4; Group C: PCV13 and
MCV4 before Tdap.
a p-value for proportion was calculated by Fishers exact test and for GMTs by ANOVA test.
b p-value for Group A versus Group C < 0.01.
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suppression could be attributed to immunological phenomena
such as CIES [17,29–32] and bystander effect [33,34]. CIES was first
described as an immunological phenomenon in which antibody
responses to haptens presented on a carrier are inhibited by prior
immunisation with the specific carrier [35]. The mechanisms of
carrier-specific epitopic suppression are not completely under-
stood, but experimental models have implied several explanations
[5,36,37]; the presence of pre-existing antibodies to the carrier
protein may prevent the binding of hapten-specific B-cells to their
epitopes. Additionally, the promotion of dominant Carrier-specific
B cells may consume local sources of immune help (T cells) result-
ing in depriving hapten-specific B-cells of necessary resources
leading to reduced antigen induced antibodies.
It is not entirely clear why enhancement occurred in some stud-
ies [18–22] while suppression resulted in others [25–28] (includ-
ing ours). Age could be an important factor as carrier priming
appear to occur more in infants and children whereas CIES is more
often seen in adults [6]. Another possible factor the dose of the car-
rier protein. It was noted in mice that the enhancement of conju-
gate polysaccharide immunogenicity occurred in response to
prior priming with a low-dose carrier protein antigen, whereas a
high dose resulted in suppression [17]. A review paper about con-
jugate vaccines interactions has highlighted the significant role of
carrier protein dose in determining the direction of interaction
[6]. There are indications that carrier overload may induce immune
suppression in individuals primed with that carrier protein [38].
Polysaccharide vaccines conjugated to CRM197 for example appear
to be at increased risk of negative immune interference when
administered together [37]. Both of the conjugate vaccines in our
trial are conjugated to CRM197, we anticipate that this increased
exposure to it has resulted in CIES.
We believe that Group A in our study has been substantially
affected by CIES. Nevertheless, CIES is thought to arise upon
sequential administration of vaccines [4], and thus the classic def-
inition of CIES is not strictly applicable to what happened in Group
B (with concomitant administration) in this study. Our findings
demonstrated that the OPA GMTs of group B were generally some-
what lower but were statistically non inferior to group C for most
of the serotypes. We believe that bystander interference could be a
more plausible explanation. The co-administration of vaccines con-
taining a given conjugate protein can induce interference that
extends to unrelated antigens that are part of the combinations
in use, so called bystander interference. The mechanism suggested
for this interference is competition for limited resources within the
lymph nodes [36].
With regards to diphtheria and tetanus antitoxin levels, our trial
showed that the conjugated CRM197 vaccines provoked an anti-
body concentration comparable to that resulting from Tdap. It is
possible that a carrier protein can per se elicit an immune response
that confers some protection against an infectious disease. It has
been reported in several trials that the administration of both TT
and CRM-based conjugates has the ability to boost tetanus and
diphtheria toxoid IgG levels among a wide variety of age groups
[22,39,40]. These findings were supported by WHO reports, though
not to a sufficient extent to replace routine immunisation with
diphtheria or tetanus toxoid containing vaccines [10].
Our three study groups have achieved a similar immune
response in terms of proportion with OPA titreP1:8 post vaccina-
tion; but this only reflects short term protection [41]. However,
prior exposure to Tdap was shown to suppress OPA titres post vac-
cination. Practically, this indicates that adults (travellers) will
receive more favorable long-term protection when a conjugate
vaccine is administered with Tdap (or just prior to it). This is
important as some GPs may wish to separate vaccines in order to
minimize AEs, particularly in preparation for high risk settings
such as Hajj travel where pilgrims may receive multiple vaccines
as a preventative measure.
To our knowledge, this is the first RCT among adults designed
specifically to compare the immunogenicity of concomitant versus
sequential administration of Tdap with other conjugate vaccines. A
limitation is the small sample size and we cannot completely dis-
regard the effect of MCV4 as PCV13 was not administered solely.
Our main finding is that Tdap has the ability to suppress the
subsequent OPA GMT of PCV13. In attempts to determine the best
sequel and combination of multiple vaccination, there are sugges-
tions that using variable carrier proteins could be advantageous to
avoid interference mechanisms [37]. Another analysis is underway
of similar design and vaccines but with different carrier protein.
In conclusion, this study shows that when multiple vaccines are
administered to adults (e.g., travellers to mass gatherings), admin-
istration of PCV13 is best given together or before Tdap vaccine,
rather than after.
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Fig. 3. GMCs and confidence intervals of diphtheria and tetanus antibodies at baseline and 3–4 weeks post-vaccination with Tdap administered either, before, concomitantly
or sequentially to PCV13 and MCV4; Graph A: Anti-diphtheria results; Graph B: Anti-tetanus results; GMC: geometric mean concentration; PCV13: 13-valent pneumococcal
CRM197 conjugate vaccine; MCV4: quadrivalent meningococcal CRM197 conjugate vaccine; Tdap: combined tetanus, reduced diphtheria and acellular pertussis vaccine;
Group A: Tdap before PCV13 and MCV4; Group B: Tdap with PCV13 and MCV4; Group C: PCV13 and MCV4 before Tdap.
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Table 4
Adverse events following vaccination when Tdap was administered concomitantly or sequentially to PCV13 and MCV4.
Separate administration of Tdap Separate administration of PCV13 Separate administration of MCV4 Concomitant administration of PCV13 + MCV4
(right deltoid)
Redness
[n (%)
(mean
mm)]
Swelling
[n (%)
(mean
mm)]
Pain [n (%)] Redness
[n (%)
(mean
mm)]
Swelling
[n (%)
(mean
mm)]
Pain [n (%)] Redness
[n (%)
(mean
mm)]
Swelling
[n (%)
(mean mm)]
Pain [n (%)] Redness
[n (%)
(mean
mm)]
Swelling
[n (%)
(mean
mm)]
Pain [n (%)]
Mild-
Moderate
Severe Mild-
Moderate
Severe Mild-
Moderate
Severe Mild-Moderate Severe
Local reactions
Day 0 22 (21) (8.3) 25 (23.8) (8) 75 (54.2) 3 (2.8) 15 (20.8) (7.8) 18 (16.6) (12) 40 (55.5) 11 (15.2) 13 (18) (3.4) 11 (15.2) (6.3) 23 (32) 3 (4) 7 (21) (5) 7 (21) (6.3) 20 (60) 3 (9)
Day 1 21 (20) (8.9) 26 (24.7) (10.5) 52 (49.4) 12 (11.4) 16 (22.2) (8.4) 16 (22.2) (19.2) 37 (51.3) 10 (13.8) 12 (16.6) (3) 9 (12.5) (3) 24 (32) 4 (5.5) 9 (27) (3.4) 9 (27) (10) 16 (48.5) 8 (24)
Day 2 17 (16) (7.7) 17 (16) (9.3) 41 (39) 5 (4.7) 15 (20.8) (14.8) 15 (20.8) (10.2) 37 (51.2) 3 (4) 6 (8.3) (1.8) 5 (7) (1.6) 16 (22.2) 2 (2.7) 8 (24) (3.6) 7 (21) (9.4) 20 (60) 3 (9)
Day 3 12 (11.4) (6.1) 11 (10.5) (8) 28 (26.5) 2 (2) 11 (15.2) (20) 9 (12.5) (14.7) 20 (27.7) 2 (2.7) 3 (4) (11) 4 (5.5) (3.2) 11 (15.2) 1 (1.3) 6 (18) (3.3) 5 (15) (6) 16 (48.5) 1 (3)
Day 4 7 (6.6) (5.7) 6 (5.7) (8) 19 (18) 2 (2) 5 (51.4) (7) 7 (9.7) (22) 11 (15.2) 0 2 (2.7) (25.5) 5 (7) (3.2) 10 (13.8) 3 6 (18) (11) 6 (18) (9) 7 (21) 2 (6)
Day 5 5 (4.7) (4.6) 5 (4.7) (7.4) 10 (9.6) 2 (2) 3 (1) (89.3) 4 (5.5) (22.2) 8 (11) 0 3 (4) (12.6) 4 (5.5) (5.7) 7 (9.7) 2 (2.7) 5 (15) (27) 6 (18) (10) 8 (24) 0 (0)
Day 6 3 (2.8) (4.3) 3 (2.8) (7.8) 7 (6.7) 2 (2) 2 (2.7) (41.5) 5 (7) (11.8) 5 (6.7) 1 (1.3) 3 (4) (9.3) 4 (5.5) (5.5) 6 (8.3) 2 (2.7) 5 (15) (23.6) 5 (15) (4) 7 (21) 0 (0)
Separate administration of Tdap Concomitant administration of PCV13 + MCV4 Concomitant administration of PCV13 + MCV4 + Tdap
Fever
(P38 C)
[n (%)]
Vomiting
[n (%)]
Diarrheal
[n (%)]
Loss of
appetite
[n (%)]
Drowsiness
[n (%)]
General
muscle
aches
[n (%)]
Fever
(P38 C)
[n (%)]
Vomiting
[n (%)]
Diarrhoea
[n (%)]
Loss of
appetite
[n (%)]
Drowsiness
[n (%)]
General
muscle
aches
[n (%)]
Fever
(P38 C)
[n (%)]
Vomiting
[n (%)]
Diarrhoea
[n (%)]
Loss of
appetite
[n (%)]
Drowsiness
[n (%)]
General
muscle
aches
[n (%)]
Systemic reactions
Day 0 0 0 1 (1.38) 2 (2.7) 4 (5.38) 25 (34.4) 1 (1.38) 3 (4) 2 (2.7) 4 (5.5) 13 (17.9) 36 (50) 1 (3) 2 (6) 1 (3) 6 (18) 12 (36.3) 23 (69.6)
Day 1 0 0 1 (1.38) 0 3 (4) 24 (33.2) 3 (4) 3 (4) 3 (4) 9 (12.2) 19 (26.2) 36 (50) 3 (9) 1 (3) 4 (12) 10 (30) 12 (36.3) 22 (66.5)
Day 2 0 1 (1.38) 0 0 2 (2.7) 16 (21.8) 2 (2.7) 2 (2.7) 1 (1.38) 6 (8) 12 (16.5) 30 (41.4) 1 (3) 0 2 (6) 8 (24) 8 (24) 22 (66.5)
Day 3 0 1 (1.38) 0 0 0 10 (11.4) 0 2 (2.7) 2 (2.7) 5 (6.7) 7 (9.5) 16 (22) 2 (6) 0 2 (6) 3 (9) 2 (6) 13 (39.3)
Day 4 0 1 (1.38) 0 0 1 (1.38) 9 (12.4) 1 (1.38) 2 (2.7) 2 (2.7) 5 (6.7) 6 (8) 13 (17.8) 1 (3) 0 2 (6) 2 (6) 1 (3) 13 (39.3)
Day 5 0 0 0 0 0 4 (5.5) 0 1 (1.38) 1 (1.38) 1 (1.38) 3 (4) 10 (13.8) 1 (3) 0 2 (6) 1 (3) 1 (3) 11 (33.3)
Day 6 0 0 0 0 0 2 (2.7) 1 (1.38) 1 (1.38) 1 (1.38) 1 (1.38) 4 (5.5) 8 (11) 0 0 1 (3) 1 (3) 1 (3) 8 (24.2)
Tdap: combined tetanus, reduced diphtheria and acellular pertussis vaccine; PCV13: 13-valent pneumococcal CRM197 conjugate vaccine; MCV4: quadrivalent meningococcal CRM197 conjugate vaccine; Group A: Tdap before
PCV13 and MCV4; Group B: Tdap with PCV13 and MCV4; Group C: PCV13 and MCV4 before Tdap.
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controlled trial.
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Hajj pilgrims are susceptible to several serious infections and are required to receive multiple vaccina-
tions. Polysaccharide-protein conjugate vaccines contain carrier proteins such as tetanus toxoid (TT),
diphtheria toxoid (DT) or a mutant of diphtheria toxoid (CRM197). These carrier proteins may interact
with other conjugate or combination vaccines containing tetanus or diphtheria on concurrent or sequen-
tial administration. We examined the immune interaction of separate and concomitant administration of
a tetanus/diphtheria/acellular pertussis (Tdap) vaccine with a TT-conjugated quadrivalent meningococcal
vaccine (MCV4) (coadministered with 13-valent pneumococcal CRM197-conjugate vaccine [PCV13]) in
adult Australian pilgrims before attending Hajj in 2015.
We randomly assigned each participant to one of three vaccination schedules. Group 1 received Tdap
3–4 weeks before receiving MCV4 coadministered with PCV13. Group 2 received all three vaccines con-
comitantly. Group 3 received MCV4 and PCV13 3–4 weeks before Tdap. Blood samples were collected at
baseline, at each vaccination visit and 3–4 weeks after vaccination and tested for response to meningo-
coccal serogroups C, W and Y using a serum bactericidal antibody (rSBA) assay with baby rabbit comple-
ment, and to diphtheria and tetanus toxoid, measuring IgG antibodies by ELISA. Participants completed
symptom diaries after each vaccination. A total of 166 participants aged 18–64 (median 42) years were
recruited, of whom 160 completed the study. Compared to the other groups, Group 1 (given Tdap first)
had significantly lower proportion of subjects achieving a 4-fold rise in rSBA for serogroup W. No dif-
ference was detected across the three groups in achieving protection threshold (rSBA  8 post vaccina-
tion) or SBA geometric mean titre (GMT) post vaccination.
Group 3, which was given MCV4/PCV13 first, had high levels of antibody against diphtheria and tetanus
than the other groups, when tested prior to receipt of Tdap; Only the anti-tetanus responses remainedd in this
ead, Cnr
e, with
ult Hajj
2 M. Tashani et al. / Vaccine xxx (2017) xxx–xxx
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or after the quadrivalent meningococcal TT-conj
pilgrims: A randomised controlled trial. Vaccinesignificantly higher after Tdap administration. No serious adverse events were reported.
In conclusion, when multiple vaccination is required for Hajj pilgrims, administering Tdap concurrently
with MCV4/PCV13 produces adequate immune responses, and avoids meningococcal immune interfer-
ence, in the convenience of a single consultation. However, giving Tdap 3–4 weeks after MCV4/PCV13
has the advantage of an enhanced tetanus toxoid response.
The trial is registered at the Australian New Zealand Clinical Trials Registry (ANZCTR):
ACTRN12613000536763.
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Neisseria meningitidis is a leading cause of bacterial meningitis
and septicaemia in infants, adolescents, and young adults [1].
Meningococci are spread from the nasopharynx of a colonized per-
son by contaminated aerosolized droplets and secretions. Patho-
genic bacteria enter the bloodstream and cause invasive disease,
such as meningitis, septicemia or both [2]. Meningococci are clas-
sified according to the characteristics of their polysaccharide cap-
sule. Twelve serogroups of N. meningitidis have been identified,
but six serogroups (A, B, C, W, X, and Y) are responsible for the
great majority of endemic and epidemic invasive meningococcal
disease worldwide [3,4]. Since the late 1990s, meningococcal
conjugate vaccine (MCV) use has become widespread in the
developed world. They are superior to polysaccharide vaccines in
eliciting B- and T-cell responses and, thus, provoke immunity in
children less than 2 years of age and immunologic memory in all
age groups [5]. Tetanus toxoid (TT), diphtheria toxoid (DT) and
the non-toxic mutant of diphtheria toxin (CRM197), have been
used as carrier proteins for meningococcal polysaccharide
conjugate vaccines [6].
In young adults, according to the current CDC guidelines, a sin-
gle dose of MCV should be given to -at-risk population concomi-
tantly with a single dose of pneumococcal conjugate vaccine
(PCV) and with diphtheria, tetanus and pertussis vaccine (DTP)
[7]. Earlier studies showed that non-concomitant administration
of multiple vaccines was a significant contributor to missed vacci-l. Effect of Tdap upon antibody
ugate vaccine (coadministered
(2017), http://dx.doi.org/10.10
81nation opportunities [8]. The American Advisory Committee on
Immunisation Practices (ACIP) has recommended the concomitant
administration of MCV4 with Tdap in adolescents 11–18 years of
age as a mechanism to increase adherence and simplify vaccine
administration [9].
However, with the availability of more conjugate vaccines,
immunisation schedules have become increasingly complex due
to the potential for unpredictable immunologic interference [10].
A critical appraisal of existing evidence shows that neither carrier
protein type nor its dose adequately explains the observed inter-
ference [11]. Thus, co-administration of conjugate vaccines can
have positive as well as negative effects, and predictors of vaccine
interactions are still lacking [11].
Hajj is the largest annual mass gathering of people on earth.
Crowded conditions lead to high rates of transmission of N.
meningitidis. Outbreaks of meningococcal disease among Hajj pil-
grims occurred in 1987, 2000 and 2001. Pilgrims, who asymp-
tomatically carry meningococci, may import virulent strains
back to their home countries [12]. Secondary cases of meningo-
coccal disease have been seen in the close contacts of returning
pilgrims [13,14]. Therefore, the Saudi Ministry of Health (MoH)
mandates a quadrivalent meningococcal vaccine for all Hajj pil-
grims. It also strongly recommends a few other vaccines such
as diphtheria, tetanus, pertussis (DTP), polio, yellow fever,
mumps, measles, influenza, and rubella (MMR) vaccines [15].
Moreover, independent experts recommend pneumococcal vac-
cine for Hajj pilgrims particularly for those who are highly sus-response to meningococcal polysaccharide when administered before, with
with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj
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M. Tashani et al. / Vaccine xxx (2017) xxx–xxx 3ceptible to the infection [16]. Hence, a considerable proportion of
Hajj pilgrims are given receiving multiple vaccines prior to their
travel [17], depending on their geographical location, past immu-
nisation history or presence of comorbidities. In such a situation,
there is potential for interactions and/or interferences, particu-
larly with vaccines that have antigens (such as Tdap) similar to
the carrier proteins (namely TT and CRM197) present in some
conjugate vaccines.
Our previous study with a similar design, has shown that prior
receipt of Tdap had a significant interference with nearly half of the
13 antigens present in PCV13 [18]. Since many pilgrims from
developing countries may receive the meningococcal conjugate
vaccine we have designed this randomised controlled trial (RCT)
to investigate the effects Tdap coadministration versus sequential
administration upon antibody responses to MCV4, among adult
Australian pilgrims who were preparing to attend Hajj pilgrimage
in Saudi Arabia in 2015.Fig. 1. Subject disposition flowchart. PCV13: 13-valent pneumococcal CRM197 conjugate
tetanus, reduced diphtheria and acellular pertussis vaccine; Group 1: Tdap before PCV13
Tdap.
822. Methods
2.1. Study design and objective
Open label randomised controlled trial conducted from the 14th
of February to 18th of August 2015 at The Children’s Hospital at
Westmead (CHW), Sydney, Australia.
The primary study objective was to determine whether prior or
concurrent exposure to Tdap, primes or suppresses antibody
responses to MCV4 co-administered with PCV13. Secondary study
objective was to assess the safety and reactogenicity of MCV4,
PCV13 and Tdap when administered concomitantly or separately.
2.2. Participants
Hajj pilgrims aged 18–64-years who were able to give written
informed consent were recruited from Greater Sydney, New Southvaccine; MCV4: quadrivalent meningococcal TT conjugate vaccine; Tdap: combined
and MCV4; Group 2: Tdap with PCV13 and MCV4; Group 3: PCV13 and MCV4 before
4 M. Tashani et al. / Vaccine xxx (2017) xxx–xxxWales (NSW) through Hajj travel agents. Persons excluded from
participation were those who, in the past three years, had received
any vaccine containing diphtheria, tetanus, pertussis, meningococ-
cal or pneumococcal antigens, or who had contraindications to
receipt of those vaccines as listed in the NHMRC Australian Immu-
nisation Handbook 10th Edition [19].
2.3. Random assignment
Allocation was done across three study groups by a ratio of
1:1:1 with the aid of computer-generated random numbers
according to the following:
2.3.1. Group 1 (n = 52)
Initially vaccinated with Tdap (BoostrixTM, GlaxoSmithKline) in
the left deltoid muscle followed 3–4 weeks later by coadministered
PCV13 (a CRM197 conjugate, PrevnarTM, Pfizer) in the right deltoid
plus MCV4 (a TT conjugate, NimenrixTM, GlaxoSmithKline) in the
left deltoid.
2.3.2. Group 2 (n = 57)
Vaccinated simultaneously with Tdap (left deltoid) plus PCV13
(upper right deltoid) and MCV4 (4 cm lower, right deltoid).
2.3.3. Group 3 (n = 51)
Initially vaccinated with PCV13 (right deltoid) plus MCV4 (left
deltoid) followed 3–4 weeks later by Tdap (left deltoid).
2.4. Blood sample collection
Each subject provided a 3–5 mL blood sample at each visit and
3–4 weeks after the last vaccination. Fig. 1 shows the timing of
blood samples analysed.
Blood samples were stored at +2 C to +8 C until, on the same
day, they were centrifuged and serum separated, divided into ali-
quots and stored at 80 C until transported frozen to the Vaccine
Evaluation Unit, Public Health England, Manchester Laboratory,
Manchester Royal Infirmary, Manchester, UK, for serum bacterici-
dal antibody (SBA) activity using baby rabbit complement for ser-
ogroups C, W, and Y. Sera were not tested for meningococcus
serogroup A rSBA due to limited funding.
Subjects achieving rSBA titers 8 post vaccination were consid-
ered seropositive which correlates with clinical protection against
invasive meningococcal disease [20]. Subjects whose rSBA titre
increase by 4-fold from pre- to post-vaccination were classed
as having made a seroresponse.
Serum aliquots were also analysed at the Immunology labora-
tory of The Children’s Hospital at Westmead using standardized
enzyme-linked immunosorbent assays (ELISA) for concentrations
of IgG antibodies against diphtheria and tetanus. Antibody concen-
trations >0.1 IU/mL and >0.16 IU/mL against diphtheria and teta-
nus toxoids respectively were considered indicative of
seroprotection [21,22].
2.5. Assessment of safety and reactogenicity
Each evening for seven days following each vaccination visit,
subjects recorded their axillary temperature, injection site reac-
tions (pain, redness, and swelling), solicited systemic adverse
events (AEs) (nausea or vomiting, diarrhoea, generalised weakness,
and loss of appetite). Serious adverse events (SAEs) were defined as
an AE that required hospitalisation or a persistent or significant
disability. Axillary temperature of 38 C was defined as a fever
[23,24]. Symptoms were graded as ‘mild’ (no interference with
daily activities), ‘moderate’ (some interference with daily83activities) and ‘severe’ (a significant impairment that prevents
daily activities).
2.6. Sample size calculation
Studies with meningococcal conjugate vaccines among adults
have shown that a minimum 4-fold response to serogroup (Y) to
be as low as 74%. With power of 80% and a two sided a = 0.025,
a sample size of 72 participants per group will give the power to
detect a 25% relative increase from 74% to 92.5%. With the same
power, this will also detect an increase from 80% up to 96%). We
will be also able to detect a reduction in response from 74% to
49.5%, and from 80% to 56%. To account for 5% loss to follow-up,
approximately 76 per group are required i.e. a total of 227 partic-
ipants in the three groups.
2.7. Statistical analysis
Data were compiled into a Microsoft Excel 2013 spreadsheet
and exported to Statistical Package for the Social Sciences (SPSS)
version 22 software program (SPSS, Inc., Chicago, IL, USA) for anal-
ysis. The outcome of principal of interest was comparing the
immune responses to vaccines either administered concurrently
or successively. Primary endpoint comparison among the three
study groups was performed by calculating geometric mean titres
(GMTs) of rSBA and geometric mean concentration (GMCs) of anti-
diphtheria and anti-tetanus; and 95% confidence intervals by treat-
ment group at each time point for each antibody assayed by build-
ing a generalised linear model. Log transformed responses were
compared using analysis of variance (ANOVA). A p value of <0.05
was considered significant. Secondary endpoint comparison
among the three study groups involved binary logistic regression
and Chi square test (or Fishers exact test when expected cell count
<5) to compare the proportions of seropositive (subjects achieving
rSBA titre 8 post vaccination), seroresponders (subjects achieving
4-fold rise in rSBA titers from pre to post vaccination) and sub-
jects achieving >0.1 IU/ml and >0.16 IU/ml for anti-diphtheria
and anti-tetanus IgG post vaccination respectively. When the over-
all p-value of the three groups was significant, further univariate
analysis was conducted between two relevant study arms. The
analysis of the reactogenicity and tolerability data were evaluated
descriptively by the proportions of subjects with events in each
group.
2.8. Ethics approval and trial registration
Informed consent was obtained from each participant.
The study was reviewed and approved by the Hunter New England
Research Ethics Committee (HREC reference number: 13/05/3.05),
NSW, Australia. The study was conducted according to the
International Conference on Harmonisation (ICH) and Good
Clinical Practice (GCP) guidelines. The trial is registered at the Aus-
tralian New Zealand Clinical Trials Registry (ANZCTR):
ACTRN12613000536763.3. Results
3.1. Demography
Of the 166 subjects enrolled, 160 (96.3%) completed the study
according to protocol (Fig. 1). Five withdrew because they could
not comply with the study schedule and one because of a non-
serious adverse event (the participant had a local tenderness at
the injection site and opted not to continue the study). The partic-
ipants were aged 18–62 (median 42) years; 85 (53%) were males.
M. Tashani et al. / Vaccine xxx (2017) xxx–xxx 5Their countries of birth were Australia (n = 37), Lebanon (29),
Indonesia (24), Pakistan (18), Bangladesh (16) plus other Asian
pacific (28) and Middle East countries (8). Thirty-two of them
had chronic medical conditions (eleven had diabetes, four had
asthma, three had high blood pressure, three had arthritis, three
had chronic back pain and one each had allergic rhinitis, cardio
vascular disease, cerebrovascular disease, diverticulitis, epilepsy,
gout and hypothyroidism).
3.2. Meningococcal rSBA results
Table 1 summarises rSBA titre results for meningococcus ser-
ogroup W, C and Y.
Comparing the proportions that achieved at least 4-fold rises
in rSBA titre, suggests significant interference with serogroup W
antibody response when Tdap was given 3–4 weeks before
MCV4/PCV13: 78.8% of Group 1 subjects who received Tdap 3–
4 weeks before MCV4/PCV13 had rSBA titre rises of 4-fold to ser-
ogroup W compared to 96.5% of Group 2 (received Tdap at the
same time as MCV4/PCV13) and 96.1% of Group 3 subjects
(received Tdap 3–4 weeks after MCV/PCV13), p < 0.0. Responses
to serogroup Y were also less but not significantly so. The propor-Table 1
Proportions of seropositive subjects (rSBA  8, 3–4 weeks after receipt of MCV4/PCV13);
4 weeks after MCV4/PCV13 receipt); and rSBA GMTs post vaccination for MCV4 (coadmin
Group 1 (n = 52) Group
Serogroup W
Seropositive, n (%) 45 (86.5) 55 (96
Seroresponse, n (%) 41 (78.8) 55 (96
rSBA GMT (95% CI) 1590 (731–4356) 2644
Serogroup Y
Seropositive, n (%) 51 (98.1) 56 (98
Seroresponse, n (%) 44 (84.6) 53 (93
rSBA GMT (95% CI) 1941 (1161–3246) 3413
Serogroup C
Seropositive, n (%) 49 (94.2) 52 (91
Seroresponse, n (%) 42 (80.8) 40 (70
rSBA GMT (95% CI) 1448 (778.8–2693) 1128
GMT: Geometric mean titre; MCV4: quadrivalent meningococcal TT conjugate vaccine; PC
reduced diphtheria and acellular pertussis vaccine; Group 1: Tdap before MCV4 and PCV
a ANOVA test.
b Fisher’s exact test.
c Chi-square test.
Table 2
GMCs and proportions of subjects reaching antibody titres 1.0 IU/ml and >0.16 IU/ml aga
with Tdap administered either, before, concomitantly or after MCV4 and PCV13.
Group 1 Group 2
Subjects with anti-diphtheria IgG > 0.1 IU/ml [n (%)]
Pre Tdap 36 (69.2%) 45 (79%)
Post Tdap 51 (98%) 57 (100%)
Subjects with anti-tetanus IgG > 0.16 IU/ml [n (%)]
Pre Tdap 35 (67.3%) 38 (66.7%
Post Tdap 50 (96.2%) 51 (89.5%
Anti-diphtheria IgG GMC (95% CI)
Pre Tdap 0.21 (0.14–0.32) 0.35 (0.24
Post Tdap 1.66 (1.25–2.2) 2.17 (1.81
Anti-tetanus IgG GMC (95% CI)
Pre Tdap 0.47 (0.29–0.77) 0.57 (0.36
Post Tdap 3.7 (2.7–5) 3.6 (2.5–5
GMC: geometric mean concentration; MCV4: quadrivalent meningococcal TT conjugate
bined tetanus, reduced diphtheria and acellular pertussis vaccine; Group 1: Tdap before M
before Tdap.
a p-value for three proportion was calculated by Fishers exact test and for GMTs by A
b p-value for Group 1 versus Group 3 < 0.05.
c p-value for Group 2 versus Group 3 < 0.05.
Please cite this article in press as: Tashani M et al. Effect of Tdap upon antibody
or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered
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8tion of seropositive subjects (rSBA titre 8) for serogroup W after
receipt of MCV4/PCV13 were also lower for Group 1 (86%) com-
pared to Groups 2 (96%) and 3 (93%), though not with the same
degree of statistical probability, p = 0.08. Serogroup W rSBA GMTs
were similar across the three Groups.
The serogroup C rSBA results showed no evidence for interfer-
ence or enhancement irrespective of the relative timing of Tdap
receipt and MCV4/PCV13 receipt (Table 1).
3.3. Diphtheria and tetanus IgG results
ELISA results for tetanus and diphtheria antibodies are dis-
played in Table 2. Three to four weeks before receiving Tdap vac-
cine, Group 3 had received MCV4 and PCV13 and, therefore, had
been exposed to the carrier proteins TT and CRM197. Compared
to the other two groups, Group 3 had significantly higher anti-
diphtheria and anti-tetanus IgG GMCs in blood samples collected
immediately before Tdap administration. Likewise, compared to
the other two groups, Group 3 subjects were more likely to have
anti-diphtheria IgG > 0.1 IU/ml and anti-tetanus IgG > 0.16 IU/ml
(90%, p < 0.05 and 92.2%, p < 0.05, respectively) in those blood sam-
ples collected immediately before receipt of Tdap. In post-Tdapseroresponders (rSBA titre increase 4-fold between serum collected before and 3–
istered with PCV13) administered before, concomitantly or after Tdap.
2 (n = 57) Group 3 (n = 51) p-valuea
.5) 49 (93.1) 0.08b
.5) 49 (96.1) <0.05c
(1570–4451) 2545 (1378–4700) 0.45a
.2) 48 (96.9) 0.45b
) 47 (92.2) 0.2c
(2349–4959) 2314 (1269–4222) 0.42a
.2) 46 (90.2) 0.77b
.2) 39 (76.5) 0.6c
(607–2098) 812 (424–1556) 0.43a
V13: 13-valent pneumococcal CRM197 conjugate vaccine; Tdap: combined tetanus,
13; Group 2: Tdap with MCV4 and PCV13; Group 3: MCV4 and PCV13 before Tdap.
inst diphtheria and tetanus respectively, at baseline and 3–4 weeks post-vaccination
Group 3 p-valuea
46 (90%) <0.05b
51 (100%) 0.3
) 47 (92.2%) <0.05b
) 51 (100%) <0.05c
–0.51) 1.13 (0.75–1.71) <0.05b
–2.59) 1.51 (1.15–1.97) 0.08
–0.92) 3.65 (2.45–5.44) <0.05b
.4) 5 (4–6) 0.3
vaccine; PCV13: 13-valent pneumococcal CRM197 conjugate vaccine; Tdap: com-
CV4 and PCV13; Group 2: Tdap with MCV4 and PCV13; Group 3: MCV4 and PCV13
NOVA test.
response to meningococcal polysaccharide when administered before, with
with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj
16/j.vaccine.2017.03.106
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Table 3
Local and systemic adverse events (AE) following vaccination when Tdap was administered concomitantly or sequentially to MCV4 and PCV13.
Solicited injection site reactions
Day 0 Day1 Day2 Day3 Day4 Day5 Day6
Tdap (n = 160, group 1
v1, group 2 v1 and
group 3 v2)
Redness [n (%) (mean mm)] 15 (3) (23) 15 (9.4) (28.3) 14 (8.8) (34) 10 (6.3) (28.3) 8 (5) (35.6) 4 (2.5) (41.7) 2 (1.3) (80)
Swelling [n (%) (mean mm)] 8 (5) (25.5) 12 (7.5) (31.8) 8 (5) (33.3) 6 (3.8) (21.7) 4 (2.5) (32.2) 2 (1.3) (12.5) 1 (0.6) (1)
Hardness [n (%) (mean mm)] 18 (11.3) (10) 21 (13) (17) 16 (10) (23.8) 10 (6.3) (33.2) 10 (6.3) (30.4) 5 (3.1) (5.8) 5 (3.1) (2)
Pain [n (%)] Mild-moderate 66 (41.3) 60 (37.5) 37 (22.5) 24 (15) 17 (10.6) 10 (6.3) 10 (6.3)
Severe 12 (7.5) 18 (11.3) 10 (6.3) 3 (2) 2 (1.3) 2 (1.3) 0
PCV13 (n = 103, group
1 v2 and group 3 v1)
Redness [n (%) (mean mm)] 12 (11.7) (3.7) 10 (9.7) (47.6) 10 (9.7) (29.8) 5 (5) (25.2) 4 (4) (3.7) 2 (2) (1) 1 (1) (30)
Swelling [n (%) (mean mm)] 13 (12.6) (12.4) 11 (10.7) (17.6) 6 (5.8) (19.8) 3 (3) (10.3) 3 (3) (5.3) 2 (2) (2) 2 (2) (8)
Hardness [n (%) (mean mm)] 21 (20.4) (19.8) 16 (15.5) (29) 8 (7.8) (25.3) 4 (4) (10.2) 3 (3) (7) 1 (1) (1) 1 (1) (10)
Pain [n (%)] Mild-moderate 55 (53.4) 54 (52.4) 38 (37) 13 (12.6) 6 (5.8) 5 (5) 5 (5)
Severe 12 (11.7) 9 (8.7) 3 (3) 3 (3) 1 (1) 1 (1) 0
MCV4 (n = 103, group 1
v2 and group 3 v1)
Redness [n (%) (mean mm)] 7 (6.7) (7.4) 4 (3.8) (12.7) 5 (13.6) (4.8) 4 (3.8) (16.5) 4 (3.8) (15.2) 4 (3.8) (12.7) 3 (3) (12)
Swelling [n (%) (mean mm)] 5 (13.6) (2.8) 2 (2) (5.5) 2 (2) (8) 1 (1) (15) 1 (1) (10) 0 0
Hardness [n (%) (mean mm)] 8 (7.7) (10.5) 6 (5.8) (12) 5 (4.8) (11.2) 2 (2) (12.2) 2 (2) (10) 1 (1) (5) 1 (1) (5)
Pain [n (%)] Mild-moderate 38 (37) 35 (34) 18 (17.5) 4 (4) 2 (2) 1 (1) 0
Severe 1 (1) 2 (2) 1 (1) 0 0 0 0
PCV + MCV4 (n = 57,
group 2 v1)
Redness [n (%) (mean mm)] 2 (10.5) (13.7) 10 (17.5) (12.2) 8 (14) (19) 3 (5.3) (2.3) 5 (8.5) (9.2) 2 (10.5) (26) 2 (10.5) (51.5)
Swelling [n (%) (mea n mm)] 10 (17.5) (18) 10 (17.5) (23) 4 (7) (47.5) 3 (5.3) (31.7) 2 (10.5) (27.5) 1 (1.8) (10) 2 (10.5) (6)
Hardness [n (%) (mean mm)] 12 (21) (6.3) 14 (24.6) (12) 10 (17.5) (12.3) 7 (12.3) (10.7) 5 (8.8) (10.8) 3 (5.3) (10.7) 4 (7) (7.5)
Pain [n (%)] Mild-moderate 32 (56) 26 (45.6) 25 (44) 18 (31.6) 10 (17.5) 8 (14) 4 (7)
Severe 6 (10.5) 10 (17.5) 3 (5.3) 2 (10.5) 0 0 1 (1.8)
Solicited systemic reactions
Day 0 Day1 Day2 Day3 Day4 Day5 Day6
Tdap (n = 103, group 1 v1 and group 3 v2) Fever (38 C) [n (%)] 0 1 (1) 1 (1) 1 (1) 0 0 0
Nausea or vomiting [n (%)] 1 (1) 0 0 0 0 0 0
Diarrhoea [n (%)] 0 0 0 0 0 0 0
Loss of appetite [n (%)] 3 (3) 1 (1) 0 0 0 0 0
Drowsiness [n (%)] 8 (7.8) 8 (7.8) 3 (3) 2 (2) 2 (2) 2 (2) 2 (2)
General muscle aches [n (%)] 31 (30) 29 (28.2) 15 (14.6) 12 (11.7) 6 (5.8) 5 (5) 4 (4)
PCV13 + MCV4 (n = 103, group 1 v2 and group 3 v1) Fever (38 C) [n (%)] 3 (3) 3 (3) 3 (3) 2 (2) 2 (2) 1 (1) 1 (1)
Nausea or vomiting [n (%)] 0 0 0 0 0 0 1 (1)
Diarrhoea [n (%)] 0 1 (1) 1 (1) 0 0 0 0
Loss of appetite [n (%)] 7 (6.7) 6 (5.8) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2)
Drowsiness [n (%)] 14 (13.5) 13 (12.6) 9 (8.7) 4 (3.8) 3 (3) 3 (3) 3 (3)
General muscle aches [n (%)] 39 (37.8) 42 (40.7) 22 (21.3) 12 (11.6) 6 (5.8) 7 (6.7) 6 (5.8)
PCV13 + MCV4 + Tdap (n = 57, group 2 v1) Fever (38 C) [n (%)] 1 (1.8) 3 (5.3) 0 0 0 0 0
Nausea or vomiting [n (%)] 3 (5.3) 4 (7) 2 (3.5) 2 (3.5) 2 (3.5) 1 (1.8) 1 (1.8)
Diarrhoea [n (%)] 1 (1.8) 2 (3.5) 1 (1.8) 1 (1.8) 1 (1.8) 0 0
Loss of appetite [n (%)] 7 (12.3) 7 (12.3) 2 (3.5) 1 (1.8) 1 (1.8) 1 (1.8) 1 (1.8)
Drowsiness [n (%)] 11 (19.3) 11 (19.3) 11 (19.3) 2 (3.5) 1 (1.8) 1 (1.8) 2 (3.5)
General muscle aches [n (%)] 27 (47.4) 25 (44) 22 (38.6) 13 (22.8) 7 (12.3) 3 (5.3) 2 (3.5)
Tdap: combined tetanus, reduced diphtheria and acellular pertussis vaccine; MCV4: quadrivalent meningococcal TT conjugate vaccine; PCV13: 13-valent pneumococcal CRM197 conjugate vaccine; Group 1: Tdap before MCV4 and
PCV13; Group 2: Tdap with MCV4 and PCV13; Group 3: MCV4 and PCV13 before Tdap; V: visit number.
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tetanus IgG > 0.16 IU/ml was significantly greater than amongst
Group 2 subjects (90%, p < 0.05). However, there was no difference
between the three groups for anti-diphtheria IgG after Tdap vacci-
nation (p = 0.3).
The pneumococcal antibody results will be presented in a sep-
arate paper when funding is obtained to perform the testing.3.4. Reactogenicity
Injection site reactions and solicited systemic reactions are
reported in details in Table 3. Most solicited local and systemic
adverse events reported within seven days of vaccine administra-
tion were mild to moderate in severity.
Injection site reaction severity was least for MCV4 alone, fol-
lowed in ascending order by PCV13 alone and Tdap alone and
was greatest when MCV4 and PCV13 were given together in the
same deltoid muscle. The most frequently reported solicited sys-
temic reactions were general muscle aches and drowsiness which
were most often reported following the coadministration of the
three vaccines followed by the concomitant administration of
MCV4 and PCV13 and least reported after administration of Tdap
alone. The duration of solicited local and systemic reactions did
not exceed seven days, and no serious adverse events were
reported.4. Discussion
This is the first RCT among adults to compare concurrent versus
sequential administration of Tdap with quadrivalent meningococ-
cal conjugate vaccine coadministered with PCV13. In this trial we
found rSBA to meningococcus serogroupW to be the only antibody
response reduced when Tdap was administered 3–4 weeks before
administration of MCV4/PCV13 (Group 1). The degree of immune
response suppression combined with the small numbers of sub-
jects in each of the Groups mean that this finding was not robustly
demonstrated: only the proportion of subjects demonstrating a
seroresponse (4-fold rise in rSBA) was statistically different
between Group 1 and the other two Groups (Tdap administered
after or at the same time as MCV4/PCV13); this is perhaps because
analysing the seroresponders with cut-off point of 4-fold, sets a
more sensitive threshold in detecting protected individuals (which
only reflects short term protection). Other ways of analysing ser-
ogroup W rSBA results (proportion of subjects achieving post-
MCV4/PCV13 rSBA titres 8 and GMTs) were less convincing.
Several studies have investigated concurrent and sequential
administration of MCV4 with Tdap (or DTP) with conflicting out-
comes [25–33].
For instance, a study among adolescents reported by Arguedas
et al. [25] found that number of seroresponders in serogroup W
were significantly lower upon sequential administration (of Tdap
first), which was consistent with our finding [25].
More trials have demonstrated this suppression effect; in a
study involving children (up to 18 years old), Burrage and col-
leagues [27] observed an adverse effect on the immunogenicity
of meningococcal C vaccine conjugated to TT (MCV-TT) upon prior
to (and to a lesser extent with concomitant) administration of
diphtheria-tetanus booster [27]. Another recent trial among tod-
dlers aged 12–23 months has shown that administration of DTP
followed by MCV4-TT resulted in significantly lower rSBA titers
against serogroups A, C, and W [30]. A trial in Korean military
recruits showed significant suppression when tetanus-diphtheria
toxoids were administered just three days before MCV4-CRM197
[29].86On the other hand, a review that evaluated the effects of coad-
ministration in infants and toddlers showed that coadministration
of MCV4-TT with other vaccines including DTPa or PCV10 did not
alter s immunogenicity [28]. A study with MCV4 conjugated to
DT showed non-inferiority with similar findings either upon con-
current or sequential administration of Tdap vaccine in adolescents
[32]. Burrage’s trial found that prior or simultaneous administra-
tion of diphtheria-tetanus booster did not affect the rSBA antibody
responses to the MCV conjugated to CRM197 [27].
However, a few trials in humans (infants and adults) and animal
models have shown enhanced immunogenicity of MCV upon either
prior [31,33] or concurrent exposure [26] to DTP or its
components.
It is not entirely clear why some studies resulted in enhance-
ment whereas the others showed suppression. However, an
inverse dose-dependent relationship of the priming agent to the
antibodies produced against the polysaccharide the conjugate vac-
cine was observed in one experiment in mice [31]. The suppression
of the conjugate immunogenicity following exposure to
diphtheria-tetanus antigens has been generally attributed to
carrier induced epitopic suppression (CIES) which is defined as a
suppressed anti-hapten polysaccharide response induced by
pre-existing immunity to the carrier protein. This occurs due to
competition between carrier- and carbohydrate-specific B cells
and impaired differentiation of memory B cells to antibody-
producing cells [34–37]. To avoid CIES when concurrent or sequen-
tial administration is necessary, manufacturing conjugate vaccines
with moderate PEGylation has been suggested (PEGylation = con-
jugation of polyethylene glycol, PEG) [38].
The variable immunogenicity of MCV4 serogroup polysaccha-
rides has been generally attributed to their structural diversity.
[39] In our study, coadministration of MCV4 with Tdap did not
affect immunogenicity of the polysaccharide antigens. The effect
was only seen with prior exposure to Tdap.
With regard to anti-diphtheria and anti-tetanus ELISA antibody
responses, our trial found that exposure to MCV4-TT and PCV13-
CRM197 significantly increases anti-diphtheria and anti-tetanus
antibody levels. It is known that TT and DT/CRM197 carriers can
induce a significant booster response against tetanus and diphthe-
ria respectively [27,40,41], but there are limited data on whether
carrier proteins per se can induce a protective immune response
to tetanus or diphtheria. A study by Dbaibo et al. concluded that
one injection of MCV-TT in formerly tetanus naïve individuals
may not be protective against tetanus and a booster is needed in
order to reach an effective immune response to TT [42]. In animal
models, conjugate vaccines based on TT and DT were able to induce
protection against lethal challenge with tetanus toxin and diphthe-
ria toxin respectively. However, even two doses of conjugate vacci-
nes based on CRM197 failed to produce such immunity against
diphtheria toxins [43]. Accordingly, CRM197 was considered to
have a lower immunogenic capacity than DT, when used as carrier
protein in meningococcal vaccines. This could be the reason in our
study why the proportion of subjects with anti-tetanus
IgG > 0.16 IU/mL was significantly greater post-Tdap in Group 3
compared to the other groups whereas anti-diphtheria antibodies
did not show as much enhancement. The former is attributed to
the presence of TT as a carrier protein of MCV4. Also Tdap has an
adult dose of tetanus but reduced dose of diphtheria and pertussis
antigens.
Consistent with our previous publication with PCV13 [18], this
trial has shown no safety issues and acceptable level of reacto-
genicity either upon concomitant or sequential administration of
the vaccines used. MCV4 was the least likely to cause any local
adverse events. Generally, the duration of solicited local and sys-
temic reactions did not exceed seven days, and no serious adverse
events were reported.
8 M. Tashani et al. / Vaccine xxx (2017) xxx–xxxConcomitant administration of multiple vaccines is common
practice in travel clinics preparing people for international travel
such as Hajj pilgrimage. This offers greater convenience (fewer
clinic visits), and improves compliance. On the other hand, some
vaccine providers tend to separate the injections in order to min-
imise adverse events.
Conjugate vaccines are widely used in developed countries. The
recent recommendations from experts, including Saudi MoH,
encourage the use of conjugate vaccines over polysaccharide due
to superiority in preventing diseases (eg pneumonia), reduction
in carriage and provision of longer protection [15,44]. A major lim-
itation of the trial is that it had a smaller sample size than what
was initially planned, however, we showed from a separate analy-
sis even a smaller sample demonstrated significant differences
[18]. Another limitation was the lack of sufficient funding to per-
form the serology for all four meningococcal serogroups. Also fund-
ing for pneumococcal serotypes took added time to secure but is
underway.
This trial in adults demonstrated adequate safety and non-
inferiority of meningococcal responses with concomitant vaccine
administration compared to separate administration. It is unlikely
that reduced seroconversion against serogroup W (in Group 1,
when Tdap was given first) will place pilgrims at significantly high
risk for invasive meningococcal disease because the frequency of
seropositive was similar among the three study groups. However,
from these limited data it appears that when multiple vaccination
is required for Hajj pilgrims, administering Tdap concurrently with
MCV4/PCV13 produces adequate immune responses, and avoids
meningococcal immune interference. Nevertheless, if separating
the vaccines was necessary, administering MCV4 before Tdap
brings the advantage of an enhanced tetanus toxoid response.Acknowledgment
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Abstract
Background: Due to their antigenic similarities, there is a potential for immunological interaction between tetanus/
diphtheria-containing vaccines and carrier proteins presented on conjugate vaccines. The interaction could, unpre-
dictably, result in either enhancement or suppression of the immune response to conjugate vaccines if they are in-
jected soon after or concurrently with diphtheria or tetanus toxoid. We examined this interaction among adult
Australian travellers before attending the Hajj pilgrimage of 2015.
Methods: We randomly assigned each participant to one of three vaccination schedules. Group A received tetanus, diph-
theria and acellular pertussis vaccine (Tdap) 3–4 weeks before receiving CRM197-conjugated 13-valent pneumococcal vac-
cine (PCV13) coadministered with TT-conjugated quadrivalent meningococcal vaccine (MCV4). Group B received all three
vaccines concurrently. Group C received PCV13 and MCV4 3–4 weeks before Tdap. Blood samples collected at baseline, at
each vaccination visit and 3–4 weeks after vaccination were tested for the pneumococcal opsonophagocytic assay (OPA).
Results: A total of 166 participants aged 18–64 (median 42) years were recruited, 159 completed the study. Compared
with the other groups, Group A had significantly (P< 0.05) lower geometric mean titres (GMTs) post-vaccination in
seven serotypes of PCV13 (1, 3, 4, 5, 14, 18C and 9V). Additionally, Group A had lower frequency of serorises (4-fold
rise in OPA titres) in serotype5 (79%, p¼ 0.01) and 18C (73.5%, p¼ 0.06); whereas Groups B and C had significantly
lower frequencies of serorises in Serotype 4 (82%) and 6A (73.5%), respectively. No statistically significant difference
was detected across the three groups in frequencies achieving OPA titre 1:8 post-vaccination.
Conclusions: Tdap vaccination 3–4 weeks before administration of PCV13 and MCV4 significantly reduced the GMTs
to seven of the 13 pneumococcal serotypes in adults. If multiple vaccination is required before travel, deferring teta-
nus/diphtheria until after administering the conjugate vaccine is recommended to avoid immune interference.
Key words: Pneumococcal conjugate vaccine, Hajj, carrier priming, carrier interference, pneumococcal opsonophagocytic assay
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Introduction
Streptococcus pneumoniae (S. pneumoniae) is a major global
pathogen that poses a risk of pneumococcal pneumonia and in-
vasive pneumococcal disease (IPD) with considerable morbidity
and mortality particularly among extreme age groups<5
and 65, particularly in travellers, including Hajj pilgrims.1–3
An increase in antibiotic resistance have led the researchers to
divert attention to search for novel vaccines such as the pneumo-
coccal conjugate vaccine (PCV) that would be providing
broader coverage for many developing countries.4
Despite the great benefits of the pneumococcal vaccines, there
are still technical factors limiting the potential impact of immuni-
zation, particularly in some developing countries, such as the cost
and the fact that many vaccines require repeated administration
in order to achieve effective protection. While PCVs are widely
available in industrialized nations, the cost of these vaccines is
still considered a great challenge to comprehensive implementa-
tion in low- and middle-income countries as these countries are
lagging behind the required schedule due to vaccine costs.5–7
From another prospective, adult international travellers
from developing and developed countries who perform Hajj pil-
grimage in Saudi Arabia are required to receive multiple vacci-
nations such as the tetravalent meningococcal vaccine which is a
mandatory visa requirement.8 Pilgrims who are incompletely
immunized are also encouraged to be up-to-date with the immu-
nization schedule in their home country; these usually include
diphtheria, tetanus, pertussis, polio, measles and mumps.8
Additionally, independent experts and the Saudi Thoracic
Society also recommend pneumococcal vaccine for Hajj pilgrims
particularly for those who are highly susceptible to the infec-
tion.3,9 This is consistent with the Australian guidelines that rec-
ommend pneumococcal vaccine to vulnerable populations such
as elderly and/or people with comorbidity.10
The requirement of receiving multiple vaccines raises the con-
cern about potential interactions between vaccine components re-
ducing desired protective effects.11,12 Glycoconjugate vaccines
are covalently bound to a carrier protein which provides T-cell
epitopes that confer a T dependent character to the saccharide
moiety. The three most common carrier proteins currently in-
cluded in licensed glycoconjugate vaccines are diphtheria toxoid
(DT), tetanus toxoids (TT) and CRM197, a non-toxic mutant of
diphtheria toxin.13 The antigenic similarity between these carrier
proteins and the components of tetanus, diphtheria and acellular
pertussis (Tdap) vaccine is the corner stone of potential interac-
tions. There have been suggestions to take advantage of conjugate
vaccine interactions especially to investigate if carrier priming oc-
curs which would enhance the immunogenicity of PCV and per-
haps spare one of the three (expensive) doses for children in
developing countries.14,15 However, this interaction has not yet
been examined thoroughly through an RCT in either children or
adults as literature suggest that prior exposure to Tdap vaccine
could unpredictably enhance or suppress the subsequent immuno-
genicity of the conjugate vaccine.16
The Hajj pilgrimage provided a unique opportunity to con-
duct several comparisons to allow for examination of coadmi-
nistration vs sequential administration of glycoconjugate
vaccines with Tdap. This examination will provide further evi-
dence on conjugate vaccine interactions, whether priming (en-
hancement) or interference (suppression).
In the year 2014, our team examined this by an RCT com-
paring concurrent vs sequential administration of Tdap with
two other conjugate vaccines conjugated to CRM197 (PCV13
and MCV4).17 This showed significant suppression to six
(of the 13) antigens of PCV13 after prior exposure to Tdap;
the suppression was attributed then to possible CRM197
overload.
The objective of this study is to present the outcome of the
next year’s RCT (2015) where we replaced the CRM197 conju-
gated MCV4 (MenveoTM) with a TT conjugated MCV4
(NimenrixTM) in order to examine the effect of concomitant ver-
sus sequential administration of Tdap of the conjugate vaccines
(PCV13 and MCV4) among Hajj travellers.
Methods
Study Design
We conducted an open label randomized controlled trial from 14
February to 18 August in the year 2015 at The Children’s
Hospital at Westmead (CHW), Sydney, Australia, in order to de-
termine in adults whether prior or concurrent exposure to Tdap
vaccine, primes or suppresses antibody responses to PCV13 co-
administered with MCV4. In this paper, we present the pneumo-
coccal serotype specific antibody data. Meningococcal, diphthe-
ria and tetanus antibody results were already reported previously
(currently under review).
Participants
Pilgrims aged 18–64 years who were able to give informed con-
sent were recruited from Greater Sydney, New South Wales
(NSW) through Hajj travel agents. Persons excluded from par-
ticipation were those who, in the past 3 years, had received any
vaccine containing diphtheria, tetanus, pertussis, meningococcal
or pneumococcal antigens, or who had contraindications to re-
ceipt of those vaccines as listed in the NHMRC Australian
Immunisation Handbook 10th Edition.10
Study Groups
Each participant was randomly assigned according to com-
puter-generated random numbers to any one of the three study
groups (Figure 1):
Group A: Initially vaccinated with Tdap (BoostrixV
R
,
GlaxoSmithKline) in the left deltoid muscle followed 3–4 weeks
later by coadministered PCV13 (a CRM197 conjugate, PrevnarTM,
Pfizer) in the right deltoid plus MCV4 (a TT conjugate,
NimenrixTM, GlaxoSmithKline) in the left deltoid.
Group B: Vaccinated simultaneously with Tdap (left deltoid)
plus PCV13 (upper right deltoid) and MCV4 (4 cm lower, right
deltoid).
Group C: Initially vaccinated with PCV13 (right deltoid)
plus MCV4 (left deltoid) followed 3–4 weeks later by Tdap (left
deltoid).
Each subject provided a 3–5 ml blood sample at each visit
and 3–4 weeks after the last vaccination.
Sample Size Calculation
This trial’s sample size was actually based on the impact on the
immunogenicity of the MCV4, one of the study vaccines.
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Studies with MCV4 among adults have shown that a minimum
4-fold response to serogroup (Y) to be as low as 74%. With
power of 80% and a two-sided a¼ 0.025, a sample size of 72
participants per group will give the power to detect a 25% rela-
tive increase from 74% to 92.5%. We would be also able to de-
tect a reduction in response approximately from 74% to
49.5%. To account for 5% loss to follow-up, approximately 76
per group are required i.e. a total of 227 participants in the three
groups. We did not do a formal sampling size calculation in re-
lation to response to pneumococcal conjugate vaccine and we
recognize that power is limited by the number of subjects
recruited.
Antibody Assays
Blood samples were stored atþ2 andþ8 C until centrifuged on
the same day of collection and serum was extracted, divided
into aliquots and stored at80C until transported frozen to
Pfizer’s Laboratory at Pearl River, NY, USA, for opsonophago-
cytic activity (OPA) assays18 for pneumococcus Serotypes 1, 3,
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
For this study, antibody titres against pneumococcal antigens
were measured using OPA as it reflects the ability of anti-
pneumococcal antibodies to induce phagocytosis and killing.19
Statistical Analysis
Data were compiled into a Microsoft Excel 2013 spreadsheet
and then exported to Statistical Package for the Social Sciences
(SPSS, Inc., Chicago, IL, USA) version 22 for analysis.
Primary comparison among the three study groups was
performed by calculating geometric mean titres (GMTs) of anti-
bodies and 95% confidence intervals, by treatment group, post-
vaccination for each antibody assayed. A generalized linear model,
with log-transformed antibody titres, was compared for the three
study groups using analysis of variance (ANOVA) test.
Secondary comparison of the three study groups involved bi-
nary logistic regression and Chi-square tests (or Fishers exact
test when expected cell count< 5) to compare the proportions
(frequencies) of subjects that achieved OPA titre1:8 post-vac-
cination or where seroresponders with a4-fold rise in OPA
titre.
Figure 1. Subject disposition flowchart. PCV13, 13-valent pneumococcal CRM197 conjugate vaccine; MCV4, quadrivalent meningococcal TT conju-
gate vaccine; Tdap, combined tetanus, reduced diphtheria and acellular pertussis vaccine; Group A, Tdap before PCV13 and MCV4; Group B, Tdap
with PCV13 and MCV4; Group C, PCV13 and MCV4 before Tdap
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When the overall p value for the model analyzing the three
study groups was significant, further univariate analysis was
conducted between two relevant study arms.
Ethical Aspects and Trial Registration
Informed consent was obtained from each participant. The trial
was reviewed and approved by the Hunter New England
Research Ethics Committee (HREC reference number: 13/05/
3.05), Newcastle, NSW, Australia. It was conducted according
to the International Conference on Harmonisation (ICH) and
Good Clinical Practice (GCP) guidelines. The trial is registered
with the Australian New Zealand Clinical Trials Registry
(ANZCTR): ACTRN12613000536763.
Results
Of the 166 subjects enrolled, 159 (95.7%) completed the study
according to protocol (Figure 1). Six withdrew because they
could not comply with the study schedule and one because of
a non-serious adverse event. The 159 participants were aged
18–62 (median 42) years; 85 (53%) were males. Their countries
of birth were Australia (n¼ 37), Lebanon (28), Indonesia (24),
Pakistan (18), Bangladesh (16) plus other Asian pacific (28) and
Middle East countries (8). Thirty-one of them had chronic medi-
cal conditions (11 had diabetes, 4 had asthma, 3 had hyperten-
sion, 3 had arthritis, 3 had chronic back pain and one each had
allergic rhinitis, cardio vascular disease, cerebrovascular disease,
diverticulitis, epilepsy, gout and hypothyroidism).
Table 1 shows that there was significantly (P<0.05) lower
GMTs in Group A compared with the other groups for seven se-
rotypes (1, 14, 18C, 3, 4, 5 and 9V). On the other hand, Group
C had significantly lower GMTs for two serotypes (19F and 6A)
compared with the other two groups; whereas Group B had
(insignificantly) lower GMTs for only one serotype (23F). The
pattern of these comparisons is illustrated in Figure 2.
Generally, upon comparing the GMTs across the three study
groups, the highest GMT among all groups and serotypes was
6A in Group B and the lowest serotype response was serotype 3
in Group A.
With regard to achieving 4-fold rise in OPA titre, Table 2
details by assigned group the numbers and proportions of those
with4-fold rise. A lower proportion of Group A subjects
achieved4-fold rise for Serotypes 18C (P¼0.06) and
5 (P¼ 0.01) compared with the other two groups. In Group B,
responses were generally better.
Group C had a significantly lower proportion of subjects
achieving the4-fold rise for, just one, Serotype 6A.
In terms of numbers and proportions of seropositive subjects
(OPA titre1:8), there was no significant differences across the
three groups in terms of achieving seropositive titres 1:8 (Table 3).
Discussion
This trial highlights that exposure to Tdap 3–4 weeks before the
coadministration of PCV13/MCV4 in adults (as in Group A) signif-
icantly suppressed the subsequent GMTs to seven (1, 14, 18C, 3, 4,
5 and 9V) of the PCV13’s polysaccharide serotypes. Additionally,
two of these serotypes (18C and 5) in Group A showed signifi-
cantly lower proportion achieving4-fold rise in OPA titres. The
concurrent exposure to Tdap in Group B resulted in a better im-
mune response and no evidence of significantly lower proportion
achieving4-fold rise for any serotype. It is noteworthy to men-
tion that concurrent administration of pneumococcal conjugate
vaccine with other vaccines such as and influenza vaccine may vari-
ably affect the response to pneumococcal vaccine.20–22
Carrier proteins can induce anti-carrier antibody responses
that may interfere with immune responses to the conjugate
Table 1. OPA GMTs for the 13 serotypes of PCV13 3-4 weeks post vaccination with PCV13 (coadministered with MCV4) administered either
before, concomitantly or after Tdap
Serotype Group A Group B Group C P valuea
OPA GMT (95% CI) OPA GMT (95% CI) OPA GMT (95% CI)
1 334 (223–501) 414 (289–594) 654 (431–992) 0.04b
14 1333 (884–2009) 1792 (1247–2575) 1896 (1457–2468) 0.02b
18C 1600 (1055–2426) 3302 (2414–4516) 3052 (2078–4483) 0.001b
19A 1585 (1176–2138) 1592 (1114–2276) 1746 (1293–2358) 0.8
19F 1765 (1197–2602) 1619 (1115–2351) 670 (403–1115) 0.005bc
23F 2451 (1549–3878) 2257 (1508–3377) 2724 (1879–3948) 0.4
3 52 (38–72) 112 (79–159) 103 (63–167) 0.004b
4 1966 (1467–2633) 2879 (2098–3949) 2459 (1590–3801) 0.038b
5 219 (116–414) 366 (222–602) 677 (405–1133) 0.01b
6A 5945 (4408–8018) 10 818 (7991–14 644) 5258 (3261–8479) 0.008c
6B 4005 (2917–5500) 4637 (3289–6538) 2602 (1471–4605) 0.1
7F 3133 (2423–4051) 2852 (2202–3692) 3832 (2899–5065) 0.1
9V 1426 (1025–1985) 3344 (2116–5285) 2865 (2113–3886) 0.000b
Group A, Tdap before PCV13 and MCV4; Group B, Tdap with PCV13 and MCV4; Group C, PCV13 and MCV4 before Tdap; MCV4, quadrivalent meningococcal TT conjugate vac-
cine; PCV13, 13-valent pneumococcal CRM197 conjugate vaccine; Tdap, combined tetanus, reduced diphtheria and acellular pertussis vaccine; OPA, opsonophagocytic assay; GMT, geo-
metric mean titre.
aP overall value for the three groups based on ANOVA test.
bP value of Group A to Group C was also statistically significant (<0.05).
cP value of Group B to Group C was also statistically significant (<0.05).
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vaccine upon concurrent or especially sequential administration
to Tdap. This trial indicates that Tdap antigens can negatively
interact with at least half of serotypes of the CRM197-
conjugated PCV13, probably as a result of the similarity of the
carrier protein CRM197 to DT in Tdap. The prominent sup-
pression in some serotypes more than others may be due to lack
of power or could be attributed to the different immunological
properties of the structurally different pneumococcal antigens.23
There are very few trials in the literature examining the
impact of sequential administration of Tdap and conjugate
vaccines. In contrast to our finding, two pre-clinical studies
in mice demonstrated that prior exposure to TT and CRM197
subsequently enhanced the immunity of TT-conjugated pneu-
mococcal vaccine and CRM-197 conjugated PCV13, respec-
tively.24,25 Furthermore, some infant and adult studies have also
found evidence that prior receipt of DTP vaccine or one of its
components enhanced the subsequent immunogenicity of PCV-
DT/CRM197.14,26–29 These findings can be attributed to carrier
priming phenomenon which arises from the increased the
number of carrier specific T lymphocytes that can provide the
Figure 2. GMTs and confidence intervals of OPA for all the PCV13 serotypes, 3–4 weeks post-vaccination with PCV13 (coadministered with MCV4) ad-
ministered either before, concomitantly or after Tdap. Group A, Tdap before PCV13 and MCV4; Group B, Tdap with PCV13 and MCV4; Group C,
PCV13 and MCV4 before Tdap; MCV4, quadrivalent meningococcal TT conjugate vaccine; PCV13, 13-valent pneumococcal CRM197 conjugate vac-
cine; Tdap, combined tetanus, reduced diphtheria and acellular pertussis vaccine; OPA, opsonophagocytic assay; GMT, geometric mean titre.
Table 2. Proportions of subjects with 4-fold rise in OPA titre for
the 13 serotypes of PCV13, 3–4 weeks post-vaccination with PCV13
(coadministered with MCV4) administered either before, concomi-
tantly or after Tdap
Serotype Group A Group B Group C Overall
n (%) n (%) n (%) P valuea
1 47 (92.2) 54 (96.4) 48 (96) 0.7
14 24 (47) 27 (50) 33 (66) 0.1
18C 36 (73.5) 51 (91) 39 (81.3) 0.06
19A 42 (82.4) 48 (89) 41 (82) 0.5
19F 41 (82) 44 (83) 35 (71.4) 0.3
23F 47 (94) 47 (87) 45 (90) 0.6
3 33 (64.7) 44 (78.6) 31 (60.8) 0.1
4 43 (84.3) 45 (81.8) 48 (96) 0.07
5 38 (79.2) 48 (90.6) 45 (97.8) 0.01
6A 41 (82) 51 (94.4) 36 (73.5) 0.01
6B 46 (92) 46 (86.8) 41 (82) 0.3
7F 36 (70.6) 41 (74.5) 38 (74.5) 0.9
9V 28 (57) 36 (65.5) 34 (69.4) 0.4
Group A, Tdap before PCV13 and MCV4; Group B, Tdap with PCV13 and MCV4;
Group C, PCV13 and MCV4 before Tdap; MCV4, quadrivalent meningococcal TT conju-
gate vaccine; PCV13, 13-valent pneumococcal CRM197 conjugate vaccine; Tdap, com-
bined tetanus, reduced diphtheria and acellular pertussis vaccine; OPA, opsonophagocytic
assay.
aP value based on Fisher’s exact test.
Table 3. Proportions of seropositive subjects (OPA titre 1:8) for
the 13 serotypes of PCV13, 3–4 weeks post-vaccination with PCV13
(coadministered with MCV4) administered either before, concomi-
tantly or after Tdap
Serotype Group A Group B Group C Overall
n (%) n (%) n (%) P valuea
1 51 (100) 56 (100) 50 (100) 1
14 50 (98) 54 (100) 50 (100) 0.65
18C 51 (100) 56 (100) 48 (100) 1
19A 51 (100) 54 (100) 50 (100) 1
19F 50 (100) 53 (100) 48 (98) 0.3
23F 50 (100) 54 (100) 50 (100) 1
3 48 (94) 53 (94.6) 46 (90.2) 0.7
4 51 (100) 55 (100) 50 (100) 1
5 45 (93.8) 51 (96.2) 46 (100) 0.3
6A 50 (100) 54 (100) 48 (98) 0.3
6B 50 (100) 53 (100) 49 (98) 0.6
7F 51 (100) 55 (100) 51 (100) 1
9V 49 (100) 54 (98.2) 49 (100) 1
Group A, Tdap before PCV13 and MCV4; Group B, Tdap with PCV13 and MCV4;
Group C, PCV13 and MCV4 before Tdap; MCV4, quadrivalent meningococcal TT conju-
gate vaccine; PCV13, 13-valent pneumococcal CRM197 conjugate vaccine; Tdap, com-
bined tetanus, reduced diphtheria and acellular pertussis vaccine; OPA, opsonophagocytic
assay.
aP value based on Fisher’s exact test.
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necessary ‘help’ for the expansion and differentiation of poly-
saccharide specific B lymphocytes.30,31
On the other hand, our trial among adults in the year 2014
with similar design has shown that prior exposure to Tdap re-
sulted in the suppression of the GMTs of six serotypes (3, 5,
18C, 4, 19A and 9V) of PCV13.17 It was thought that the
suppression was due to the overload of CRM197 which was
present in the PCV13 (PrevnarTM) and MCV4 (MenveoTM).
However, the suppression also occurred in this 2015 trial even
with a lower CRM197 dose as we replaced Menveo with
TT-conjugated MCV4 (NimenrixTM). The suppression in 2014
and 2015 occurred nearly in the same serotype which implies
that it is a serotype-specific suppression.
This suppression could be attributed to immunological phe-
nomena such as CIES24,32–35 in which antibody responses to
haptens presented on a carrier are inhibited by prior immuniza-
tion with the specific carrier.36 This occurs due to the presence
of pre-existing antibodies to the carrier protein that may prevent
the binding of hapten-specific B-cells to their epitopes.
Additionally, the promotion of dominant carrier-specific B cells
may consume local sources of immune help (T cells) resulting in
depriving hapten-specific B-cells of necessary resources leading
to reduced antigen induced antibodies.37–39
It is not entirely clear why carrier priming occurred in some
studies while in CIES others, but the mice models with carrier
priming attributed the results to the very large amount of the
pneumococcal polysaccharide compared with CRM (antigen to
carrier molecular size ratio of _> 2) which means that anti-CRM
antibodies would not cause steric hindrance, whereby pre-existing
carrier-specific antibody prevent access of B cells to the haptens re-
sulting in CIES.25 An inverse dose-dependent relationship of the
priming agent to the antibodies produced against the polysaccha-
ride the conjugate vaccine was observed.24 This highlights that the
relative size of antigen and carrier influences the extent of such im-
mune suppression by pre-existing anti-carrier antibody.
Several solutions have been suggested to avoid CIES, for in-
stance, animal models have shown that moderate conjugation of
polyethylene glycol (PEGylation) of the vaccine has reduced
CIE.40 Additionally, it has been suggested that increasing hapten
load, use of less prevalent carriers or providing novel carriers
might help to overcome immune interference in multi-valent vac-
cines containing several polysaccharide-conjugate antigens.13,25
The three study groups in this trial have achieved a similar im-
mune response in terms of proportion with an OPA titre 1:8
post-vaccination; this best reflects short term protection41;
whereas the GMTs of OPA which are more representative of
long-term protection showed significant suppression upon prior
exposure to Tdap. An important limitation is the small sample
size, also we cannot completely disregard the effect of MCV4 as
PCV13 was not administered solely. However, we showed from
our analysis of the 2014 RCT that even a smaller sample size was
associated with significant differences.17 Nevertheless, our find-
ings have a substantial implication for travellers from developing
and/or developed countries where multiple vaccines are required.
Typical travel vaccines include DTP or DTPolio vaccines which
may potentially interfere with conjugate vaccine responses. This
indicates that when multiple vaccination is required, travellers
will receive favourable long-term protection when a conjugate
vaccine is administered with Tdap (or before it).
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3.1 Chapter overview
The purpose of this final chapter, ‘Discussion’, is to review the overall results to
determine the implications of the findings on immunisation practice. It will briefly
overview the concept of conjugate vaccine interactions and possible explanations of
the variable outcomes. A summary of the main findings of the publications will be
integrated. Given that each individual publication has been discussed in detail
already, this chapter will review combined findings.
3.2 Overview of the concept of conjugate vaccine interactions
The conjugation of capsular polysaccharides to a protein carrier has the advantage of
the differentiation of B cells with recruitment of T and B cells (T-dependent
response) (50). This advantage makes the conjugate vaccines superior, though more
expensive, than their polysaccharide counterpart in terms of immunogenicity,
particularly in infants (because of their immature immune system) (50).
Successful childhood immunisation programmes usually involve both concurrent and
co-administered vaccinations. This reduces the number of routine visits required and
allows easier incorporation of new vaccines into the schedule (50). However, with
the desire to add more new vaccines and the possibility of adding a higher number
of serotypes to conjugates, concern arises over potentiation interaction and/or
interference between the conjugate vaccines and other vaccines. The interaction is
partly attributable to the nature of the carrier proteins. Due to their antigenic
similarity, the carrier proteins on the conjugate vaccines have the ability to interact
with other vaccines with similar antigens such as DTP/Tdap vaccines.
Carrier proteins well chosen for several reasons: they are non-toxic and non-
reactogenic and also obtainable in sufficient amount and purity. They include
inactivated bacterial toxins such as DT, CRM197 and TT (55). The possibility of
immunological interaction between different vaccine components of combination
vaccines remains relatively unexplored. The interaction could either enhance or
suppress the immune response to individual vaccine components (56). For instance,
a concurrent or sequential exposure of DTP in relation to giving a conjugate vaccine,
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may result in a positive interaction, leading to the enhancement of the subsequent
immunogenicity of the conjugate vaccine, or a negative interaction, resulting in
suppression of the immunogenicity of the polysaccharide component of the
conjugate vaccine.
 The following immunological explanations have been found in the literature:
3.2.1 Carrier priming (Carrier-specific enhancement of T-cell help)
The first explanation is that carrier priming which is an immunological phenomenon
where the immunogenicity of a conjugate vaccine is enhanced by prior or concurrent
exposure to a carrier protein. Immunisation with free carrier may prevent the
binding of the conjugate vaccine to carrier-specific B cells and redirect the conjugate
to polysaccharide-specific B cells, leading to better antibody responses to the hapten
(polysaccharide) (56). Additionally, an increased number of carrier-specific T-helper
cells may be induced leading to the enhancement of the conjugate polysaccharide
immunogenicity (56). However, the end result may be divergent as the outcome is
dependent on multiple variables, including when priming occurs, the age at
administration, the type of the carrier protein, the priming dose of carrier
protein, and the specific hapten (57).
3.2.2 Carrier-induced-epitopic suppression (CIES)
The second type of interaction is called carrier-induced-epitopic suppression (CIES).
CIES is defined as interference with the antibody response to a hapten coupled to a
carrier protein among recipients previously immunised with that specific carrier
protein (58). CIES mechanisms are related to pre-existing immunity to a carrier
protein, which may suppress the immune response to a hapten (i.e. a
polysaccharide) linked to the same carrier, thus reducing the hapten’s)
immunogenicity. Several mechanisms have been suggested to explain CIES, that may
occur either separately or simultaneously:
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· Pre-existing antibodies to the carrier may prevent the access of hapten-specific
B-cells to their epitopes by steric hindrance, favouring anti-carrier B-cell
responses and suppressing the anti-hapten B-cell responses (59).
· Dominant carrier-specific memory B-cells may deprive hapten-specific B-cells
of necessary resources such as T-cell help through competitive mechanisms
between the capsular polysaccharides and the carrier proteins. The result is an
increase in the antibody response to the carrier and a decrease in the response
to conjugated peptides or polysaccharides (58).
Each of these processes lead to suboptimal anti-hapten antibody and memory B-cell
responses (27). The epitopic suppression may occur particularly when the conjugate
contains a low ratio of hapten to carrier (60). This is consistent with a recent trial in
mice where McCluskie and colleagues found that that the very large size of the
pneumococcal polysaccharides compared to CRM (antigen to carrier molecular size
ratio of _>2) reduced the steric hindrance from the anti-CRM antibodies, and thus
reducing CIES (61). The trial highlighted the importance of the relative size of antigen
and carrier in influencing the extent of such immune suppression by pre-existing
anti-carrier antibodies (61).
3.3.3 Bystander interference
The third type of interactions is known as bystander interference. This interaction
leads to a suppression of the immune response and may extend to even non-
conjugated antigens when administered simultaneously. Possible mechanisms
include competition for limited resources within the lymph nodes (e.g. access to
antigen, activation signals, follicular T-helper cells, etc.), changes in T helper cell
balance or induction of T-cell regulatory mechanisms. It is of note that both
conjugated and non-conjugated antigens differ in their vulnerability to bystander
interference (27).
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3.3 Summary of this thesis’ findings in the light of potential interactions
The literature contains many, often contradictory, studies about the outcome of
conjugate vaccine interactions. In the light of the above mechanisms of interactions,
this thesis’ literature review (Publication#1) and the retrospective data analysis
(Publication#6), provided some evidence of carrier priming particularly for PCV in
infants (Diagram 2). Publication#6 demonstrated evidence of promising clinical
protection from IPDs which could be the result of protection afforded by a single
PCV7 dose enhanced by carrier priming.
While several countries are lagging in introducing some important vaccines like PCV,
there have been several proposed solutions to reduce the cost of vaccines in
general. For instance, it has been suggested that microneedle techniques would
reduce the cost of vaccination delivery. The development of a needle-free,
thermostable vaccine could revolutionise the field by reducing the cold - chain,
needle-phobia and delivery constraints (not needing a health care worker to
vaccinate) (62). Another suggestion in relation to reducing the cost of the conjugate
vaccines, particularly PCV, is the reliance on herd immunity. Following the control of
pneumococcal vaccine-type disease and reduced colonisation and transmission
induced by vaccination, a PCV schedule with a single priming and a booster dose
might be sufficient to sustain control at reduced costs and should be evaluated (63).
In addition, this thesis proposes taking advantages of conjugate vaccine interactions
with DTP to reduce the costs of infant immunisation schedules by carrier priming. If
carrier priming is proven to induce commensurate immunogenicity with fewer doses
of conjugate vaccine, by a specially designed trial in infants, immunisation schedules
could be rearranged in order to enhance the immunogenicity of the PCV (or any
other conjugate vaccine) and spare one of the three costly doses of the PCV vaccine.
On the other hand, my RCTs in adults, namely Hajj travellers (Publications #7-9)
demonstrated an opposite direction of the interaction resulting in a suppression of
PCV13 and MCV4 immunogenicity by prior receipt of DTP (Diagram 2).
The subjects who had concurrent exposure to the three vaccines
(PCV13/Tdap/MCV4) in 2014 and 2015 had next to no reduction in the
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immunogenicity of the conjugate vaccines, possibly attributable to ‘bystander’
interference.
In the 2014 trial, prior exposure to Tdap vaccine significantly suppressed the GMTs of
6 (of the 13) serotypes of the CRM-197 conjugated PCV13 (co-administered with
CRM197-conjugated MCV4). Moreover, there was insignificant suppression in other
5 serotypes (1, 14, 23F, 7F and 6A). In the 2015 trial, the CRM conjugated MCV4 was
replaced with a TT-conjugated MCV4 which reduced the CRM overload in the trial.
This resulted in the GMTs of 7 serotypes of PCV13 being significantly reduced and a
reduction in the proportion achieving a ≥4-fold rise in rSBA for the serogroup W in
TT-conjugated MCV4 (Diagram 2). It is not totally clear why priming appears to
predominate in infants whereas suppression happened in adults; but perhaps this
could be attributed to the accumulation of antibody levels and memory from active
and/or passive exposure to antigens over the years.
CIES appears to have occurred in the 2014 trial when PCV13 and MCV4 were both
conjugated to CRM197. It was thought then that the CRM197 overload was the likely
reason behind the suppression. In order to overcome this type of interference, it has
been argued that using different carriers could be advantageous (27). However, my
findings during the following year showed that the suppression occurred despite
using different carriers (TT and CRM197).
At present, interactions among various vaccines conjugated to TT, CRM197 or other
carrier proteins are not entirely predictable and must be evaluated in thorough
empirical trials (58). There have been several suggestions to overcome CIES and
minimise such interference:
· Since an inverse dose-dependent relationship of the priming agent to the
antibodies produced against the polysaccharide the conjugate vaccine was
observed (64, 65), it has been suggested that increasing hapten load or
providing novel carriers might help to overcome immune interference (61, 66).
The saccharide–protein ratio for a conjugate is known as the degree of
glycosylation. Conjugate vaccines with a higher carbohydrate to protein ratio,
might be less susceptible to this inhibitory CIES effect because less carrier
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specific-B cell epitopes could be exposed and available to interact with pre-
existing anti carrier antibodies (67).
· Animal models have shown that moderate conjugation of polyethylene glycol
(PEGylation) of the vaccine has reduced CIE (68). The moderate PEGylation of a
carrier protein could mildly reduce its immunogenicity, and yet maintain its T-
cell activating properties. This will eventually lead to increase in the
polysaccharide specific immunogenicity and avoidance of CIES (68).
· Another suggested solution to overcome CIES is by the manipulation of the
adjuvant. The adjuvants generally can be used for various purposes: (i) to
increase the immunogenicity of the antigens; (ii) to reduce the amount of
antigens or the number of immunisations needed for protective immunity.
Accordingly, increasing the dose of the adjuvant might reduce the required
dose of the carrier by increasing its immunogenicity. Carrier dose reduction
may eventually minimise CIES (7) and increase the carrier’s immunogenicity
leading to  decrease of its required dose and subsequently reduced CIES (7).
· One more suggested solution to avoid CIES was producing a bi-carrier
glycoconjugate .i.e manufacturing a vaccine with nearly half of its antigen
bound to one carrier protein while the other half is conjugated to another type
of carrier protein (69). However, this suggestion carries less weight as my trial
in 2015 with different carrier proteins did not show any reduction in CIES.
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Diagram 2. Summary of the key findings of this Thesis
• Sequential administration of DPT vaccine before a
conjugate vaccine results in a variable response;
enhancement is likely in infants, young adults show
some supression while no available data in elderly
Carrier priming or suppression:
Understanding carrier priming enhancement
of anti-polysaccharide antibody response to
conjugate vaccines
• There is a potential implication of carrier priming for
young children in poor settings by enhancing the
immunogenicty of PCV and reducing the number of
required doses
Carrier priming to improve pneumococcal
disease control and reduce the international
program’s cost in children
• The pneumococcal vaccine uptake among Hajj travelers
was suboptimal
Pneumococcal Vaccine Uptake Among
Australian Hajj Pilgrims in 2011-13
• Hajj travellers' lack adequate knowledge about potentially
serious infectious hazards at Hajj
Australian Hajj pilgrims’ knowledge about
MERS-CoV and other respiratory infections
• The lack of optimum vaccine uptake among Hajj
travellers could be attributed to lack of awareness about
serious diseases and their respective vaccines
Barriers of vaccinations against serious
bacterial infections among Australian Hajj
pilgrims
• There is a an appearent benefit of carrier priming to
enhance the clinical protection PCV in infants
Potential carrier priming effect in Australian
infants after 7-valent pneumococcal
conjugate vaccine introduction
• Among adult Hajj travellers, prior exposure to Tdap
significantly suppressed the immune response to PCV-
CRM (coadministered with MCV4-CRM)
Effect of Tdap when administered before,
with or after the 13-valent pneumococcal
conjugate vaccine (coadministered with the
quadrivalent meningococcal conjugate
vaccine) in adults: A randomised controlled
trial
• Among adult Hajj travellers, prior exposure to Tdap
suppressed the immune response to serogroup W in
MCV4-TT (coadministered with PCV-CRM)
Effect of Tdap upon antibody response to
meningococcal polysaccharide when
administered before, with or after the
quadrivalent meningococcal TT-conjugate
vaccine (coadministered with the13-valent
pneumococcal CRM197-conjugate vaccine)
in adult Hajj pilgrims: a randomised
controlled trial
• Among adult Hajj travellers, prior exposure to Tdap
significantly suppressed the immune response to PCV-
CRM (coadministered with MCV4-TT)
Tetanus-diphtheria-pertussis vaccine may
suppress the immune response to
subsequent immunisation with
pneumococcal CRM197-conjugate vaccine
(coadministered with quadrivalent
meningococcal TT-conjugate vaccine) — a
randomised, controlled trial
Paper title Main finding
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3.4 PCV and MCV coadministration
It is hard to interpret the outcome of Tdap apparently suppressing subsequently
administered PCV13 and MCV4 vaccine responses without also considering the fact
that PCV13 and MCV4 were co-administered together; this co-administration per se
may have caused an interference, particularly with bearing in mind that both of
them were conjugated to CRM197 (in the 2014 trial anyway). There are arguments
that too much exposure to CRM197 may induce interference when formulations go
above a certain number of conjugates and/or CRM197 dosage (70, 71). There are not
many trials comparing concurrent versus separate administration of PCV13 and
MCV4; however, there was one trial in infants that found a reduction in anti-MenCV
(SBA) titers when PCV7-CRM197 vaccines were co-administered with MenCV-
CRM197 (72). Another trial demonstrated that PCV9-CRM197 and MenCV- CRM197
combination vaccine administered to infants demonstrated reduced group C
meningococcal immunogenicity compared with MenCV vaccine given alone (73). In
the 2014 trial, CRM197 could have contributed to the suppression; however,
interference occured even with a lower dose CRM197 in the following year.
3.5 Immunogenicity of the carriers
The immunogenicity of a conjugate vaccine is determined by its complex formulation
and production process. The use of a certain protein as carrier is just one of several
factors that determine the overall potency of a vaccine (74). The three most
commonly used carrier proteins (DT, CRM197 and TT), differ remarkably in their
immunogenicity (27), and also in their  ability to induce interference mechanisms. In
some animal studies, there were important differences between CRM197 and DT in
the context of possible interaction. For instance, one trial in mice demonstrated that
CRM197 did not induce CIES, while DT did. This was justified by the authors as being
due to the low immunogenicity of CRM197 as compared to DT, (75). It is noteworthy
to mention that carrier proteins themselves are immunogenic and can induce some
immunity against diphtheria or tetanus depending on the type of the carrier protein
(76). However, there are still doubts surrounding their ability to induce a protective
(a toxin-neutralising) immune response in man (74). For example, it was found that
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one dose of each of Hib-MenCV-TT and MCV-DT was able to protect mice and guinea
pigs against a lethal challenge with tetanus and diphtheria toxins respectively (74).
However, even two doses of conjugate vaccines based on CRM197 (MenCV-CRM;
MCV4-CRM) failed to protect guinea pigs against a lethal challenge with diphtheria
toxin (74). It therefore appears that CRM197 has lower immunogenic capacity than
DT, and perhaps lower interference potential too. My trials in 2014 and 2015 have
shown that administering TT or CRM197 conjugate vaccines has the ability to induce
a substantial immune response to diphtheria and tetanus. This was more prominent
in the 2015 trial with the tetanus component where the proportion of subjects with
anti-tetanus IgG >0.16 IU/mL was significantly higher post-Tdap in the study arm that
received PCV13/MCV4 before Tdap, compared to the other two arms. This warrants
considering that when separating vaccines is desired to minimise AEs, administering
the conjugate vaccine before DTP vaccine could avoid interference and brings the
additional advantage of boosting the diphtheria/tetanus immunogenicity for both
vaccines.
3.6 The issue of interpreting and comparing several studies
In order to come out with a wider conclusion about conjugate vaccine interactions,
we need to compare several outcomes including mine with other national and
international trials.
In this investigation, the serology tests performed in three different labs:
(pneumococcal serology in Pfizer’s USA lab, on 2 occasions too; meningococcal
serology in a UK reference lab whereas the DT serology was done at my institution in
Australia. Therefore, it is hard to generalise or make comparisons of my findings with
others’. The comparison may be unreliable due to differences in study populations,
populations and age groups across other countries and most importantly, the lab
methods.
Such comparisons are problematic, especially due to being performed in different
laboratories or variability in vaccines, study populations and assay methods that can
all affect the reported data. For example, although most laboratories adhere to the
basic methods for the SBA (77) and use the same N. meningitidis strains for
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serogroups A and C, the various manufacturers of quadrivalent conjugate vaccines
use different N. meningitidis in their SBAs for serogroups Y and W-135.
There are no internationally recognised standards on which to base between-study
comparisons. There was inconsistent SBA titre reporting in one interlaboratory
study, even when the same SBA method with the same serogroup strain of N.
meningitidis was used and with the same complement source (78). The methods for
titer determination can also vary between laboratories (79, 80). Moreover, there are
no standardised methods for qualifying use of human and/or baby rabbit
complement in the SBA (81). All these reasons should be considered because they
limit our ability to interpret or compare my findings with that of others’.
3.7 Safety and reactogenicity of the administered vaccines
Although the main focus of this thesis revolves around the conjugate vaccine
interactions, the safety and reactogenicity of these vaccines were also assessed. In
both 2014 and 2015 trials, most local and systemic AEs reported within seven days of
vaccine administration were mild to moderate in severity and rarely exceeded seven
days. Generally, the frequencies of local reactions were similar across the study
arms. However, administration of MCV4 alone resulted in the least local AEs in both
trials (2014 and 2015). The most frequently reported solicited systemic reactions
during the two studies  were general muscle aches and drowsiness which were most
often reported following the concurrent administration of the three vaccines. The
least reported solicited systemic reaction was shown after the administration of
Tdap alone both trials (2014 and 2015). Most importantly, no serious AEs were
reported during the trial periods. Practically, this indicates that adult travellers may
receive the three vaccines concomitantly with minimal interference and
acceptable/tolerable AEs.  The receipt of multiple vaccines by adult international
travellers such as Hajj pilgrims, offers greater convenience (fewer clinic visits), and
improves compliance.
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3.8 Limitations of this thesis
One limitation of this thesis is small sample sizes, particularly for the retrospective
data analysis in infants (Publication#6). The successive two RCTs provided a
somewhat larger number of participants and showed several statistically significant
results. Another limitation of this thesis, is that because of resource constraints,
serology for MCV4 in the 2014 RCT could not be done. Pertussis serology for both
years could not be done either.
Comparing my findings (particularly, the literature review, Publication#1) with
others’ being conducted in different labs; the interpretation and generalisability of
my RCTs’ findings are limited by the absence of internationally recognised standards
on which to base between-study comparisons. In order to explore carrier priming
more thoroughly, rigorous trials are needed to account for different carriers and the
amount/dose of each carrier protein and should best be done using standardised
laboratory methods and techniques.
Given the fact that infants showed more promising results towards carrier priming, it
may be more fitting to conduct such RCTs to explore carrier priming in infants. I am
aware of a similar project under way in Tanzania, Africa and had some contribution
to the proposal.
With regard to the survey assessing the uptake of the vaccine among travellers
(Publication# 3), the main limitation was the inability of the participants to
differentiate conjugate from polysaccharide vaccine. Also, responses may have been
subject to recall bias. The meningococcal and DTP vaccines were not assessed in the
survey.
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3.9 Conclusion
Modern childhood routine immunisation schedules include the administration of
several vaccines simultaneously or in close sequence, which raises concern about
possible interactions between the vaccines, particularly between the conjugates and
DTP. There have been several studies examining the effect of concurrent
coadministration. However, there are limited data examining the effect of sequential
administration. Scrutiny of the literature reveals some contradictory findings on
impact of carrier proteins (as presented in DTP) on the immunogenicity of
conjugates with respect to their sequential interaction. There are some clinical
studies that showed evidence of immune interference while others showed synergic
interactions. The synergic interaction, known as carrier priming was seen more in
infants and young children particularly for PCV. The literature review (Publication #1)
was consistent with the original data analysis (Publication #6) in this thesis. The
latter suggested evidence of substantial clinical protection ensued from a single
carrier primed dose of PCV7 as a result of prior exposure to DTP vaccine. However,
from another prospective, my two RCTs’ in adults demonstrated evidence of an
opposite effect. There was a significant suppression of the immunogenicity to
polysaccharide antigen of two conjugate vaccines used in the trial (PCV13 and MCV4)
irrespective of their carrier proteins. The suppression was, however, minimal (or
absent) if there was a concurrent administration with DTP but prominent upon
sequential administration with DTP first, which was attributed to CIES.
In practical settings, adult travellers attending mass gatherings such as Hajj, might
receive a more favourable outcome if they receive the conjugate vaccine along with
DTP; nonetheless, if separating the vaccines was desired to minimise AEs,
administering DTP vaccine after the conjugate vaccines might yield a better
immunogenicity for DTP and may also avoid any interference to the conjugate
vaccine.
This thesis sheds light on the importance of examining the interaction resulting from
sequential conjugate vaccines administration. With the fact that the review paper
(Publication #1) and the data analysis (Publication #6) showed a promising role for
carrier priming in infants, further RCTs are required to investigate carrier priming in
109
this age group. If significant priming occurs, an adjusted 2-dose schedule (where the
first PCV is given at least a month following DTPa) may be sufficient and also more
cost-effective for vulnerable populations, especially in poor settings that have used
PCV for several years so that substantial herd immunity is also operating.
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5.1 Prizes, presentation and scholarships arising from this thesis 
• Prizes
➢ In the year 2013 this research was awarded the PhD merit scholarship from the
Islamic Development Bank (IDB).
➢ In the year 2014 Mohamed Tashani was awarded the International Robert Austrian
Research Award in Pneumococcal Vaccinology during the ninth International
Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-9) held at
Hyderabad, India.
➢ In the year 2017 Publication # 1 was ranked 3rd among curated 30 excellent articles
on conjugate vaccines published in Vaccine journal, celebrating 30 years of conjugate
vaccines.
➢ In the year 2017 Mohamed Tashani was Awarded the Fresh Science NSW 2017 award
for young scientists based on his research to improve pneumococcal disease control
and reduce the international program’s cost in children.
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February 26, 2014
Mohamed Tashani
Australia
Re: Robert Austrian Research Awards in Pneumococcal Vaccinology
Dear Mohamed Tashani, 
On behalf of the Robert Austrian Research Awards Committee and the ISPPD Board, it is my pleasure to 
inform you that your application for the research project entitled, Optimising immune responses to 
vaccination in Australian Hajj Pilgrims, has been accepted for a 2014 Robert Austrian Research Award.  
You will be awarded $25,000 USD to carry out your research.    These grants are supported by Pfizer. 
The Committee agreed that your application was more than deserving of the award and that your 
research is relevant to the goals of the Robert Austrian Research Awards. 
You are requested to attend the Robert Austrian Research Awards Ceremony at ISPPD-9, in Hyderabad, 
India, on Wednesday, March 12, 2014 at 16:35 for the announcement of the award recipients.   The 
award funds will be transferred to you via bank transfer after the Symposium.  
 The 2014 Robert Austrian Research Award recipients are requested to present their results at
. ISPPD-10, which will take place in Glasgow, UK on June 26-30, 2016
We look forward to seeing you in Hyderabad in 2014 and to hearing the outcomes of your research in 
Glasgow in 2016. 
Sincerely, 
Ingileif Jónsdóttir 
Chair, Robert Austrian Research Awards Committee 
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· Presentations
The outcome of this thesis was presented at the following conferences:
Ø Tashani M, Jayasinghe S, Booy R. Does carrier priming protect infants after one dose of
pneumococcal conjugate vaccine? 14th National Immunisation Conference; June 2014;
Melbourne.
Ø Tashani M et al. Pneumococcal vaccine uptake among Australian Hajj pilgrims in 2011–
13 [poster]. 14th National Immunisation Conference; June 2014; Melbourne
Ø Tashani M et al. Effect of concomitant versus sequential administration of Tdap upon
antibody responses to pneumococcal conjugate vaccine coadministered with
meningococcal conjugate vaccine in adults. The 10th International Symposium on
Pneumococci and Pneumococcal Diseases (ISPPD 2016). June 2016; Glasgow, UK.
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Barcode for Visit 1…..                                                                                 Participant Group (study arm)……
1
Questionnaire_Version1_Date [22/April/2013]
Today’s date ……..|………|……… dd/mm/yy
QUESTIONNAIRE
Surname:  ……………………..... First name: ……………….……… DOB|____/_____/_____| Sex (M / F) |___|
                                                                                                                            dd  /mm / yy
Country of birth …………………………………… …………………………………......
Address ………………………………………………………..State  |__|__|__|  Post Code  |__|__|__|__|
Mobile ……………………Home Phone( …………………… Email:………………………………….
GP Name…………………………………………   GP phone…………………………………………….
GP Address………… ………………………………………………………………………………………
Name of Hajj Tour Group (Travel Agency)……………………………………… Phone( ……………
Name of Hajj Tour Group Leader (Travel Agent)…………….. …………...…….Phone( ……………
Instructions:
We are interested in knowing how you feel about vaccination in general; your answer will help us
improve the health of Hajj pilgrims. Please read carefully the following questions and provide your
answer by putting a tick (✓) in the box that best describes your feelings. Please answer all questions.
Questions (Please tick what applies; you can tick more than one answer):
1) Do you have any chronic medical condition
diagnosed by a doctor?
2) What is your highest level of education?
¨ Yes, If yes, please describe………………
     ……………………………………………
    ……………………………………………
     ……………………………………………
     …………………………………………….
¨No
£ None
£ Primary school
£ High school
£ TAFE Diploma
£ University (Bachelor)
£ Masters
£ Doctorate
£ Other, please specify………………………
    ………………………………………………
Corner Hawkesbury
Road and Hainsworth
Street
Locked Bag 4001
Westmead NSW 2145
Sydney Australia
DX 8213 Parramatta
Tel +61 2 9845 0000
Fax +61 2 9845 3489
www.chw.edu.au
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2
Questionnaire_Version1_Date [22/April/2013]
3) Do you have regular contact with children
under 2 years of age?
4) Do you have a healthcare card?
¨Yes
¨No
¨Yes, if yes please specify: …………….....
………………………………………………
………………………………………………
¨No
5) Have you been to Hajj before? 6) Have you been to Umrah before?
¨ Yes, → If yes, which of the following year(s)?
¨2010
¨2009
¨2008
¨2007
¨2006
¨Other year(s)……………
¨ No
¨ Yes → If yes, which of the following year(s)?
¨2010
¨2009
¨2008
¨2007
¨2006
¨Other year(s)……………
¨ No
If you answer (No) to question 5 or 6, please go to question 10
7) In preparing for your previous Hajj or
Umrah, did you take influenza vaccine?
8) In preparing for your previous Hajj or
Umrah, did you take pneumococcal
vaccine?
¨ Yes
¨ No →If No, please provide reason why:
¨ Busy
¨ I don’t think it’s important
¨ I don’t think it’s effective
¨ I prefer to rely on natural immunity
¨ Fear of needle
¨ Not aware about the vaccine
¨ Concerns about side effects
¨ Other, please specify……………..
                  ………………………………………
                   ……………………………………..
¨ Yes
¨ No →If No, please provide reason why:
¨ Busy
¨ I don’t think it’s important
¨ I don’t think it’s effective
¨ I prefer to rely on natural immunity
¨ Fear of needle
¨ Not aware about the vaccine
¨ Concerns about side effects
¨ Other, please specify…………….
            ………………………………………..
            ………………………………………..
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3
Questionnaire_Version1_Date [22/April/2013]
9) In preparing for your previous Hajj or
Umrah, did you take pertussis (whooping
cough) vaccine?
10) In what language would you prefer to
receive medical information?
¨ Yes
¨ No →If  No, please provide reason why:
¨ Busy
¨ I don’t think it’s important
¨ I don’t think it’s effective
¨ I prefer to rely on natural immunity
¨ Fear of needle
¨ Not aware about the vaccine
¨ Concerns about side effects
¨ Other, please specify…………….
            ……………………………………….
            ……………………………………….
¨ In English
¨ In Arabic
¨ In Turkish
¨ In Persian
¨ Other, Please specify……………………
……………………………………………..
11) Please indicate how the following diseases can be transmitted from one person to another:
Food Drinking
water
Sharing
shaving razors
Air
(coughing, sneezing)
I don’t know
Meningococcal □ □ □ □ □
Pneumococcal pneumonia □ □ □ □ □
Influenza □ □ □ □ □
Food poisoning □ □ □ □ □
HIV/ AIDS □ □ □ □ □
Hepatitis A □ □ □ □ □
Hepatitis B/C □ □ □ □ □
Pertussis (whooping cough) □ □ □ □ □
12) How are your Hajj vaccines paid for? 13) Have you heard any rumors or bad news
about any vaccine in the past 5 years?
¨ They are covered completely by Medicare
¨ They are covered partially by Medicare
¨ They are paid out of pocket (not covered)
¨ I don’t know
¨ Yes, If yes, please describe………………
     ……………………………………………
    ……………………………………………
     ……………………………………………
     …………………………………………….
¨No
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14) Please indicate the answer that expresses your opinion:
Strongly
agree
Agree Don’t
know
Disagree Strongly
disagree
Vaccinating healthy adult before travel
is necessary
□ □ □ □ □
Vaccination does not help the
development of immune system
□ □ □ □ □
When my GP recommends a vaccine for
me, I have a concern about its side
effects
□ □ □ □ □
When my GP recommends a vaccine for
me, I have a concern about its cost
□ □ □ □ □
Meningococcal is a serious disease □ □ □ □ □
Pneumococcal pneumonia is a serious
disease
□ □ □ □ □
Pertussis (whooping cough) is a serious
disease
□ □ □ □ □
Influenza is a serious  disease □ □ □ □ □
Viral hepatitis B/C is a serious a disease □ □ □ □ □
There is a high risk of catching
meningococcal infection at Hajj
□ □ □ □ □
There is a high risk of catching
Pneumococcal pneumonia at Hajj
□ □ □ □ □
There is a high risk of catching influenza
at Hajj
□ □ □ □ □
There is a high risk of having food
poisoning at Hajj
□ □ □ □ □
There is a high risk of catching HIV at
Hajj
□ □ □ □ □
There is a high risk of catching viral
hepatitis A at Hajj
□ □ □ □ □
There is a high risk of catching viral
hepatitis B or C at Hajj
□ □ □ □ □
There is a high risk of catching pertussis
(whooping cough) at Hajj
□ □ □ □ □
Too many vaccines may weaken the
immune system
□ □ □ □ □
I have access to all information I need to
make a decision about vaccination
□ □ □ □ □
I prefer to take multiple vaccines at the
same time
□ □ □ □ □
I trust the information I receive about
vaccines from TV
□ □ □ □ □
I trust the information I receive about
vaccines from Internet
□ □ □ □ □
I trust the information I receive about
vaccines from my GP
□ □ □ □ □
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15) Have you heard about the Novel Corona
Virus (Middle East Respiratory
Syndrome)?
16) Have you had your Flu shot (influenza
vaccine) this year?
¨Yes
¨No
¨Yes
¨No I didn’t have it but I’m intending to have it
¨No I didn’t have it and I’m not intending to
have it→ Please provide reason why…………..
…………………………………………………
…………………………………………………
…………………………………………………
17) Have you heard any Fatwa against any
vaccine in the past 5 years?
18) What is your weekly income? i.e
wages/salaries, government benefits,
pensions, allowances and other income
¨Yes→ If Yes, please describe :
      ………………………………………………
      ………………………………………………
      ………………………………………………
      ………………………………………………
¨No
¨ $2,000 or more
¨$1,500 - $1,999
¨$1,250 – $1,499
¨$1,000 – $1,249
¨ $800 - $999
¨$600 - $799
¨ $400 - $599
¨ $300 - $399
¨ $200 - $299
¨ $1-$199
¨Nil income
¨ I prefer not to
disclose
Do have any comments?
……………………………………………………………………………………………………….
……………………………………………………………………………………………………….
……………………………………………………………………………………………………….
This is the end of the questionnaire. Thank you very much for your cooperation
We can assure that your answers are completely PRIVATE and CONFIDENTIAL and no
medical personnel involved in your care will have access to this questionnaire.
*******************************************************************************
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Flyer_Version 1_Date [22/April/2013]
Dear Australian pilgrims:
We invite you to participate in a study entitled:
Optimising immune response to
vaccination in Australian Hajj pilgrims
Hajj is one of the great mass gatherings in the
world. It involves a lot of crowding and there is
a high risk of catching serious infectious
diseases such as Meningococcal disease,
Pneumococcal disease, and Whooping cough
In order to be eligible to enter Saudi Arabia for
Hajj or Umrah, there is a compulsory vaccine
to be taken against meningococcal disease
(inflammation of the lining of the brain and
blood poisoning).
There are other important vaccines against
pneumococcal pneumonia (chest infection) and
pertussis (whooping cough). We will offer you
vaccines to protect you from these diseases.
We are not testing new vaccines; the vaccines
in this study are already registered and are
widely used for adults.
No study has been done before to find out the
best order of which to give the vaccines
recommended for pilgrims
What does the research involve?
Currently, there is no specific order to give
Hajj vaccines. However, we suspect that
giving the vaccines in a different order may
have different effects; we want to find the
best protection for Muslim pilgrims.
Therefore we encourage you to participate in
this study; you will be offered 3 registered
vaccines free of charge. You will be
randomised into 3 groups
§ Group 1: Will be initially vaccinated against
pertussis (DTP) followed by pneumococcal
and meningococcal a month later.
§ Group 2: Will be vaccinated against pertussis
(DTP), pneumococcal and meningococcal
diseases at the same time
§ Group 3: will be initially vaccinated against
pneumococcal and meningococcal diseases
followed by pertussis (DTP) a month later.
We will take a blood sample before and after
vaccination
What are the benefits of joining
this study?
§ You will be offered 3 registered vaccines for
Hajj, free of charge.
§ You will be protected from at least 3 serious
infections at Hajj (Meningococcal,
Pneumococcal, and Whooping cough)
§ You will be given vaccine certificate so that you
can apply for Hajj VISA
§ We will reimburse you for any travel costs
Why is this research important?
Participating in this study will help us
improve the health of the pilgrims
Who is eligible?
Australian adults aged 18 to 64 years, who
have not received any of the study vaccines
in the past 3 years and are intending to go to
Hajj or Umrah
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What do I need to do now?
If you are eligible and you would like to
take part in our study, you can contact us
at any of the contacts below, or attend at
our first induction sessions
Also you can visit our website under
(Active clinical studies) tab in the
following link:
http://ncirs.edu.au/clinical-
studies/active/index.php
This project has been approved by Hunter
New England Ethics Committee and we
have the support and collaboration of the
Grand Mufti of Australia
If I would like to know more, whom
do I contact?
If you wish to know more about the
study, please contact us at the National
Centre for Immunisation Research and
surveillance [NCIRS]:
________________________
_
Dr Mohamed Tashani:
Mobile: 0435752969
Mohamed.tashani@health.nsw.gov.au
_________________________________
Laura Rost:
Telephone: (02) 98451430
_____________________________
Professor Robert Booy MBBS MSc MD FRACP
FRCPCH Head of Clinical Research
“Together we can build a healthier
future for people of all ages.”
The National Centre for Immunisation Research and
Surveillance of Vaccine Preventable Diseases
A Centre of Clinical Research Excellence
 Corner Hawkesbury Road and
Hainsworth Street Locked Bag 4001 Westmead
NSW 2145 | Visit: www.ncirs.edu.au
Do you know that you must have a
vaccination to get a Hajj VISA?
Join us in our study and we will provide
you with the vaccines free of charge
Telephone: 0435752969
A new research project from
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Participant Information Sheet (Information Statement):
“Optimising immune response to vaccination in Australian Hajj
pilgrims”
A study by investigators at the National Centre for Immunisation Research and
Surveillance (NCIRS):
Research Team:
· Professor Robert Booy: Head of the Clinical Research team at the (NCIRS)
· Professor Melanie Wong: Director of the Immunology Laboratory and head of the
Immunodeficiency service at The Children’s Hospital at Westmead (CHW),
· Dr. Iman Ridda, MD and PhD in public health, clinical research fellow at the (NCIRS)
· Dr Harunor Rashid, MD in the Epidemiology of respiratory infections, clinical research
fellow at the (NCIRS)
· Dr Leon Heron: MBChB FRCPA FAFPHM, Medical Manager, Vaccine Trials at the
(NCIRS)
· Dr Mohamed Tashani*: MPH, PhD fellow at University of Sydney, (NCIRS)
· Mohammad Irfan Azeem* B Pharm, M ClinPharm, PhD fellow at University of Sydney
(NCIRS)
Invitation:
You are invited to participate in the research project entitled “Optimising immune response to
vaccination in Australian Hajj pilgrims” which is being conducted by Professor Robert Booy from
the NCIRS. The research team is made up of several research experts and two PhD fellows*, their
names and affiliations is listed above
This study involves giving three vaccines to Australian Muslims who intend to perform Hajj or
Umrah. The vaccines are to protect the pilgrims from serious diseases such as Meningitis, Pneumonia,
and whooping cough.
The findings of this study will help us at the NCIRS to determine how to improve health protection of
pilgrims.
Before you decide whether or not you wish to participate in this study, it is important for you to
understand why the research is being done and what it will involve. Please take the time to read the
following information carefully and discuss it with others if you wish.
1. Why is the research being done?
The purpose of this study is to determine which order of the vaccines will result in the best
protection to Australian Muslims going to Hajj or Umrah. Before vaccination we will also ask you
some questions about vaccines; this will tell us what you know about vaccines and diseases at Hajj.
Corner Hawkesbury Road
and Hainsworth Street
Locked Bag 4001
Westmead NSW 2145
Sydney Australia
DX 8213 Parramatta
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2. Why am I being invited to take part in this study?
You will be able to take part in study, if you are aged 18 to 64 years, you are intending to go to Hajj
or Umrah this year and you have not received any of the study vaccines in the past 3 years. We will
ask your permission to check with your local doctor for vaccine history.
3. What if I don’t want to take part in this study, or if I want to withdraw later?
Participation in this study is voluntary. It is completely up to you whether or not you participate. If
you decide not to participate, it will not affect treatment you receive now or in the future. Whatever
your decision, it will not affect your relationship with staff caring for you.
New information about the vaccines being studied may become available during the course of the
study. We will tell you about any new findings that may affect your willingness to continue in the
study.
If you wish to withdraw from the study once it has started, you can do so at any time without having
to give a reason. However, it will not be possible to return your samples or withdraw your
previously collected information from the study as they will form part of the data that must be
analysed for the study.
4. What will you be asked to do?
If you agree to participate in this study, you will be asked to sign and return the attached participant
consent form in person.
Ø Your participation will be over 3-8 weeks period
Ø We are not testing new vaccines; the vaccines of this study are already registered and
are widely used for adults. The study will find out if the order of the vaccines will result in
a different immune response to the vaccines.
Ø These vaccines will be given by an experienced immunisation nurses and doctors.
Ø We will take blood samples before and after vaccination, each sample will be 5-8ml (1 to 2
teaspoons). If you wish, we can use a local aesthetic cream. However, dermatitis,
methaemoglobinaemia, glucose-6-phosphate deficiency and mollusca contagiosa may
prevent from using the local anaesthetic cream.
Ø Before vaccination, you will be asked to answer few questions about travel health; this will
take approximately 10-15 minutes.
Ø Before vaccination, we will swab your throat with a cotton swab to check if you are carrying
meningococcal or pneumococcal bacteria. We will swab your throat one more time just after
you return from Hajj.
Ø Once vaccinated, you will be given a diary to keep a record of any side effects you may
encounter after vaccination.
Ø If you have not taken the flu shot this year, and you wish to do so, please wait until you
complete your final visit and then you could take it through your GP (This is to avoid any
possible interference with the study)
Ø Flu vaccine is not part of our study, but we will offer it for you in your last visit in case you
want it as a preparation for your Hajj trip
You will be randomly assigned by a computer into one of 3 groups; the results will be compared to
see whether one group will gain a higher protection.
Group 1: Will be initially vaccinated against diphtheria/tetanus/pertussis followed by
pneumococcal and meningococcal vaccines 3-8 weeks later.
Group 2: Will be vaccinated against diphtheria/tetanus/pertussis, pneumococcal and meningococcal
disease at the same time
Group 3: will be initially vaccinated against pneumococcal and meningococcal diseases followed,
by diphtheria/tetanus/pertussis vaccine 3-8 weeks later.
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Neither the doctor nor the study participant can decide in which group you will be. For further
details, please see table1
We will offer you pneumococcal vaccine only if you are at risk of catching pneumococcal disease
.i.e. if you have one of the following conditions: chronic heart disease, chronic lung disease,
diabetes mellitus, alcoholism, chronic liver disease or tobacco smoking
5. Are there risks in taking part in this study?
You may get some of the following side effects from the vaccines. These are usually mild and
similar to those seen following vaccination with the same vaccines administered outside this study.
· For meningococcal vaccine you may experience pain at the injection site (41%), headache
(30%), tiredness (17%) and nausea (10%).
· For diphtheria/tetanus/pertussis vaccine you may experience pain at the injection site (66%),
swelling (21%), redness (25%), headache (34%), vomiting (22%) and tiredness (22%).
· For the pneumococcal vaccine you may experience pain at the injection site (50%), redness
(10%) and swelling (10%); tiredness (30%) and headache (20%).
It is preferable that women participating in this study are not pregnant and do not become pregnant
during  the  study.  If  you  are  a  woman of  childbearing  age,  the  researchers  will  need  to  perform a
urine pregnancy test before you are given any vaccine.
6. What happens if I suffer complications as a result of participating in the study?
If  you  suffer  any  injuries  or  complications  as  a  result  of  this  study,  you  should  contact  the  study
doctor as soon as possible, who will assess the situation and if needed will assist you in arranging
appropriate medical treatment.
You may have the right to take legal action to obtain compensation for any injuries or complications
resulting from the study. Compensation may be available if your injury or complication is
sufficiently serious and is caused by unsafe drugs or equipment, or by the negligence of one of the
parties involved in the study (for example, the researcher or the treating doctor). If you receive
compensation that includes an amount for medical expenses, you will be required to pay for your
medical treatment from those compensation monies. You do not give up any legal rights to
compensation by participating in this study. If you are not eligible for compensation for your injury
or complication under the law, but are eligible for Medicare, then you can receive any medical
treatment required for your injury or complication free of charge as a public patient in any
Australian public hospital.
7. Will I benefit from the study?
You may not benefit from participating in this study
8. Will taking part in this study cost me anything, and will I be paid?
Participation in this study will not cost you anything. The vaccines will be provided to you free of
charge.
9. What will happen to my tissue samples after it has been used?
The blood samples you provide during the study will be destroyed after results are clearly known.
Samples will be retained long enough for the purpose of retesting if necessary.
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10. How will my confidentiality be protected?
Of the people dealing with you, only those named above or their delegates will have access to your
information. Any identifiable information that is collected about you in connection with this study
will remain confidential and will be disclosed only with your permission, or except as required by
law. Only the researchers named above will have access to your details and results that will be held
securely. The study may be audited by: The approved human research committee. Medical
regulatory agencies such as Therapeutic Goods Administration (TGA). Auditing officers are
required to keep your information confidential
11. What happens with the results?
We plan to publish the results in medical peer-reviewed journal. In any publication, information
will be provided in such a way that you cannot be identified. Results of the study will be provided
to you once the study is complete.
12.  What should I do if I want to discuss this study further before I decide?
You may seek advice from you GP or any doctor of your choice
13. Complaints about this research:
This research has been approved by the Hunter New England Human Research Ethics Committee of
Hunter New England Local Health District, Reference number (13/05/15/3.05)
Should you have concerns about your rights as a participant in this research, or you have any complaint
about the manner in which the research is conducted, it may be given to the researcher, or, if an
independent person is preferred, to Dr Nicole Gerrand, Manager Research Ethics and Governance,
Hunter New England Local Health District, Locked Bag 1,  New Lambton NSW 2305, telephone (02)
49214950, email Hnehrec@hnehealth.nsw.gov.au
This project has also been authorised to be conducted at The Children’s Hospital at Westmead. If you have any
concerns about the conduct of this study at this site please do not hesitate to contact the Research Governance
Officer on (02) 9845 3011.
14. Who is funding this research
This research is primarily funded by the National Centre for Immunisation Research and Surveillance
(NCIRS). Also, the cost of vaccine and testing blood samples is being supported by vaccine companies
(BioCSL, Pfizer, GSK)
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Table1: Study visit schedule and assessment:
Vaccine Group
Group 1 Group 2 Group 3
dTpa dTpa + PCV13+ MCV4 MCV4+PCV13
1st visit Information statement
Consent
Questionnaire filling
Throat swab
* Taking blood samples
Vaccinate ( dTpa)
Observation.
1st subject **diary card.
Information statement
Consent
Questionnaire filling
Throat swab
Taking blood samples
Vaccinate
(dTpa+PCV13+MCV4)
Observation.
1st subject diary card.
Information statement
Consent
Questionnaire filling
Throat swab
Taking blood samples
Vaccinate
(PCV13+MCV4).
Observation.
1st subject diary card.
3-8 weeks
after the 1st
visit
Review 1st diary card
***AEs
Taking blood samples
Vaccinate (PCV13+
MCV4)
Observation.
2nd diary card.
Review 1st diary card.
AEs
Taking blood samples
Review 1st diary.
AEs
Taking blood samples
Vaccinate
(dTpa)
Observation
2nd diary card.
 3-8 weeks
after the 2nd
visit
Review 2nd diary card.
AEs
Taking blood samples.
Review 2nd diary card.
AEs
Taking blood samples.
Post Hajj
follow-up
Throat swab Throat swab Throat swab
*Each blood sample will approximately be 5-8ml.
**Diary card: solicited local and systematic reactions and unsolicited adverse events will be monitored and documented
in the post vaccination diary card.
***Adverse events
**********************************************************************************************
Thank you for taking the time to consider this study.
If you wish to take part in it, please sign the attached consent form.
This information sheet is for you to keep.
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CONSENT TO PARTICIPATE IN RESEARCH
Title of Research Project: “Optimising immune response to vaccination in
Australian Hajj pilgrims”
1. I acknowledge that I have read, or have had read to me the Participant
Information Sheet relating to this study. I acknowledge that I understand the Participant
Information Sheet.  I acknowledge that the general purposes, methods, demands and possible
risks and inconveniences which may occur to me during the study have been explained to me by
[……………….] and I, being over the age of 18 acknowledge that I understand the general
purposes, methods, demands and possible risks and inconveniences which may occur during the
study.
2. I acknowledge that refusal to take part in this study will not affect the usual treatment of my
condition.
3. I acknowledge that this research has been approved by the Hunter New England Human
Research Ethics Committee of Hunter New England Local Health District
4. I acknowledge that I have received a copy of this form and the Participant Information Sheet,
which I have signed.
Before signing, please read ‘IMPORTANT NOTE’ following.
IMPORTANT NOTE:
This consent should only be signed as follows:
1. Where a participant is over the age of 18 years, then by the participant personally.
Name of participant _______________________ ____________________________________
Address of participant ___________________________________________________________
____________________________________________________________________________
Signature of participant _______________________________________Date: _____________
Signature of Research Team Member Name _____________________ Date: _____________
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   Optimising immune response to vaccination in Australian Hajj Pilgrims | 7 Day Diary Card | Visit number………….| Participant Number
Name……………………………………………………………………..
Dear pilgrim: Please record any of the following general symptoms each day after vaccination, starting on Day 0    / /
Day
and
Date
➙
Day 0
 /
evening
Day 1
 /
evening
Day 2
 /
evening
Day 3
 /
evening
Day 4
 /
evening
Day 5
 /
evening
Day 6
 /
evening
Ongoing
after
Day 6?
Date of last
symptom
(if ongoing
after day 6)
Medical
Visit
Sought?
Type
of
Medical
visit
Causality
(Study Dr
to
complete)
Study Dr
to initial
and
date
KEY **F
Temperature N/A
…..............
℃
…..............
℃
..............
℃
…..............
℃
…..............
℃
…..............
℃
…..............
℃
☐ No
__/___/___
☐ No
measured
under the arm
☐ Yes ☐ Yes
Vomiting A* ☐ No
__/___/___
☐ No
(0-3) ☐ Yes ☐ Yes
Diarrhoea B* ☐ No
__/___/___
☐ No
(0-3) ☐ Yes ☐ Yes
Loss of
appetite
C* ☐ No
__/___/___
☐ No
(0-3) ☐ Yes ☐ Yes
Drowsiness D* ☐ No
__/ ___/___
☐ No
(0-3) ☐ Yes ☐ Yes
General
muscle aches
(0-3)
E* ☐ No
__/___/___
☐ No
☐ Yes ☐ Yes
A*,B*,C*,D*,E*:
0: Absent
1: Easily tolerated, minimum discomfort and does
not interfere with everyday activities
2: Interfere with normal everyday activities
3: prevents normal everyday activities or requires
medical intervention
F** Type of medical visit:
1: Hospitalisation
2: Emergency room visit
3: GP visit
If you have any problems remember to contact Dr. Mohamed Tashani on: 0435752969
________________________________________________________________________________
1
.
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Optimising immune response to vaccination in Australian Hajj Pilgrims | 7 Day Diary Card | Visit number………….| Participant Number
Please record any of the following local symptoms each day after vaccination, starting on Day 0 ___/___/____
Day
and
Date➙
Day 0
   /   /
evening
Day 1
   /   /
evening
Day 2
   /   /
evening
Day 3
   /   /
evening
Day 4
   /   /
evening
Day 5
   /   /
evening
Day 6
   /   /
evening
Ongoing
after Day
6?
Date of last
symptom (if
ongoing)
Medical
Advice
Sought
?
Type of
Medical
Advice
Causality
(Study Dr
to
complete)
Study Dr
to initial
and date
Left
Shoulder
KEY Study staff: record Vaccine given in source document………………………… ***C
Redness
(mm)
*A ☐ No
☐ Yes  /  /
☐ No
☐ Yes
Swelling
(mm)
*A ☐ No
☐ Yes  /  /
☐ No
☐ Yes
Hardness
(mm)
*A ☐ No
☐ Yes  /  /
☐ No
☐ Yes
Pain
(0-3)
**B ☐ No
☐ Yes  /  /
☐ No
☐ Yes
Right
Shoulder
KEY Study staff: record Vaccine given in source document…………………………
Redness
(mm)
*A ☐ No
☐ Yes  /  /
☐ No
☐ Yes
Swelling
(mm)
*A ☐ No
☐ Yes  /  /
☐ No
☐ Yes
Hardness
(mm)
*A ☐ No
☐ Yes  /  /
☐ No
☐ Yes
Pain
(0-3)
**B ☐ No
☐ Yes  /  /
☐ No
☐ Yes
*A Redness, Swelling or
Hardness:
Please measure (in mm) the
largest size experienced each day
**B Pain (at injection site)
0: Absent
1: Minor reaction on touch or does not interfere with daily activities
 2: Moderate reaction on touch or Interferes with daily activities
3: Severe pain when limb is moved / spontaneously painful or Prevents daily activities
***C Medical Advice
1: Hospitalisation
2: Emergency Room visit
3: GP visit
PLEASE bring this diary to your next appointment on………/……………/…………..
We would like to confirm that all information you provide is strictly confidential. Our research reports will NOT identify any participant.
Thank you for completing this important and valuable part of our Hajj research.
__________________________________________________________________________________
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Immunisation Research
Date ……../…….../……..
The participant
……………………………………………..
Name
Date of Birth ……../…….../……..
is enrolled in the study entitled: “Optimising immune responses to vaccination in Australian
Hajj Pilgrims”
HNEHREC reference number: 13/05/15/3.05
NSW HREC reference number: HREC/13/HNE/160
The study has been approved by the Hunter New England Human Research Ethics
Committee; the participant has received:
· Tetanus, diphtheria and acellular pertussis vaccine (Tdap) (Boostrix) on ……/……./2015.
· 4-valent Meningococcal conjugate vaccine (ACYW) (Nimenrix) on ……/……./2015.
· 13-valent Pneumococcal conjugate vaccine (PCV13) (Prevnar 13)  on ……/……./2015.
· Seasonal influenza vaccine (Fluvax) on    ……/……./2015.
Sincerely yours
Prof. Robert Booy
Head of clinical research
National Centre for Immunisation Research and Surveillance
t: (02) 9845 1415 |robert.booy@health.nsw.go.au | w: www.ncirs.edu.au
Kids Research Institute, The Children's Hospital at Westmead
Cnr Hawkesbury Road and Hainsworth Street, Westmead
Locked Bag 4001, WESTMEAD NSW 2145, Australia
Corner Hawkesbury Road
and Hainsworth Street
Locked Bag 4001
Westmead NSW 2145
Sydney Australia
DX 8213 Parramatta
136
Vaccine certificate 5.6
137
APP1066323                   Participant number: ___ ___ ___ ___ ___ ___
    Version 3, 14 February 2014.             Page 1
CONFIDENTIAL
Subject Name ________________________________
Age _______________years
DOB_____________________
Sponsor: CHW
Optimising immune responses to vaccination in Australian Hajj Pilgrims
Principal Investigator: Prof Robert Booy 0423 800 128 NCIRS The Children’s Hospital at Westmead
Random assignment
o A=Subject to receive Boostrix first
o B=Subject to receive all 3 vaccines at once
o C=Subject to receive Nimenrix/Prevenar first
Contact details
Gender:  Male  Female
Phones
Home _______________________ Mobile _____________________
Email:  ____________________________________________________________________________
2nd Contact
Name ______________________________________ Relationship _____________________________
Phones
Home _____________________ Mobile ______________________
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VISIT ONE
Date of visit: ___ ___ / ___ ___ ___ / 2015(dd/mmm/yyyy)      Venue ________________________
Inclusion criteria
In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.
Yes No
1 Aged 18-64 years. (From day of 18th birthday until but not including the day of the 65th birthday)
2 Informed consent form has been signed and dated
3 Understands the study, its procedures, and agrees to comply with the requirements of
the study, including keeping a daily record of symptoms in a diary
4 Able to attend all scheduled visits
5 For a woman of childbearing potential, use of an effective method of contraception, or
abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after
the last vaccination.
To be considered to be not of childbearing potential, a woman must either have undergone surgical sterilization (hysterectomy or
bilateral tubal ligation) or be post-menopausal (at least one year without menses) at the time of vaccination.
Effective methods of contraception include hormonal (e.g. oral, injection, transdermal patch, implant, cervical ring), intrauterine
device, diaphragm or condoms used with sponge, contraceptive foam or cream, each and every time during intercourse, or sexual
abstinence or monogamous relationship with partner who has been vasectomized for six months or more prior to subject’s study
entry.Contraception must continue until one month after the last study vaccination
Exclusion criteria
In order to participate in this study, all subjects must meet NONE of the exclusion criteria described.
Yes No
1 History of any severe allergic reaction
2 Severe allergy to any component of the vaccines.
Aluminium salts, formaldehyde, phenoxyethanol, polysorbate 80, glycine, succinic acid, OR any CRM197, diphtheria toxoid,
tetanus toxoid, pertussis antigen, pneumococcal polysaccharide or meningococcal polysaccharide-containing vaccine.
3 Pregnancy or breast feeding
4 Receipt of blood, immunoglobulins or blood-derived products in the past 3 months
5 Known or suspected congenital or acquired immunodeficiency; or receipt of
immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy
within the preceding 6 months; or long-term systemic corticosteroid therapy
(prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
6 Confirmed or suspected serious chronic illness or suspected neurologic disease or
seizure
7 Received, in the last 3 years, any vaccine that contains antigens of the study vaccines
Medical history
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
Relevant physical examination findings:
Skin…………………………………………………………………………………………………
Musculoskeletal and connective tissue………………………………………………………....
Cardiovascular…………………………………………………………………………………….
Respiratory…………………………………………………………………………………………
Gastrointestinal…………………………………………………………………………………….
Nervous system……………………………………………………………………………………
Subject inclusion certification by investigator or investigator delegate
I certify that I have assessed this person who fulfils all inclusion criteria, has no exclusion criterion and has no contraindication for the study product.
I therefore authorise this person’s inclusion in the study.
Name: _____________________ Signature: __________________ Date: _____ / ______ / ______
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Pregnancy test All female subjects of childbearing potential
Has a urine pregnancy test been done?
 Yes, Date of collection__ __/__ __ __/___
Result Negative
 Positive (exclude this subject)
 Not of child bearing potential ® reason:
 Post-menopausal (More than 1 year since last menses)
 Tubal ligation at least one year earlier
 Bilateral oophorectomy or hysterectomy
 Male
Blood sample
Has a blood sample been collected?
 Yes
 No. Reason _________________________________
Pre-vaccination temperature
Record here temperature measured on day of vaccination ONLY ________oC Orally Axillary
If the subject has a temperature ≥38.0 oC or the subject has moderate or severe acute illness/infection
(according to Investigator’s judgment), vaccination must be deferred.
Vaccination 1
Date of vaccination __ __ / __ __ __ / 20__ __.
day month year
This subject has been randomly assigned to:
 A) Boostrix first – give in left deltoid
 B) All three vaccines at once – give Nimenrix in upper right deltoid
             Prevenar 2.5cm lower in right deltoid
             Boostrix in left deltoid
 C) Pneumo/Meningo first – give Nimenrix in right deltoid
             Prevenar in left deltoid
Strike from vaccinator’s record boxes those vaccines NOT to be received
Vaccinator only Time vaccines given _____ : _____ (24-hr clock)
Study product administration
(only the correct boxes must be marked)
Administration details (Intramuscular)
(non-dominant arm preferred)
 Boostrix given
Batch
IM  left deltoid
 Nimenrix given
Batch
IM  right deltoid
 Prevenar given
Batch
IM Left deltoid right deltoid 2.5cm below Nimenrix
Vaccination performed by
Name: _____________________ Signature: ________________ Date: _____/______/______
Write date and subject name and number on each vaccine box
This is Day 0
Attach bar code here
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Post vaccination observation period
Time observation period ended: _____ : _____
Reportable immediate adverse events
Did a reportable adverse event occur?
No
Yes record AE details/ clinical management and mark the reportable event checklists appropriately.
Checklist for reportable events Note: one event may qualify for more than one action – mark all that apply.
Immediately notify Principal Investigator if any reportable event occurs or any other event gives rise to concern.
Reportable event types identified Action required (Mark box(es) when done)
An event contraindicating further Study Vaccine For any reportable event
Principal Investigator advised by
Name: ________________________
Sign: _________________________
Date: ______ / _________ / 20__ __
As appropriate
 Write the reason for contraindication
of the next dose in the next visit pages by
Name: ________________________
Sign: _________________________
Date: ______ / _________ / 20__ __
 Reported to sponsor within 24 hrs by
Name: ________________________
Sign: _________________________
Date: ______ / _________ / 20__ __
Reported to HREC within 72 hrs by
Name: ________________________
Sign: _________________________
Date: ______ / _________ / 20__ __
See instructions page
Anaphylaxis or other significant allergic reaction to study product.
Other type of SAE related to the study product
An SAE (serious adverse event)
Death
Is life-threatening (i.e., the Subject was, in the opinion of the
investigator, at immediate risk of death from the event as it
occurred); it does not refer to an event which hypothetically might
have caused death if it were more severe.
Required and prolonged hospitalization
Persistent or significant disability/incapacity (i.e., the event
causes a substantial disruption of a person’s ability to conduct
normal life functions).
Is a congenital anomaly / birth defect
Medically significant event
An important and significant medical event that may not be immediately life
threatening or resulting in death or hospitalization but, based upon appropriate
medical judgment, may jeopardize the Subject or may require intervention to
prevent one of the other outcomes listed above.
AE leading to withdrawal
 Record the facts below and in the eCRF
New Onset of Chronic Disease
 An AE that represents a new diagnosis of a chronic medical condition that was not
present or suspected in a Subject prior to study enrollment. Record the facts below
and in the eCRF
Pregnancy
 Any pregnancy in a subject who received a study vaccine must be reported to the
sponsor within 24 hours of the site learning of its occurrence.
Pregnancy is not an SAE, but spontaneous abortions, foetal death and congenital abnormalities are SAEs.
Additional notes regarding follow-up of AEs, NOCDs, pregnancy, assigning causality, etc
Attach extra sheets, if required
Onset date, end date, severity (mild, moderate, severe, life threatening), action taken (none, uncertain, procedure or physical therapy, blood or blood products, withdrawal due to AE, treating
doctor(s), prescription or non-prescription medications start/stop dates, causal relationship to study product, action taken in relation to study product (none, next vaccination interrupted, no
further study vaccination due to AE), arrangements for follow-up of baby etc.
Make all notes in chronological order, name/sign/date all entries
Assign AE causality (investigator responsibility) before data entered into eCRF. See instructions page for definitions of AE causality.
Visit 1 actions check list (Mark all actions appropriately)
A copy of consent form and information sheet given.
Vaccination certificate
Questionnaire given
Diary card for Dose 1 provided. Diary card must be brought to next visit. Explanations of recording AEs given.
Serious AEs definition described and subject asked to report SAEs or a serious AE as soon as possible.
Thermometer and ruler provided and explained.
Vaccinations. It is preferable that no other vaccines be given until after the final blood sample is collected.
Visit 2 appointment: Time __________ Date _____ / __________ / 20 __ __ Venue _______________
Visit conclusion performed by
Name: _____________________ Signature: ________________ Date: _____/______/______
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VISIT 2 (V1+ 21-56 days) all subjects     Date of visit __ __/__ __ __/20 __ __
Collect and check the diary card and Questionnaire in the presence of the subject.
Has the diary card been returned?
 Yes.
 No. ® Action taken………………………………………
Check the diary card thoroughly and resolve any issues
Has a new reportable event been identified?
No
Yes record AE details/ clinical management and mark the reportable event checklists appropriately.
Has the questionnaire been returned?
 Yes.
 No. ® Action taken………………………………………
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Pregnancy test All female subjects of childbearing potential
Has a urine pregnancy test been done?
 Yes, Date of collection__ __/__ __ __/___
Result Negative
 Positive (exclude this subject)
 Not of child bearing potential ® reason:
 Post-menopausal (More than 1 year since last menses)
 Tubal ligation at least one year earlier
 Bilateral oophorectomy or hysterectomy
 Male
Blood sample
Has a blood sample been collected?
 Yes
 No. Reason _________________________________
                This bar code number is the subject number
Pre-vaccination temperature
Record here temperature measured on day of vaccination ONLY ________oC Orally Axillary
If the subject has a temperature ≥38.0 oC or the subject has moderate or severe acute illness/infection
(according to Investigator’s judgment), vaccination must be deferred.
Vaccination 2
Date of vaccination __ __ / __ __ __ / 20__ __.
day month year
This subject has been randomly assigned to:
 A     Give       Nimenrix in right deltoid
                Prevenar in left deltoid
 B)    Offer      Flu vaccine
 C)    Give      Boostrx in left deltoid
Strike from vaccinator’s record boxes those vaccines NOT to be received
Strike out vaccines NOT given
Vaccinator only Time vaccines given _____ : _____ (24-hr clock)
Study product administration
(only the correct boxes must be marked)
Administration details (Intramuscular)
(non-dominant arm preferred)
 Boostrix given
Batch
IM  Left deltoid
 Nimenrix given
Batch
IM  Right deltoid
 Prevenar given
Batch
IM Left deltoid
 Flu vaccine
Batch
IM Left deltoid
Vaccination performed by
Name: _____________________ Signature: ________________ Date: _____/______/______
Write date and subject name and number on each vaccine box
Attach bar code here
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Post vaccination observation period
Time observation period ended: _____ : _____
Reportable immediate adverse events
If a reportable event occurs, use the reportable events grid on the previous page
Visit 2 actions check list (Mark all actions appropriately)
Vaccination certificate
Diary card for Dose 2 provided. Diary card must be brought to next visit. Explanations of recording AEs given.
Serious AEs definition described and subject asked to report SAEs or a serious AE as soon as possible.
Thermometer and ruler provided and explained.
Window = V2+21 to 56 days
Next visit : Visit 3 appointment: Time __________ Date _____ / __________ / 20 __ __ Venue
_______________
Visit conclusion performed by
Name: _____________________ Signature: ________________ Date: _____/______/______
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Visit 3 V2 +21-56 d for subjects who received vaccine at visit 2
Collect and check the diary card in the presence of the subject.
Has the diary card been returned?
 Yes.
 No. ® Action taken………………………………………
Check the diary card thoroughly and resolve any issues
Has a new reportable event been identified?
No
Yes record AE details/ clinical management and mark the reportable event checklists appropriately.
Has the questionnaire been returned?
 Yes.
 No. ® Action taken………………………………………
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Pregnancy test All female subjects of childbearing potential
Has a urine pregnancy test been done?
 Yes, Date of collection__ __/__ __ __/_ _ _
Result Negative
 Positive (exclude this subject)
 Not of child bearing potential ® reason:
 Post-menopausal (More than 1 year since last menses)
 Tubal ligation at least one year earlier
 Bilateral oophorectomy or hysterectomy
 Male
Blood sample
Has a blood sample been collected?
 Yes
 No. Reason _________________________________
Pre-vaccination temperature
Record here temperature measured on day of vaccination ONLY ________oC Orally/ Axillary
If the subject has a temperature ≥38.0 oC or the subject has moderate or severe acute illness/infection
(according to Investigator’s judgment), vaccination must be deferred.
This subject can be offered   Flu vaccine
Vaccinator only Time vaccines given _____ : _____ (24-hr clock)
Study product administration
(only the correct boxes must be marked)
Administration details (Intramuscular)
(non-dominant arm preferred)
 Flu vaccine
Batch
IM Left deltoid
Vaccination performed by
Name: _____________________ Signature: ________________ Date: _____/______/______
Write date and subject name and number on each vaccine box
Post vaccination observation period
Time observation period ended: _____ : _____
Reportable immediate adverse events
If a reportable event occurs, use the reportable events grid on the previous page
Visit 3 actions check list:
Vaccination certificate
Visit 3 conclusion performed by
Name: _____________________ Signature: ________________ Date: _____/______/______
Attach bar code here
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Termination summary
Study completion or withdrawal
A subject may be withdrawn from the study:
· At the discretion of the Investigator or Sponsor due to safety concerns without the subject’s permission
· At the request of the subject (dropout or voluntary withdrawal)
Documented clearly the reason for a withdrawal or dropout
· Determine whether voluntary withdrawal is due to safety concerns or for another reason.
Follow-up of discontinuations
All scheduled safety follow-ups should be completed for any subject who terminates prematurely irrespective of
reason. Withdrawn subjects will be followed up to 6 months after the last vaccination. Set this up at the time of any
contact during which the subject indicates a wish to withdraw. NB If the subject requires that we do not contact
him/her again, that wish will be respected.
Lost to Follow-up Procedures
For subjects who fail to return for a follow-up examination, document reasonable effort (telephone calls or certified
mail) to locate or recall them, or at least to determine their health status while fully respecting their rights.
Termination record
Termination date       __ __ / __ __ __ / __ __ __ __
Additional notes regarding early termination
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
Study termination record completed by
Name: _____________________ Signature: ________________ Date: _____/______/______
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29 July 2016 
 
 
 
Professor Robert Booy 
Kerry Packer Research Building 
The Children’s Hospital at Westmead 
Cnr Hawkesbury Rd & Hainsworth St 
Westmead  NSW  2145 
 
 
 
Dear Professor Booy 
 
Re: Cluster-randomised controlled trial to test the effectiveness of facemasks in preventing 
respiratory virus infection among Hajj pilgrims: RCT to test the effectiveness of masks against ILI 
(13/07/17/3.04) 
 
HNEHREC Reference No: 13/07/17/3.04 
NSW HREC Reference No: HREC/13/HNE/265 
 
Thank you for submitting the renewal application for the above project which was considered by the Hunter 
New England Human Research Ethics Committee at its meeting held on 29 July 2016. This Human 
Research Ethics Committee is constituted and operates in accordance with the National Health and 
Medical Research Council’s National Statement an Ethical Conduct in Human Research 2007 and the 
CPMP/ICH Note for Guidance on Good Clinical Practice.  
 
I am pleased to advise that the Hunter New England Human Research Ethics Committee has granted 
ongoing ethical approval of the above protocol having confirmed that the project continues to meet the 
requirements of the National Statement on Ethical Conduct in Human Research. 
 
Approval from the Hunter New England Human Research Ethics Committee for the above protocol 
is given for a maximum of 5 years from the date of this letter, after which a renewal application will 
be required if the protocol has not been completed. 
 
The National Statement an Ethical Conduct in Human Research 2007, which the Committee is obliged to 
adhere to, include the requirement that the committee monitors the research protocols it has approved.  In 
order for the Committee to fulfil this function, it requires:  
 
• A report of the progress of the above protocol be submitted at 12 monthly intervals.  Your review date is 
July 2017.  A proforma for the annual report will be sent two weeks prior to the due date.     
 
• A final report must be submitted at the completion of the above protocol, that is, after data analysis has 
been completed and a final report compiled. A proforma for the final report will be sent two weeks prior 
to the due date. 
 
• All variations or amendments to this protocol, including amendments to the Information Sheet and 
Consent Form, must be forwarded to and approved by the Hunter New England Human Research 
Ethics Committee prior to their implementation. 
 
Hunter New England Research Ethics & Governance Office 
Locked Bag No 1 
New Lambton  NSW  2305 
Telephone: (02) 49214950 
Email: HNELHD-HREC@hnehealth.nsw.gov.au  
http://www.hnehealth.nsw.gov.au/ethics/Pages/Research-Ethics-and-Governance-Unit.aspx 
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• The Principal Investigator will immediately report anything which might warrant review of ethical 
approval of the project in the specified format, including: 
 
- any serious or unexpected adverse events 
 
• Adverse events, however minor, must be recorded as observed by the Investigator 
or as volunteered by a participant in this protocol.  Full details will be documented, 
whether or not the Investigator or his deputies considers the event to be related to 
the trial substance or procedure. 
 
• Serious adverse events that occur during the study or within six months of 
completion of the trial at your site should be reported to the Professional Officer of 
the Hunter New England Human Research Ethics Committee as soon as possible 
and at the latest within 72 hours.   
 
• Copies of serious adverse event reports from other sites should be sent to the 
Hunter New England Human Research Ethics Committee for review as soon as 
possible after being received. 
 
• Serious adverse events are defined as: 
 
- Causing death, life threatening or serious disability. 
- Cause or prolong hospitalisation. 
- Overdoses, cancers, congenital abnormalities whether judged to be 
caused by the investigational agent or new procedure or not. 
- Unforeseen events that might affect continued ethical acceptability of the 
project. 
 
• If for some reason the above protocol does not commence (for example it does not 
receive funding); is suspended or discontinued, please inform Dr Nicole Gerrand, the 
Manager, Research Ethics & Governance Office as soon as possible. 
 
The Hunter New England Human Research Ethics Committee also has delegated authority to approve the 
commencement of this research on behalf of the Hunter New England Local Health District.  This research 
may therefore commence.  
 
Should you have any queries about your project please contact Dr Nicole Gerrand as per the contact 
details at the bottom of the page.  The Hunter New England Human Research Ethics Committee Terms of 
Reference, Standard Operating Procedures, membership and standard forms are available from the Hunter 
New England Area Health Service website. 
 
Please quote 13/07/17/3.04 in all correspondence. 
 
The Hunter New England Human Research Ethics Committee wishes you every success in your research. 
 
Yours faithfully 
 
 
 
 
 
For: Ms M Hunter 
 Chair 
Hunter New England Human Research Ethics Committee 
 
Hunter New England Research Ethics & Governance Office 
Locked Bag No 1 
New Lambton  NSW  2305 
Telephone: (02) 49214950 
Email: HNELHD-HREC@hnehealth.nsw.gov.au  
http://www.hnehealth.nsw.gov.au/ethics/Pages/Research-Ethics-and-Governance-Unit.aspx 
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 5.9 List of other publications or manuscripts have not been included in this 
thesis, but they were published or submitted during the candidature and are 
related to the topic 
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Hajj pilgrims in 2013. Virol Sin. 2014  
4) Ridda I, Dastouri F, King C, Yin JK, Tashani M et al . Vaccination of Older Adults with 
Dementia Against Respiratory Infections. Infect Disord Drug Targets.  2014 Jul 13. 
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20, Issue 12, 26 March 2015. 
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needed. Trop Med Int Health. 2015 Mar 30. 
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the prevalence of influenza-like illness and influenza vaccine uptake among Hajj 
pilgrims: A 10-year retrospective analysis of data. Vaccine. 2015. 
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gathering: Hajj pilgrimage 2014. J Epidemiol Glob Health. 2015. 
9) Seale H, Leem J-S, Gallard J, Kaur R, Chughtai AA, Tashani M, et al. “The cookie 
monster muffler”: Perceptions and behaviours of hospital healthcare workers around 
the use of masks and respirators in the hospital setting. International Journal of 
Infection Control. 2014;11(1). 
10) Alqahtani AS, Wiley KE, Tashani M, et al. Camel exposure and knowledge about MERS-
CoV among Australian Hajj pilgrims in 2014. Virol Sin 2016. 
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